

Leveraging science to enhance the quality of life

GlaxoSmithKline Pharmaceuticals Limited

Annual Report for the 15 months period ended 31st March 2015



# A word from the Managing Director

Consistent with GSK's mission to improve the quality of human life by enabling people to do more, feel better and live longer, your Company has over the years, endeavoured to bring the latest in pharmaceuticals, both from the parent company as well as through licensing opportunities. In the current year, a medicine for metastatic colorectal cancer, a difficult disease to treat was launched from one of our Licensor partners. In addition, given its expertise in the respiratory area, it has launched the Ventorlin Mini Spacer which is an add-on device for asthma and COPD patients. A face mask is to be used along with the Ventorlin Spacer and Inhaler to help paediatric and geriatric population suffering from asthma and COPD.

Your Company's other ambition is to provide access to its medicines to as many patients as possible. To this end, given the recent price drop on the flagship product Augmentin, your Company has taken a number of steps to ensure much wider access to the product. This has been responsibly done keeping in mind the problem of antibiotic resistance. Significant increase in the prescription share, a reflection of access, has been achieved. This has been done for other products which have been impacted by price control as well. This is a demonstration of a unique business model of the Company, where it strives to not only add value by leveraging science to enhance the quality of life of its patients, keeping in mind access pricing, but also adding value in the process to other stakeholders as an outcome.

Efforts have also been made to improve the diagnosis and treatment of thyroid diseases by not only educating healthcare professionals widely, but also patients. The whole focus on access has also reflected in the continuing emphasis on the rural initiatives to support patients in rural markets. It has been gratifying to note the success of the oncology business by providing state-of-the-art cancer treatments at affordable prices for the benefit of a large number of patients during the year. In the area of preventive health, your Company continues to be a leading provider of the widest range of vaccines to as many patients as possible with continued innovation to improve access. In this context, a cost effective extension of the market leading pneumococcal vaccine in the form of vials was launched to help more children.

Given its healthcare heritage, your Company's focus on CSR has been in the area of access to healthcare, preventing infant and maternal mortality, apart from other health initiatives.

A recent transaction with Novartis will, during the course of the coming year, see the transfer of the oncology business to Novartis and in return, your Company will receive a market leading vaccine for dog bites, apart from addition to its portfolio of vaccines for meningitis.

Over the last few years, an attempt has been to broad base the offerings of your Company to increase its healthcare impact footprint through entry in new therapeutic areas as well as channels. This will benefit many more patients in the time to come.

Above all, your Company remains a benchmark in terms of compliance and ethical behaviour, and in the current year, a novel incentive system for its frontline field force which is not linked to direct sales was introduced. Many initiatives in this area are planned in the time to come.



GSK is a company that puts people at the heart of everything that we do to help them do more, feel better and live longer.

However, even today, millions of people still do not have access to basic healthcare and there are thousands of diseases without effective treatments. We want to change this and are working to develop innovative new medicines and vaccines while also finding new ways to get them to everybody who needs them.

## Leveraging science to enhance the quality of life

At GSK, the aim is to improve quality of human life by putting people at the heart of everything that we do to help them do more, feel better and live longer. The Company develops and makes medicines to treat a broad range of acute and chronic diseases. GSK India continues to be a leader in many of the therapy areas in which it provides healthcare solutions to patients. By straddling the domains of preventive and curative, the Company effectively leverages the power of science to enhance the quality of life.

The year has witnessed key brands in the Mass Markets portfolio such as Zinetac, Calpol, Neosporin, Betnesol, Zyloric, Zentel, and Cetzine maintain dominant market leadership positions. In keeping with the Company's vision of improving access and reach of medicines to as many patients as possible, the Company targeted the adjacent and direct category competition to drive unit sales. The rural initiative, REACH, is being expanded further to ensure prescription leadership and support to patients in rural markets.

The Mass Specialty business continued its growth trajectory with Augmentin regaining the No. 1 position in the amoxy-clav market with a remarkable recovery despite the NLEM (National List of Essential Medicines List) impact.

To help rapid and early diagnosis of Thyroid disorders, GSK conducted around 2,600 one-to-one Scientific Promotion Meetings (SPMs) on "Maternal Thyroidism" and translated Thyroid guidelines to equip HCPs for appropriate disease management. In addition, the team also conducted disease awareness initiative on Congenital Hypothyroidism (CH) in various cities.

Apart from this, Ceftum also registered a double digit prescription growth in major specialty areas, while the new launch, Avamys showed a positive value growth and became the 6th brand among 52 brands in INCS (intranasal corticosteroids) market with a market share of 5.8%.

In the Specialty business, the Company continued to retain a strong leadership position in Dermatology. Within clinical dermatology, brands like Betnovate, TBACT, Tenovate sustained strong growth while the cosmetology portfolio of brands comprising Ansolar, Oilatum and Physiogel continued to benefit increasing number of patients requiring these therapeutic options. Creating unique platforms for patients and physicians with programmes like SKIN SENSE (aimed at enabling patients and physicians for early diagnosis of skin problems) and SPEAK campaign (aimed at spreading awareness for conditions like Psoriasis and Eczema) resonated with its strong patient focused approach. The Oncology division's vision to improve patient care in cancer management at affordable prices has benefited almost 7,000 patients during the year. Apart from innovative solutions in the form of key brands such as Tykerb, Revolade, Votrient and Hycamtin used to treat various types of cancer, the year saw the division driving unique and unstinted commitment to patient care for brands like XGEVA (indicated for Skeletal related disorders) with programmes like "SWASTI" aimed at improving patient access. This division also launched Vectibix (in licensed from AMGEN) a novel innovative monoclonal antibody for patients with certain types of metastatic colorectal cancer.

The Respiratory team made inroads into the asthma / Chronic Obstructive Pulmonary Disorder (COPD) category with products like Seretide and Ventorlin, while the Evohaler device with dose counter continued to create a new mark in the category for patients with asthma. The CNS team created unique awareness campaigns for patients and physicians in areas such as Epilepsy and Bipolar Disorders. Lamictal became the second largest prescribed brand of Lamotrigine in Epilepsy. In the Cardiology division, focus on areas like hypertension and dyslipidemia continued with brands like Benitec, Rosutec, Carzec and Volibris. The team organised screening camps across the country to enable physicians and patients to diagnose conditions like dyslipidemia early and thereby improve treatment outcomes.

In the area of preventive healthcare, GSK Vaccines continues to be the No.1 vaccines Company in the private vaccines market in India. In keeping with the Company's philosophy of offering access to vaccines to as many patients as possible, a more cost effective extension of the flagship pneumococcal vaccine in the form of vials was launched, which will help protect more kids from pneumococcal diseases (one of the leading causes of infant mortality in India).

# New Products launched in 2014-15



**Vectibix** is a fully human monoclonal antibody for the treatment of patients with metastatic colorectal cancer (mCRC). **Vectibix** is a novel anti-epidermal growth factor receptor (EGFR) drug and has been granted an approval for a controlled indication in all 3 lines of mCRC based on the RAS gene status of the patient.


**Ventorlin mini spacer** is a device to be used along with Ventorlin Inhaler as an add-on device for asthma and COPD Patients. Face mask is to be used along with Ventorlin mini spacer and Ventorlin Inhaler especially for paediatric and geriatric population suffering from asthma and COPD.

# Mini Space

# Sustaining Excellence

Enhancing the quality of life by ensuring seamless supply of our medicines to patients is the hallmark of a responsible organisation.

The India manufacturing and supply operations undertook various global programmes to ensure smooth operations throughout the year. The Nashik site is being upgraded with a special focus on Good Manufacturing Practices (GMP), Safety and Sustainability. Further, the site has embarked on the GSK Production System (GPS) Deployment journey in line with Global Manufacturing and Supply initiative to achieve Zero Accidents, Zero Defects & Zero Waste with an ambitious target to deploy GPS to 50% of direct value stream zones in 2015.





### **Board of Directors**

(As on 18.05.2015)

Chairman D. S. Parekh

Vice-Chairman V. Thyagarajan

### Managing Director

Dr. H. B. Joshipura

### Directors

A. Aristidou (w.e.f. 01.12.14)
R. R. Bajaaj
Ms. A. Bansal
P. V. Bhide
S. Harford (upto 18.05.15)
M. B. Kapadia (upto 30.11.14)
N. Kaviratne CBE
R. Krishnaswamy
P. V. Nayak
A. N. Roy
R. C. Sequeira
R. Simard (w.e.f. 18.05.15)
D. Sundaram

### Audit Committee

D. Sundaram – Chairman P. V. Bhide N. Kaviratne CBE P. V. Nayak D. S. Parekh V. Thyagarajan

### Stakeholders' Relationship Committee D. S. Parekh – Chairman R. R. Bajaaj P. V. Bhide

Dr. H. B. Joshipura

### Nomination & Remuneration Committee N. Kaviratne CBE – Chairman Ms. A. Bansal D. S. Parekh V. Thyagarajan

Corporate Social Responsibility Committee D. S. Parekh – Chairman Ms. A. Bansal Dr. H. B. Joshipura A. N. Roy

### Management Team

Managing Director Dr. H. B. Joshipura

### Executive Directors A. Aristidou – Chief Financial Officer R. C. Sequeira – Human Resources R. Krishnaswamy – Technical

**Commercial Head** 

S. Venkatesh – Pharmaceuticals Executive Vice-Presidents B. Akshikar – Pharmaceuticals R. Bartaria – Pharmaceuticals H. Buch – Pharmaceuticals K. Hazari – Legal & Corporate Affairs

### Vice-Presidents

Dr. (Ms.) V. Desai – *Medical & Clinical Research* S. Dheri – *Biologicals* S. Khanna – *Finance* 

Registered Office Dr. Annie Besant Road, Mumbai 400 030. Tel.: 24959595, Fax: 24959494 Website: www.gsk-india.com Email: askus@gsk.com CIN: L24239MH1924PLC001151

Factory Ambad, Nashik

Solicitors Gagrat & Co. General Manager – Administration & Company Secretary A. A. Nadkarni

Auditors Price Waterhouse & Co Bangalore LLP

Cost Auditors R. Nanabhoy & Co.

Bankers Citibank N.A. Deutsche Bank HDFC Bank Limited Hongkong and Shanghai Banking Corporation Limited

### **Registrars & Share Transfer Agents**

Karvy Computershare Private Limited Unit: GlaxoSmithKline Pharmaceuticals Limited Karvy Selenium Tower B, Plot No. 31 & 32 Gachibowli, Financial District Nanakramguda, Serilingampally Hyderabad, Telangana-500 032 Tel. No.: 040 67162222 Fax No.: 040-23001153 Email : einward.ris@karvy.com

### Share Department

Dr. Annie Besant Road Mumbai 400 030 Telephone: 022-24959415/434 Fax: 022-24981526 Email: ajay.a.nadkarni@gsk.com

### Contents

Directors' Report3
Annexure to Directors' Report 14
Report on Corporate Governance 17
Business Responsibility Report
Independent Auditors' Report
Financial Statements 40
Statement pursuant to Section 212 68
Biddle Sawyer Limited69
Consolidated Financial Statements 77

Note: Members are requested to kindly bring their copy of the Annual Report to the Meeting.

### **Performance Summary**

(Amounts in Rupees Lakhs)	15 Months Ended	2013 *	2012 *	2011 *	2010	2009	2008	2007	2006	2005
	March 2015 *									
PROFIT AND LOSS ACCOUNT										
Sales	3358,54	2593,39	2669,97	2391,73	2155,08	1912,77	1751,56	1712,84	1677,57	1575,89
Profit before tax	800,51	703,17	994,78	921,60	867,27	758,48	679,90	606,73	555,95	477,91
Tax	(278,10)	(226,19)	(317,59)	(290,24)	(285,89)	(253,59)	(231,54)	(209,94)	(194,23)	(171,63)
Profit after tax and before exceptional items	522,41	476,98	677,19	631,36	581,38	504,89	448,36	396,79	361,72	306,28
Exceptional items (net of tax)	(50,76)	24,90	(99,93)	(200,76)	(17,69)	7,40	128,21	140,87	183,79	195,80
Net Profit	471,65	501,88	577,26	430,60	563,69	512,29	576,57	537,66	545,51	502,08
Balance brought forward	1099,94	1142,95	1110,59	1164,53	1049,23	882,41	759,89	632,75	441,19	259,75
Dividends	(529,39)	(423,51)	(423,51)	(381,16)	(338,81)	(254,11)	(338,81)	(304,93)	(262,58)	(237,17)
Tax on distributed profit	(107,77)	(71,19)	(63,66)	(60,32)	(53,21)	(40,13)	(57,58)	(51,82)	(36,82)	(33,26)
Transfer to General Reserve	(47,16)	(50,19)	(57,73)	(43,06)	(56,37)	(51,23)	(57,66)	(53,77)	(54,55)	(50,21)
Balance carried forward	887,27	1099,94	1142,95	1110,59	1164,53	1049,23	882,41	759,89	632,75	441,19
BALANCE SHEET										
Equity Capital	84,70	84,70	84,70	84,70	84,70	84,70	84,70	84,70	84,70	84,70
Reserves	1766,96	1932,49	1925,31	1835,23	1846,11	1674,45	1456,39	1276,21	1110,01	863,91
Borrowings	3,12	4,14	4,59	4,91	5,16	5,42	5,65	5,77	5,54	4,85
-	1854,78	2021,33	2014,60	1924,84	1935,97	1764,57	1546,74	1366,68	1200,25	953,46
Fixed Assets	238,28	161,93	133,19	115,32	117,65	114,17	100,35	92,90	94,46	96,94
Investments	47,67	57,67	102,58	159,80	160,35	190,91	751,87	1333,32	1139,41	913,06
Net Deferred Tax	82,91	92,11	86,54	61,47	56,40	44,69	29,60	20,14	24,61	29,76
Net Assets (Current and Non-Current)	1485,92	1709,62	1692,29	1588,25	1601,57	1414,80	664,92	(79,68)	(58,23)	(86,30)
	1854,78	2021,33	2014,60	1924,84	1935,97	1764,57	1546,74	1366,68	1200,25	953,46
* 15 Months Ended March 2015, and Years 2013, 20	12 and 2011 base	d on Revised	Schedule VI							
OTHER KEY DATA										
Rupees per Rs.10/- Equity Share										
DIVIDENDS	62.50	50.00	50.00	45.00	40.00	30.00	22.00	18.00	17.00	14.00
SPECIAL ADDITIONAL DIVIDEND		—		_		—	18.00	18.00	14.00	14.00
TOTAL	62.50	50.00	50.00	45.00	40.00	30.00	40.00	36.00	31.00	28.00
EARNINGS PER EQUITY SHARE	55.68	59.25	68.15	50.84	66.55	60.48	68.07	63.48	64.40	58.51
BOOK VALUE	218.61	238.16	237.31	226.67	227.96	207.69	181.95	160.67	141.05	112.00
Number of employees	4657	5034	4706	5055	4338	4006	3722	3620	3850	4016

NO


ES The Company has divested its Fine Chemicals business on 30<sup>th</sup> September, 2007 and its Animal Health business on 31<sup>st</sup> July, 2006. The Company has bought back and extinguished 26,19,529 equity shares during 2005. 1.

2.


The accounting year of the Company has been changed from January-December to April-March with effect from the current year. Consequently, the current year's financial statements are for the 15 months from 1<sup>st</sup> January, 2014 to 31<sup>st</sup> March, 2015. The current year's figures therefore, are not comparable with those of the previous year. Figures have been adjusted/regrouped wherever necessary in line with the financial statements, to facilitate comparison. 3.


4


### Charts













### **Directors' Report**

The Directors have pleasure in submitting their Report for the fifteen months period ended 31<sup>st</sup> March 2015. The Accounting year of the Company has been changed from January-December to April-March in line with the provisions of the Companies Act, 2013, which prescribe a uniform financial year. Accordingly, current year's Annual Accounts and Report of the Company are for a period of fifteen months from 1<sup>st</sup> January 2014 to 31<sup>st</sup> March 2015. These figures, therefore, are not comparable with those of the previous year ended 31<sup>st</sup> December 2013.

### 1. Financial Results & Dividend for the fifteen months ended 31st March 2015

			15 months ended 31 <sup>st</sup> March 2015 Rs. in lakhs	Year ended 31 <sup>st</sup> December 2013 Rs. in lakhs
Sale of Products (Net of Excise Duty)			3253,40.98	2520,17.24
Other Operating Revenue			34,16.82	25,97.50
Revenue from Operations			3287,57.80	2546,14.74
Profit before Exceptional Items and Tax			800,50.43	703,16.57
Less: Exceptional Items			(51,88.14)	26,15.46
Profit before Tax			748,62.29	729,32.03
Less: Tax expense			276,97.71	227,43.79
Net Profit for the year			471,64.58	501,88.24
Add: Opening Surplus brought forward from	the previ	ious year	1099,93.27	1142,94.60
Less: Appropriations:				
Proposed Dividend (including tax on c	distribute	d Profits)	637,16.78	494,70.75
Transfer to General Reserve			47,16.46	50,18.82
Closing Surplus carried forward			887,24.61	1099,93.27

### 2. Dividend

The Directors recommend a Dividend of Rs. 62.50 per Equity Share for the fifteen months period (previous twelve months period: Rs. 50 per Equity Share). If approved by the Shareholders at the Annual General Meeting, the Dividend will absorb Rs. 529 crores. The Dividend Distribution Tax borne by the Company will amount to Rs. 108 crores.

### 3. Management Discussion and Analysis

### (a) Finance and Accounts

Sale of Products (net of Excise Duty) increased by 29% for the fifteen months period 31<sup>st</sup> March 2015 as compared with the previous year twelve months period ending 31<sup>st</sup> December 2013. The fifteen months period was impacted by the full year effect of the Prices Control Order introduced in mid 2013. The Pharmaceuticals business continues to be affected by supply constraints mainly from local supplies during the period to meet the demands of the market.

The Gross Margin has remained flat compared to last year mainly driven by the full period absorption of the Price Control Order. Other expenses such as field force recruitment were restricted to segments that required resourcing for growth and significant investments continued to be made for the consumer brands lodex and Ostocalcium which are marketed by GlaxoSmithKline Consumer Healthcare Limited.

Profit before Exceptional items and Tax amounted to 25% of Net Sales for the fifteen months period, compared to the twelve months previous year of 28%. Profit after Exceptional items and Tax for the corresponding periods amounted to 14% of Net Sales for the fifteen months

period, as compared to 20% in 2013. This is mainly due to the profit on disposal of property in 2013 of Rs. 21.18 crores (pre-tax) as compared to Exceptional costs of Rs. 52 crores in the current fifteen months period. These costs include Rs. 21.51 crores relating to actuarial loss on employee benefits and a charge of Rs. 30.37 crores for the rationalization of capital assets for one dosage form at the Nashik facility.

Cash generation from Operations continued to remain favourable this year and is in line with business performance. Your Company continues to look for ways and means of deploying accumulated cash balances which remain invested largely in bank deposits.

Your Company has not accepted any fixed deposits during the year. There was no outstanding towards unclaimed deposit payable to depositors as on 31<sup>st</sup> March 2015.

### Key Comparable Figures for the 12 months period ending April-March 2015 as compared to April-March 2014

As mentioned above, the audited results for the fifteen months period ended 31<sup>st</sup> March, 2015 are not comparable with those of the previous year ended 31<sup>st</sup> December, 2013. However, on a memorandum basis, for comparative purposes, unaudited results for the twelve months ended 31<sup>st</sup> March, 2015 are given below:

- Net Sales at Rs. 2653.4 crores (2013-14: Rs. 2488.1 crores) grew by 6.6% with a Gross Margin improvement of 1.8% to 54% in the current period.
- Profit from operations (excluding Other Income and Exceptional items) at Rs. 499.3 crores (2013-14: Rs. 447.9 crores) grew at 11.5%, enhancing Operational profit margin by 0.8% to 18.8%.
- Profit before tax at Rs. 371.5 crores (2013-14: Rs. 418.4 crores) decreased by 11.2% mainly due to exceptional gains in 2013-14 of Rs. 21.18 crores arising from profit on sale of property and Rs. 5.78 crores from actuarial gain on employee benefits, as compared to an exceptional charge in 2014-15 towards the actuarial loss on employee benefits (Rs. 22.5 crores) as well as charge of Rs. 30.4 crores towards the rationalization of capital assets for one of the dosage forms at a manufacturing facility.

### **Novartis Transaction**

In April 2014, GlaxoSmithKline Plc (GSK), London, UK, entered into three inter-conditional agreements with Novartis AG (Novartis), Basel, Switzerland. In one such agreement GSK agreed to acquire Novartis's Vaccines Business (excluding influenza vaccine) and manufacturing capabilities and facilities from Novartis, and in the second agreement, GSK agreed to sell the rights of its Marketed Oncology Portfolio, related R&D activities and AKT Inhibitors currently in development to Novartis. Globally, these transactions with Novartis were completed on March 2<sup>nd</sup>, 2015.

In connection to the above transactions, the GlaxoSmithKline Pharmaceuticals Limited ("Company") Board in its meeting held on 12<sup>th</sup> February 2015, approved the transactions on an Asset Sale basis with Novartis Healthcare Private Limited, a private unlisted Company incorporated under the Companies Act 1956. Pursuant to the global deal, the Company will have its distribution rights terminated for the oncology portfolio and it will acquire distribution rights for vaccines portfolio. The transaction is expected to be profit neutral for the Company.

GSK Plc and Novartis AG have obtained the approval from Competition Commission of India. The Company and Novartis Healthcare Private Limited have filed separate applications for approval with Foreign Investment Promotion Board (FIPB). The closing of the asset sales between the companies is subject to the receipt of all applicable legal and regulatory approvals, consent, permissions and sanctions as may be necessary from the concerned authorities.

#### (b) Pharmaceuticals Business performance and outlook

Your Company continues to enjoy a leadership position in the therapy areas in which it provides health care solutions to patients.

The speciality business continued to make rapid strides during the year with strong leadership position in therapy areas like Dermatology. Within the Clinical dermatology area, brands like



Betnovate, TBact and Tenovate sustained strong growth while the Cosmetology portfolio of brands like Ansolar, Oilatum and Physiogel continued to benefit increasing number of patients requiring these therapeutic options. The cornerstone of the Dermatology business continues to be a strong patient focused approach. This division created unique platforms for patients and physicians with programs like SKIN SENSE (aimed at enabling patients and physicians for early diagnosis of skin problems) and SPEAK campaign (aimed at spreading awareness for conditions like Psoriasis and Eczema).

The Oncology team articulated vision to improve patient care with affordability benefited over 7000 patients during the year. Apart from the innovative solutions in the form of key brands like Tykerb, Revolade, Votrient & Hycamtin used to treat various types of cancer, the year saw this division driving unique and unstinted commitment to patient care for brands like Xgeva (indicated for Skeletal related disorders) with programs like "SWASTI" aimed at improving patient access. This division also launched VECTIBIX (in licensed from AMGEN), a novel innovative monoclonal Antibody for patients with certain types of metastatic colorectal cancer.

The Respiratory team made new inroads for patients with asthma/Chronic Obstructive Pulmonary Disorder (COPD) with products like Seretide and Ventorlin. The "EVOHALER" device continues to create a new mark in the category for patients with asthma with dose counter. The Central Nervous System (CNS) team created new and unique awareness campaigns for patients and physicians in areas like Epilepsy and Bipolar Disorders. "Lamictal" became the 2<sup>nd</sup> largest prescribed brand of Lamotrigine in Epilepsy. The Cardiology team continued to focus on areas like hypertension and dyslipidemia with brands like Benitec, Rosutec, Carzec and Volibris. This team deployed screening camps across the country as a patient awareness initiative to enable physicians and patients to diagnose conditions like dyslipidemia early and thereby improve treatment outcomes.

The Mass Speciality business continued its growth trajectory and "Augmentin" the flagship brand of your Company regained the No. 1 position in the "Amoxy Clav" market, showing a remarkable recovery after it was bought under the NLEM (National List of Essential Medicines List) list and under DPCO 2013 with an annual prescription growth of 46%. Your Company used the opportunity of the price control induced downward correction to improve access to patients and improve outcomes as is evidenced by the growth of prescriptions. The team remains focused to enable Augmentin achieve the status of volume leader in the market and be the highest prescribed brand in the "Amoxy Clav" market. Eltroxin, the Company's flagship therapeutic solution for Thyroid management achieved an annual growth of 5%. Many recent advances in prevention and management of Hypothyrodism need to be translated into practice for Health Care Professionals (HCPs) in Tier 1 and Tier 2 cities.

To help rapid and early diagnosis of Thyroid disorders, your Company undertook several 1:1 Scientific Promotion meetings on "Maternal Thyrodism" and "Translating of Thyroid guidelines". As many as 2600 such meetings took place during the year. The 'One to One' SPMs were a good example in our pursuit of being a patient focused organisation and taking a lead to 'door deliver' knowledge to equip HCPs for appropriate disease management. The Disease Awareness initiative on Congenital Hypothyroidism(CH) was conducted in many cities during the year. Feedback from doctors was encouraging as they believed that the Company is spreading awareness in the society and thus improving the future of children with CH. Ceftum also registered a double digit prescription growth in major specialities areas. The new launch, "Avamys" showed a positive value growth and became No. 6 brand amongst 52 brands in INCS market with a market share of 5.8%.

The key brands in Mass markets like Zinetac, Calpol, Neosporin, Betnesol, Zyloric, Zentel, and Cetzine all have maintained dominant market leadership positions. Brands like Betnesol and Zinetac sell almost double the number of units as compared to total population of the country. Your Company's strategy was to expand the access opportunities to patients by targeting the adjacent and direct category competition and drive unit Sales consistent with the Company's policy of improving access to their medicines to as many patients as possible. The rural initiative is being expanded further which will ensure prescription leadership and support to patients in rural markets.

In the area of preventive healthcare, GSK Vaccines continues to be the No. 1 vaccines Company in the private vaccines market in India. Again, consistent with the Company philosophy of offering access to enable as many patients as possible to use them, a more cost effective presentation of a flagship pneumococcal vaccines in the form of vials was launched which will help protect more kids from pneumococcal diseases which is one of the leading causes of infant mortality in the country. Sudden changes in interpretation of licensing requirements coupled with constraints of supplies from the Parent's facility led to shortages of number of vaccines through the year. Notwithstanding that, the measure of the ability of your Company's vaccines to benefit children and women health is indicated in the healthy growth registered. The vaccines team is gearing up for the launch of the combined MMRV vaccine- the first of its kind to be launched in India in 2016.

Exports recorded a sales turnover of Rs. 6.3 crores for the fifteen months period ended 31<sup>st</sup> March 2015.

### (c) Opportunities, risk, concerns and threats

The health budget of the Government saw an overall decline of 5.7 percent, however, it has announced the move towards Universal Health Assurance with a set of drugs, diagnostics and services to be made free of cost to the population. State governments are expected to play a larger role in pooling resources and taking the health agenda forward. Your Company's early initiative of having a tender focused team should help in supporting this initiative in a small way.

Importantly the Insurance Bill was approved in the Parliament replacing the previous ordinance that increased FDI in the insurance sector to 49% from 26%. The approval in the Parliament brings more certainty to the foreign investor and from a health insurance view point, the potential investment flow and the increase in foreign holding in the insurance ventures can shape the health insurance sector in a faster pace than it used to be before. The strong growth in demand for quality healthcare over the last few years has been driven by the opening of the health insurance sector. Support for this sector will continue to strengthen demand for quality healthcare of pharmaceuticals.

With the expansion of Jan Aushadhi schemes the government is also likely to explore possible legislative changes to increase generic prescription. Whilst there is a positive sentiment in the Pharmaceuticals Industry further guidance is required on formalising and implementing the schemes.

The Drug Price Control Order (DPCO) which had a significant impact on the fortune of your Company in 2013 has resulted in widening the access of medicines of your Company to a larger pool of patients then before and the outlook for continued strong growth continues to remain positive.

#### (d) Regulatory Affairs, Clinical Research, Medical Affairs and Medical Governance

During the year under review, in order to support the commercial availability of new drugs that would benefit and improve the quality of life of Indian patients suffering from various diseases, your Company submitted several applications for New Products in India to the CDSCO (Central Drugs Standard Control Organization), Ministry of Health and Family Welfare, Government of India. After a thorough review of these applications, your Company has received approval for some of these products from CDSCO, which will enable timely access to new and innovative therapeutic options to patients in our country.

Some of the innovator products approved by the regulatory agency in India during the year under review include a biological oncology product of atumumab (Arzerra) for the treatment of patients with refractory or previously untreated chronic lymphocytic leukaemia (CLL), another biological product denosumab 60 mg/ml (Prolia) for treatment of post-menopausal osteoporosis in women as well as male osteoporosis, a line extension for micafungin injection (Mycamine 100 mg) for treatment of systemic fungal infections by candida and aspergillus sp., a new combination vaccine for prophylaxis of measles, mumps, rubella and varicella (MMRV) infections (Priorix Tetra), new indication for panitumumab (Vectibix) for use in first line and second line therapy of colorectal cancer (CRC), new indication for eltrombopag (Revolade) for use in patients with Hepatitis C patients for treatment of thrombocytopenia, new indication for pazopanib (Votrient) for treatment of advanced soft tissue sarcoma, expansion of indication for use of lapatinib (Tykerb) in combination with trastuzumab for treatment of metastatic breast cancer, expansion of label of varicella vaccine (Varilrix) to include 2-dose vaccination schedule



and expansion of label of pneumococcal vaccine (Synflorix) to include catch up schedule for infants as well as vaccination schedule for pre-term infants. All these new products and indications approved for the Company during the year under review will be beneficial to Indian patients.

GlaxoSmithKline continues to be committed to Research and Development of medicines that will improve the quality of life of people around the world and truly make a difference to patients. GlaxoSmithKline conducted clinical studies in infectious diseases, oncology and respiratory diseases. The team has established robust clinical trial processes, with a focus on patient-centricity, in the fast-evolving Indian clinical research landscape. Quality continues to be a priority as demonstrated by a number of successful compliance audits. To strengthen quality of data, the team meticulously reviewed quality checks, simplified systems and processes to ensure compliance to regulations. This will help generate accurate and meaningful data, and ensure that the rights, dignity and safety of patients taking part in our studies are protected.

The Medical Affairs team has provided valuable medical inputs for the development and execution of launch strategy and for supporting the Health Care Physician in treating patients with new medicines such as Vectibix (panitumumab) and new indications for Revolade (Eltrombopag), Votrient (Pazopanib) and Tykerb (Lapatinib). The team played a crucial role in communicating high-quality scientific information to the medical fraternity. It was involved in conducting scientific engagement activities such as advisory board meetings, congress presentations, publications, satellite symposia and provision of evidence-based medical information to healthcare practitioners. The Medical Affairs and the Medical Governance teams ensure that your Company's promotional activities and HCP engagements are consistent with the path breaking global standards which the parent Organisation of your Company is known for and in line with all the applicable guidelines and standard operating practices.

### (e) Internal Control Framework

Your Company conducts its business with integrity and high standards of ethical behaviour, and in compliance with the laws and regulations that govern its business. Your Company has a well-established framework of internal controls in operation, supported by standard operating procedures, policies and guidelines, including suitable monitoring procedures and self-assessment exercises. In addition to external audit, the financial and operating controls of your Company at various locations are reviewed by the Internal Auditors, to report significant findings to the Audit Committee of the Board. The Audit Committee reviews the adequacy and effectiveness of the implementation of audit recommendations including those relating to strengthening the Company's risk management policies and systems. Compliance with laws and regulations is also monitored through a matrix of a well laid down framework which requires individual functions to confirm and report statutory compliances on all laws and regulations concerning their respective functions and which gets integrated with the overall compliance reporting on all laws and regulations for the purposes of review and monitoring by the Audit Committee.

Your Company expects all employees to act transparently, respectfully and with integrity and to put the interests of patients and consumers first at all times. Your Company aims to put these core values at the heart of everything it does and every decision it makes. GSK Code of Conduct and accompanying training, seeks to ensure everyone in your Company understands how to put values into practice. Mandatory training on the Code of Conduct helps our employees gain the confidence to make the right decisions and become familiar with the policies and procedures applicable to their areas of operation, avoid conflicts of interest and report all unethical and illegal conduct. Your Company also has an Anti-Bribery and Corruption (ABAC) programme designed to prevent non-compliance through controls, practical guidance and mandatory training. The programme complies with the principles laid down under US Foreign Corrupt Practices Act and British anti-bribery laws.

Additionally, employees are required to certify on an annual basis whether there have been any transactions which are fraudulent, illegal or violative of the Code of Conduct. Strong oversight and self monitoring policies and procedures demonstrate your Company's commitment to the highest standards of integrity.

The Company has a Risk Management and Compliance Board (RMCB). Risk maps stating the significant business risks, potential consequences and mitigation plans are prepared by

each function and reviewed by the RMCB on a regular basis. Business Continuity Plans are periodically reviewed and tested to enhance their relevance.

Your Company's policies and updated Global Code of Practice for Promotion and Customer Interactions prescribe the nature of practices and prohibits specifically those which are unethical. Your Company is a signatory to the OPPI (Organisation of Pharmaceuticals Producers in India) Code of Marketing Conduct.

#### Vigil Mechanism

Your Company has a Speak Up Programme. The Programme offers people within and outside GSK a range of channels to voice concerns and report misconduct. The Speak Up culture and procedures encourage everyone to raise concerns about potential unethical or illegal conduct and assures confidentiality and protection from retaliation, retribution or any form of harassment to those reporting such concerns. Confidential Speak Up integrity line phone numbers are available to people within and outside GSK. An independent company manages these reporting lines and calls are logged through their central system to ensure integrity of the programme. The Company endeavours to treat all questions or concerns about compliance in a confidential manner, even if the person reporting a question or concern identifies themselves. The Company also has a well laid down process to prevent, take disciplinary action and deter acts of sexual harassment. Your Company has constituted a complaint mechanism and a complaint committee to deal in a timely manner with all instances of sexual harassment and to ensure that no victims or witnesses are victimized or discriminated.

### (f) Human Resources

Your Company, in 2014, has seen progress and focus on various initiatives in the Human Resources function. These have been in the areas of Talent Management, Rewards & Recognitions, Capability Building & Employee Engagement.

In 2014, your Company has placed greater emphasis on 'patient focused selling' and it has become the pioneer in the industry to move away from incentive rewards linked to sales targets for its front line sales force. The new framework encompasses the three areas of capability: Scientific Knowledge, Business Acumen and Customer Engagement. The selling model sits within the Customer Engagement component. In addition to this change, business now is focusing on multi channel marketing to engage with HCPs differently using digital platforms.

In the area of talent management the Leadership and Human Resources team continued to focus on identifying and investing in Talent to build a strong Leadership pipeline. In line with its development framework, differentiated development plans for the individuals identified as talent have been put in place with a 70% focus towards on the job development, 20% towards relationship/coaching and 10% towards formal development/classroom training. Towards enhancing the pipeline of talent the "GMAC – GSK Marketing Accreditation Program" was launched, focusing on an 18 months development plan for high potential Sales Managers. The Company continues to invest in its 'future leaders' programme drawing on fresh talent from leading universities/business schools around the country. Through the launch of its Hi-Potential Frontline Sales development programme, employees who have directly joined the sales force are also being provided the structured cross functional development programme through the 'future leaders programme'.

Your Company's employee engagement initiatives have allowed employees to volunteer in small group activities like the 'Empowerment League' Programme, the PULSE and Orange day programme – a volunteering program encouraging employees to work with identified NGOs on select community service projects. The Pulse project was targeted at giving a different experience to talented individuals allowing them to work full time for three to six months on these projects. Recognition scheme "AAA – Acknowledge, Appreciate & Applaud" continues to motivate and recognize performance and high performance behavior of your Company. In 2014 close to 20% of employees have been recognized through this and other recognition schemes.

Your Company has a commitment to conduct its operations in a responsible manner to protect its employees, the environment and community in which it operates. Extensive work has been carried out in our Nasik site to train and create awareness on Employee Health and



Safety. All employees are responsible for implementing the appropriate controls for effective management of Employee Health Safety (EHS) risks in their respective areas. Your Company has run safety awareness programmes for its sales force relating to safe two wheeler riding. Training programmes like 'Energy for Performance' and 'Personal Resilience' have been run to promote employee health, wellbeing and resilience.

Learning and Development has provided various learning platforms which include classroom and online self learning modules to meet the development need of employees to help build their skills, knowledge & capability. Extensive sales training programmes have also been conducted. Leadership programs continue to be key focus with programs such as – First Line Leader, Leading Delivery to develop high potential employees to take on leadership roles in future.

Your Company also went through a Values Maturity Assessment facilitated by the global team to understand how much do leaders and employees live our values (Transparency, Respect for People, Integrity & Patient Focused). Surveys along with interviews were conducted to hear from employees about values in practice. These results have been shared with employees and specific action plans are being put in place to improve the scores and further embed our values in the organization.

Your Company has been recognized by Fortune India as the Most Admired Company consecutively for the 3<sup>rd</sup> time this year, ranked 19 overall amongst the top 50 & No. 3 in the Drugs, Pharmaceuticals & Healthcare segment.

### (g) Supply Chain

### Manufacturing

India manufacturing operations ended with a positive note in terms of EHS, Quality and product delivery. The Nashik site continues its journey on the roadmap of the long term strategy and has made significant progress in terms of building capability through implementing GPS, recruitment of professionals specifically in Quality, EHS and Manufacturing. Further enhancement of the existing Eltroxin facility in terms of safety standards was completed. Similar initiatives are also being implemented at contract manufacturing units. The Nashik site is ready to launch new products in Creams (Bactroban - 7.5 gms) early next year. Other site initiatives currently on-going are site decongestion plan, serialization requirements and vision system. Manufacturing of ampoules and liquids has been discontinued in December 2014 to be in line with the Company's long term strategy.

The Company is upgrading the Nashik site by investing in infrastructure across all areas with special focus on Good Manufacturing Practices (GMP), Safety and Sustainability. The remediation of the Nashik site is progressing as per plan with significant investments in processes as well as infrastructure.

### New Manufacturing Site

Your Company has decided to create a new Greenfield manufacturing Site at Vemgal, Bangalore. This location has been identified for a number of reasons including amongst others; recognised Pharmaceutical/Biotech hub, availability of skilled staff, located close to the Southern Distribution hub, moderate climate, easy accessibility, availability of State based investment incentives, availability of Government owned land. This new Site is part of the strategic plan to rationalize, streamline and reduce costs in the supply network, whilst increasing capacity to meet the growing demands for important medicines. Quality, safety and compliance are the key drivers for the Project Team along with rigorous cost management and control.

The new site, which represents up to Thousand crores in investment, will be the first Greenfield pharmaceutical site GSK has built across the globe over the past ten years. This site will be 'state of the art' and will be the first factory designed for the new 'GSK Production Systems', whereby it will deliver by first design intent the concepts of zero accidents, defects and waste. The site has been designed with the future in mind; an innovative design will support easy expansion well into the future as the need arises. Initially the site will supply a range of solid dose form products. The site is expected to be operational in 2017. The site will have an installed capacity of more than 9 billion tablets and capsules per year to supply to the Indian market.

### Manufacturing Excellence

Nashik site has embarked into the GSK Production System (GPS) Deployment journey in line with Global Manufacturing and Supply initiative to achieve Zero Accidents, Zero Defects & Zero Waste. Aligned to this objective, the entire site leadership team & target area First Line Leaders along with operators were extensively trained in each standard. They were also mentored by Regional GPS coaches for effective deployment. For 2015, there is an ambitious target to deploy GPS to 50% of direct value stream zones. In addition, Nashik site also conducted overall equipment efficiency diagnostics event for Eltroxin & Ointment Value Streams & the team came up with Kaizens to improve delivery performance while adhering to Safety & Quality requirements.

### End to End Supply Chain & Logistics

The Company has launched a Regional Transformation plan with a special focus on a number of key areas including Core Commercial Cycle, Selling and Distribution Hub, End to End Quality and Portfolio optimization etc. Despite several products coming under price control due to NLEM during the year, the Company ensured supplies of our medicines to the patients.

### (h) Corporate Social Responsibility Initiatives

Healthy communities are the backbone of strong, sustainable societies. As a part of its social development initiatives, your Company continued to improve access to healthcare and support people in vulnerable communities through partnerships. Your Company supported various ongoing social projects and initiated new CSR projects in partnership with not-for-profit organisations successfully touching the lives of 200,000 people across the country during the period.

Your Company supported Niramaya Health Foundation to improve healthcare access by supporting healthcare centres and mobile clinics in the tribal districts of Peth and Trimbak, Nashik and in two slum communities of Rafique Nagar and Shanti Nagar, near the waste dumping grounds of Deonar, Mumbai. At these clinics qualified doctors and paramedics delivered quality healthcare services to over 75,000 underserved people. In addition, the health workers attached to these clinics also raised awareness in the communities on communicable diseases, family planning and preventive healthcare measures. Your Company also supported AmeriCares through product donation for their mobile health clinics, which provided healthcare services to slum populations across Maharashtra.

During the year, your Company continued its support to various organisations working towards cancer care. Your Company's support to Sri Chaitanya Seva Trust has enabled over 40,000 people across 39 villages/slums in Maharashtra and U.P. to access screening and awareness for early detection of cancer. In addition, your Company's support to Indian Cancer Society has provided vocational training with stipend to over 100 cancer patients and has enabled them to continue their treatment through support for their stay at *Dharamshalas*. Your Company also supported St. Jude India Child Care Centres to build a new centre in Mumbai, which provides residential, nutritional, educational and transportation facilities to children affected with cancer and their parents. This centre supported 40 children affected with cancer to complete their treatment and follow-up. Since some cancer cases are not treatable, your Company continued its support to Bangalore Hospice Trust to provide palliative care to over 5,000 cancer patients through home based and facility based care.

Your Company continued its partnership with the Institute for Indian Mother and Child to provide medical support, nutritional supplements, counselling and monitoring of pregnant, lactating, new mothers and children below 5 years in West Bengal. During the year, your Company extended support to Society for Nutrition, Education and Health Action to run a women's OPD in Kalwa hospital, Thane, which provided counselling, legal and other support interventions for survivors of domestic violence. The project addressed 253 cases of domestic violence, of which 56 were satisfactorily resolved and others are under resolution. Your Company has also taken steps to address the entire continuum of care for newborn survival, from facility based newborn care to community based newborn care. Your Company has chosen to work in high burden districts in Rajasthan and Madhya Pradesh and aims to reduce the neonate mortality significantly over the next few years.



Your Company continued its support to projects to address the healthcare needs of the differently abled – The Paraplegic Foundation in Mumbai provided residential, therapy and nutritional care to over 70 orthopaedically differently abled; The Aured Charitable Trust, Hyderabad, provided early intervention, parents' counselling and auditory and speech therapies to over 45 children with hearing impairment and Sanjeevani Social Welfare Society, Delhi, provided nutritional and educational care to the mentally differently abled.

Your Company sought to address the holistic care of vulnerable children, at risk of child labour, abuse and exploitation by supporting residential care for boys and girls. Your Company's continued support to Pratham shelter homes at Bahraich, Uttar Pradesh and Jodhpur, Rajasthan supported 95 vulnerable boys and the support to Nai Dharti, Patna extended to 70 vulnerable girls.

To promote education related to healthcare, your Company initiated a project to support diploma and degree courses in eye care in partnership with The Medical Research Foundation, Chennai.

Your Company was quick to contribute to the relief operations in Jammu and Kashmir by donating medicines, including anti-inflammatory, antibiotics, antihistaminics, vitamins and minerals to the National Disaster Management Authority. More than 4,50,000 units of medicines were donated and the field teams ensured that the medicines were utilized as per the identified medical need in the region.

### (i) Cautionary Note

Certain statements in the "Management Discussion and Analysis" section may be forwardlooking and are stated as required by applicable laws and regulations. Many factors may affect the actual results, which could be different from what the Directors envisage in terms of future performance and outlook.

### 4. Directors

Mr. Mehernosh Kapadia retired as Director from 30<sup>th</sup> November 2014. Mr. Simon Harford resigned as a Director from 18<sup>th</sup> May 2015. The Board places on record its appreciation of the valuable services rendered by Mr. Kapadia and Mr. Harford during their tenure as Directors and for their contribution to the deliberations of the Board.

The Board of Directors has appointed Mr. Andrew Aristidou as Executive Director & CFO with effect from 1<sup>st</sup> December 2014, in the casual vacancy caused by the resignation of Mr. Mehernosh Kapadia. The Shareholders have approved his appointment by Postal Ballot. Approval to his appointment from Central Government is awaited. The Board has also appointed Mr. Regis Simard as Non-Executive Director with effect from 18<sup>th</sup> May 2015 in the casual vacancy caused by the resignation of Mr. Simon Harford.

In terms of the provisions under Section 149 of the Companies Act, 2013, the Board and Shareholders have approved the appointment of all the existing Independent Directors viz. Mr. R. R. Bajaaj, Ms. A. Bansal, Mr. P. V. Bhide, Mr. N. Kaviratne, Mr. P. V. Nayak, Mr. A. N. Roy and Mr. D. Sundaram for a term for five years from 30<sup>th</sup> March 2015. The Independent Directors have submitted the Declaration of Independence, as required pursuant to Section 149(7) of the Companies Act, 2013, stating that they meet the criteria of Independence as provided in sub-section (6).

Glaxo Group Limited U.K. have rights enshrined in the Articles of Association to appoint Directors not exceeding one-third of the total number of Directors. Accordingly they have appointed four Non-retiring Directors. In terms of the provisions of the Companies Act, 2013, the Independent Directors will be excluded for ascertaining the number of Directors liable to retire by rotation. In view of this Glaxo Group Limited will have right to appoint one third of the retiring Directors and can appoint two Non-retiring Directors. Accordingly, Mr. V. Thyagarajan and Mr. Regis Simard will now be the Directors retiring by rotation and, being eligible, offer themselves for re-appointment.

During the fifteen months period eight Board Meetings were held. The details of which are given in the Corporate Governance Report. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

### **Remuneration Policy and Board Evaluation**

In compliance with the provisions of the Companies Act, 2013 and Clause 49 of the Listing Agreement, the Board of Directors on the recommendation of the Nomination & Remuneration Committee, adopted a Policy on remuneration of Directors and Senior Management. The Remuneration Policy is stated in the Corporate Governance Report.

Performance evaluation of the Board was carried out during the period under review. The details are given in the Corporate Governance Report.

### 5. Related Party Transactions

All related party transactions that are entered into during the fifteen months period were on arms length basis and were in the ordinary course of business. There were no materially significant related party transactions made with the Promoters, Directors or Key Managerial Personnel which may have a potential conflict of interest of the Company at large.

### 6. Directors' Responsibility Statement

Your Directors confirm:

- (i) that in the preparation of the annual accounts, the applicable accounting standards have been followed;
- (ii) that the Directors have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the fifteen months period ended 31<sup>st</sup> March 2015 and of the profit of the Company for that period;
- (iii) that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (iv) that the Directors have prepared the annual accounts on a going concern basis.

### 7. Corporate Governance & Business Sustainability Report

Your Company is part of the GlaxoSmithKline plc group and conforms to norms of Corporate Governance adopted by them. As a Listed Company, necessary measures are taken to comply with the Listing Agreements with the Stock Exchanges. A report on Corporate Governance, along with a Certificate of Compliance from the Auditors, given in Annexure 'B', forms a part of this Report. Further a Business Responsibility Report, describing the initiatives taken by your Company from an environmental, social and governance perspective, given in Annexure 'C', also forms a part of this Report.

### 8. Auditors

M/s. Price Waterhouse & Co Bangalore LLP, Chartered Accountants (Firm Registration No. 007567S/S-200012), the Statutory Auditors of the Company, will hold office until the conclusion of the ensuing Annual General Meeting and are eligible for re-appointment as per Section 139 of the Companies Act, 2013. Members are requested to re-appoint M/s. Price Waterhouse & Co., Bangalore LLP, Chartered Accountants, as the Auditors of the Company and authorise the Board of Directors to fix their remuneration.

Pursuant to Section 148 of the Companies Act, 2013, the Board of Directors on the recommendation of Audit Committee have appointed M/s. R. Nanabhoy & Co., Cost Accountants for conducting the audit of the cost accounting records maintained by the Company for its Formulations for 2015-2016 and have recommended their remuneration to the members of the Company for their ratification at the ensuing Annual General Meeting.



### 9. General

The particulars relating to conservation of energy, technology absorption and foreign exchange earnings and outgo are given in Annexure 'A' forming part of this Report. The particulars of employees required to be furnished under Section 217(2A) of the Companies Act, 1956, read with the rules thereunder, forms part of this Report. However, as per the provisions of Section 219(1) (b) (iv) of the Companies Act, 1956, the reports and accounts are being sent to all the Shareholders of the Company excluding the statement of particulars of employees. Any Shareholder interested in obtaining a copy may write to the Company Secretary at the Registered Office of the Company. Further, attached to the accounts of the Company are the Report and Audited Accounts of Biddle Sawyer Limited a, subsidiary company.

### 10. Employees

The Directors express their appreciation for the contribution made by the employees to the significant improvement in the operations of the Company and for the support received from all other stakeholders, including shareholders, doctors, medical professionals, customers, suppliers and business partners.

The Board and the Management of your Company are indeed appreciative of the substantial support being received from GSK plc the parent organization in providing new healthcare solutions which are products of its discovery labs and the technology improvements which benefits your Company immensely.

### 11. Disclaimer

The Ministry of Corporate Affairs vide its Circular No. 8/2014 dated 4<sup>th</sup> April 2014 clarified that the financial statements and the documents required to be attached thereto, the Auditor's and Boards' Report in respect of the financial year under reference shall continue to be governed by the relevant provisions of the Companies Act, 1956 schedules and rules made thereunder. Accordingly, whilst the financial statements and the Auditor's Report as aforesaid are prepared as per the requirements of the Companies Act, 1956, the Company as a good governance practice has provided the information to the extent possible in the Directors' Report as per the Companies Act, 2013.

On behalf of the Board of Directors D. S. Parekh Chairman

Mumbai, 18<sup>th</sup> May 2015

### Annexure 'A' to the Directors' Report

### Conservation of Energy:

Nashik Site has undertaken various initiatives for energy conservation in the year 2014 & 2015 that resulted in reduced energy consumption by 212430 units, with several initiatives like HVAC upgrading, (including replacement of 5 Air handling units), rationalization of compressed air consumption, cooling towers and other systems. At the same time, there has been an impact of additional energy consumption of 349847 units due to additional periods of operation of HVAC and increased areas covered under Air handling systems for maintaining room temperature conditions in various areas (like sterile ampoules). This has resulted in an overall increase in Energy consumption by 137417 units.

The site is working on various options of reducing energy consumption in 2015, including conversion to biomass for boiler, consumption and controls optimisation for HVAC systems, boiler and water reduction.

### Power and fuel consumption:

			Fifteen Months period ended	Year ended 31 <sup>st</sup> December
			31 <sup>st</sup> March 2015	2013
1.	Electricity			
	(a) Purchased units	KWH'000	17,873.63	14,816.70
	Total amount	Rs. Lacs	1,422.84	1,213.15
	Rate / Unit	Rs.	7.96	8.19
	(b) Own generation			
	(i) Through DG			
	Units	KWH'000	48.28	38.82
	Units/Itr of HSD		3.12	1.76
	Cost per unit	Rs.	15.96	30.23
	(ii) Coal		NA	NA
2.	Furnace Oil, LDO & LSHS			
	Quantity	KL	1,267.81	938.22
	Total amount	Rs. Lacs	569.41	428.81
	Average rate	Rs./KL	44,912.75	45,704.86

### Consumption per unit of production:

		Fifteen Months Period		Year e	nded
	_	ended 31 <sup>st</sup> I	March 2015	31 <sup>st</sup> Decen	nber 2013
		Chemicals	Formulations	Chemicals	Formulations
		(Incl. Bulk	Per Million	(Incl. Bulk	Per Million
		Drugs)	Packs	Drugs)	Packs
		Per Tonne		Per Tonne	
Electricity	(Units)	-	95,967	-	79,657
Furnace Oil, LDO & LSHS	Kltrs	-	6.81	-	5.25
Natural Gas	Th.NM3	-	_	-	-

#### Research and Development (R&D):

The Company R&D unit, namely Pharmaceutical Research & Development (PR&D) is approved by Department of Science and Industrial Research, Government of India.

### Pharmaceutical Research and Development (PR&D), Nashik

During the year, Pharmaceutical R&D has been restructured, resized and reshaped to align to Global Technical functional principle and to site value stream model and created more headspace & technical capability to support the Site and Regional Supply Chain demand.

Pharmaceutical R&D has transferred the in-house developed Branded Generics Losartan Tablet product to F268 site in Pakistan, with successful Bio-Equivalent study by following GSK standard "BGx Blue Print" approach. PR&D has led the implementation of standard global business process such as, Technical Risk Assessment (TRA) and Product control strategy (PCS) & standard work translated to the shop floor for number of key products at the Nashik site. In addition, Process Robustness Diagnostic



has been completed for Eltroxin tablets range of products and output of the same is being implemented for enhancing the process capability and reducing waste. PR&D has provided vital support to resolve the challenges to handle chemical exposure risk in Eltroxin & beta area through risk assessment of process and equipment change.

The department undertook a number of Product transfer activities (23) and completed by applying Global Technical Transfer blue print process, and through product transfer performance management principles. PR&D also, led the procurement material source change initiatives for API and Excipients (26 alternate source change projects) through MRA (Material Risk Assessment) process and successfully implemented most of them and supported to avoid potential stock outs situations.

The Company continues to be privileged to have access to various research databases used worldwide and to latest technologies developed by GlaxoSmithKline Group.

### Important milestones achieved by PR&D:

- Transferred the in-house developed Branded Generics Losartan products for emerging markets, with successful Bioequivalent study completed.
- Process Robustness has been implemented for Eltroxin range products, and has resulted in
  positive outcome with respect to reduction in the cost of waste disposal and increase in process
  capability. Technical Risk assessment has been completed for key products and product control
  strategy and standard has been translated to shop floor.
- Successfully transferred 23 products by applying Technology Transfer blue print process through Product transfer performance management principles and standard ways of working.
- Manufacturing capacity enhancement completed for Betnovate-C product.
- Significant stock outs has been avoided, by successfully implementing 26 alternate new sources by applying GSK Standard business process of material risk assessment.
- Supported Greenfield Site in India from Scheme design, continuous manufacturing process as well batch process perspective to cater the increased demand/patient requirement.

### Future Plans:

- Introduction of new pack size for Bactroban and T-Bact Cream products.
- Introduction of new strengths for Eltroxin Tablets.
- Product Lifecycle Management implementation for key products.
- Support to new Eltroxin facility/Derms facility/Site Master Plan projects.
- Continue support to new Greenfield project team to implement latest technology like continuous manufacturing processes.
- Support Project Secure through material risk assessment for alternate source development.
- Technical capability build within South Asia to support regional strategy and increased business demand and expectation.
- Roll out of the process robustness diagnostic program to reduce waste.

#### Expenditure on R&D:

•									Rs. Lakhs
Capital							 	 	88.30
Recurring							 	 	219.35
Total							 	 	307.65
Total R&D	otal R&D expenditure as a percentage of turno						 	 	0.10%

GSK plc, the parent organization of your Company, is one of the biggest investors in R&D to bring new products and vaccines to the market. Your Company has been a beneficiary of this significant investment in R&D and it is the effort of the parent organization which has enabled your Company to bring a number of new drugs to market since inception.

### Technology Absorption, Adaptation and Innovation

The Nashik Site is focused on the immediate need to complete remediation in 2015 to ensure sustainable capability and performance in Safety, Quality, Service and Cost. A continued focus is being placed on the development of our people to Build Capability in line with the expectations for the future. A number of key programmes of work will be implemented over the next 1-3 years:

- Finalize remediation of the Nashik Site in 2015.
- Introduction of new strengths for Eltroxin Tablets in 2015.
- Identify and work on various opportunities in pack redesign, configuration, barcoding and serialization.
- Drive process robustness diagnostic to reduce the waste.

### Foreign Exchange Earnings and Outgo

- (1) Exports amounted to Rs. 631 lakhs for the fifteen months period ended 31st March 2015
- (2) Total Foreign Exchange used and earned during the 15 months period includes, the foreign exchange outgo of Rs. 76809 lakhs (which includes amounts spent on import of raw and packing materials and finished goods aggregating to Rs. 41754 lakhs and Dividend payment of Rs. 31764 lakhs) as compared to Rs. 53804 lakhs in the year 2013. The foreign exchange earned was Rs. 6993 lakhs mainly on account of exports and clinical research and data management as compared to Rs. 6255 lakhs in the twelve months period ending 31<sup>st</sup> December 2013. Details have been given in Notes 41 to 44 to the financial statements.



### Annexure 'B' to the Directors' Report Report on Corporate Governance

(Pursuant to Clause 49 of the Listing Agreements entered into with the Stock Exchanges)

### 1. Company's philosophy on Code of Governance

The Company's philosophy of Corporate Governance is aimed at assisting the management of the Company in the efficient conduct of its business and in meeting its obligations to stakeholders, and is guided by a strong emphasis on transparency, accountability and integrity. For several years, the Company has adopted a codified Corporate Governance Charter, which is in line with the best practice, as well as meets all the relevant legal and regulatory requirements. All Directors and employees are bound by Code of Conduct and the associated standards of Conduct that sets out the fundamental standards to be followed in all actions carried out on behalf of the Company.

### 2. Board of Directors

### Composition and size of the Board

The present strength of the Board is fourteen Directors. The Board comprises of Executive and Non-Executive Directors. The Non-Executive Directors bring independent judgement in the Board's deliberations and decisions. Four Directors, including the Managing Director, are Executive Directors. There are ten Non-Executive Directors, of which, seven are Independent Directors.

Glaxo Group Limited, U.K., have rights enshrined in the Articles of Association relating to the appointment and removal of Directors not exceeding one-third of the total number of retiring Directors.

Board meetings and attendance

Seven Board meetings were held during the fifteen months period ended 31<sup>st</sup> March 2015 and the gap between two Board meetings did not exceed four months. The annual calendar of Board meetings is agreed upon at the beginning of each year.

The information as required under Annexure I to Clause 49 of the Listing Agreement is made available to the Board. The agenda and the papers for consideration at the Board meeting are circulated at least three days prior to the meeting. Adequate information is circulated as part of the Board papers and is also made available at the Board meeting to enable the Board to take informed decisions.

Sr. No. Date of Meeting **Board Strength** No. of Directors present 14 11 18th February 2014 1. 2. 17th April 2014 13 14 З. 12th August 2014 14 13 6<sup>th</sup> November 2014 4. 14 14 5. 10th January 2015 14 12 6. 12th February 2015 14 11 20th March 2015 7. 14 12

The dates on which meetings were held are as follows:

 Attendance of each Director at the Board meetings and last Annual General Meeting (AGM) and the number of companies and committees where he is a Director/Member (as on the date of the Directors' Report)

Name of Director	Category of Directorship	Number of Board Meet- ings attended	Atten- dance at the last AGM held on 17 <sup>th</sup> April 2014	Number of Director- ships in other companies (excluding Director- ships in foreign and private companies)	Numk mand comn position in o comp	nittee ns held ther
					Chairman	Member
Mr. D. S. Parekh Chairman	Non-Executive	7	Yes	8	1	2
Mr. V. Thyagarajan Vice-Chairman	Non-Executive	5	Yes	1	Nil	2
Dr. H. B. Joshipura Managing Director	Executive	7	Yes	2	Nil	Nil
Mr. A. A. Aristidou (w.e.f. 01.12.2014)	Executive	3	N.A.	1	Nil	Nil
Mr. R. R. Bajaaj	Non-Executive & Independent	6	Yes	2	Nil	Nil
Ms. A. Bansal	Non-Executive & Independent	5	Yes	2	Nil	Nil
Mr. P. V. Bhide	Non-Executive & Independent	7	Yes	6	1	4
Mr. S. Harford (upto 18.05.2015)	Non-Executive	5	Yes	Nil	Nil	Nil
Mr. M. B. Kapadia (upto 30.11.2014)	Executive	4	Yes	1	Nil	Nil
Mr. N. Kaviratne	Non-Executive & Independent	6	Yes	1	Nil	Nil
Mr. R. Krishnaswamy	Executive	7	Yes	1	Nil	Nil
Mr. P. V. Nayak	Non-Executive & Independent	6	Yes	1	Nil	1
Mr. A. N. Roy	Non-Executive & Independent	5	Yes	2	2	Nil
Mr. R. C. Sequeira	Executive	7	Yes	2	Nil	Nil
Mr. R. Simard (w.e.f. 18.05.2015)	Non-Executive	N.A.	N.A.	Nil	Nil	Nil
Mr. D. Sundaram	Non-Executive & Independent	6	Yes	4	1	1

• Directors with materially significant related party transactions, pecuniary or business relationship with the Company

There have been no materially significant related party transactions, pecuniary transactions or relationships between the Company and its Directors that may have potential conflict with the interests of the Company at large.



### • Details of Directors being appointed/re-appointed

As per the Statute, two-third of the Directors excluding the Independent Directors should be retiring Directors. One-third of these retiring Directors are required to retire every year and if eligible, these Directors qualify for re-appointment.

Mr. V. Thyagarajan and Mr. R. Simard retire by rotation at the ensuing Annual General Meeting and being eligible offer themselves for re-appointment.

A brief resume of Directors appointed/eligible for re-appointment along with the additional information required under Clause 49 (VI) (A) of the Listing Agreement is as under:

### Mr. A. Aristidou

Andrew has a B.Sc. (Hons.) in Economics and Accountancy from Loughborough University in the United Kingdom. He is also a Fellowship Chartered Accountant of the ICAEW (Institute of Chartered Accountants in England and Wales) having qualified with Price Waterhouse in London.

Andrew has most recently been Head of Corporate Development, Europe and International Finance for ViiV Healthcare in London. He first joined GlaxoSmithKline in 1999 holding a number of roles of increasing importance including North Andes Finance Director based in Venezuela, as well as Corporate Development Director and Southern & Eastern European Finance Director. In 2007 he joined Gilead Sciences as International Director of Financial Planning and Analysis before rejoining the GlaxoSmithKline Group in 2010 into the ViiV Healthcare organization.

Andrew is appointed as Executive Director and Chief Financial Officer of the Company from 1<sup>st</sup> December 2014. He is a Director of Biddle Sawyer Limited which forms part of the GlaxoSmithKline Group Companies in India. He does not hold any shares of the Company.

### Mr. V. Thyagarajan

Mr. Thyagarajan who is a Bachelor of Technology from the Indian Institute of Technology, Delhi and an MBA from the Indian Institute of Management, Ahmedabad, joined Glaxo India in 1970. He held a series of senior positions culminating in his appointment as Managing Director of the Company in 1994. In between, Mr. Thyagarajan worked for Glaxo Wellcome in Europe, Middle East, Africa and Asia Pacific. At the time of the merger between Glaxo Wellcome and SmithKline Beecham in 2001, he was appointed as Vice-President, South Asia and concurrently as Vice-Chairman and Managing Director of the Company in India. He is the Vice-Chairman of the Company since January 2003. Mr. Thyagarajan is a Director of TCS Limited and is a member of their Audit Committee and Stakeholders Relationship Committee. He does not hold any shares of the Company.

### Mr. R. Simard

Regis Simard is a Mechanical Engineer and also holds an MBA. He has held senior management positions in the Electronic and Tech industries (Sony, Konica-Minolta) and in the Healthcare and Medical devices industries (Covidien) where he gained valuable experience working with Japan, China, UK and France. Regis joined GlaxoSmithKline in 2005 as Site Director at the GSK France plant at Notre Dame de Bondeville, then moved to GSK House UK to lead the Antibiotics and Latina Manufacturing cluster. In January 2011, Regis was appointed Commercial Partner Emerging Markets & Asia Pacific.

In January 2013 Regis was appointed to his current role as Senior Vice-President/ Head of Europe and EMAP Pharma Supply. Regis is a member of both the Supply Chain Executive team and the Emerging Markets Commercial leadership team. Diverse and broad experience of manufacturing, leadership to distil complexity and convey clear strategic direction, high levels of commerciality and customer/patient focus, incisive and focused when it comes to driving delivery, strong interest in people development. He is appointed as Non-Executive Director of the Company w.e.f. 18<sup>th</sup> May 2015. He does not hold any shares of the Company.

### 3. Audit Committee

• Terms of Reference

The terms of reference of this Committee are wide enough to cover the matters specified for audit committee under Section 177 of the Companies Act, 2013 and Clause 49 of the Listing Agreements with Stock Exchanges and are as follows:

- a) Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statements are correct, sufficient and credible;
- b) to review with Management the financial statements at the end of a quarter, half year and the annual financial statements and Auditor's report thereon before submission to the Board for approval, focusing particularly on:
  - matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of Sub-Section 3 of Section 134 of the Companies Act, 2013;
  - ii) changes, if any, in accounting policies and practices and reasons for the same;
  - iii) major accounting entries involving estimates based on the exercise of judgment by management;
  - iv) significant adjustments made in the financial statements arising out of audit findings;
  - v) compliance with listing and other legal requirements relating to financial statements;
  - vi) disclosure of any related party transactions; and
  - vii) qualifications in the draft audit report.
- c) to consider the appointment, re-appointment, remuneration and terms of appointment of the statutory auditors, any questions of resignation or dismissal and payment to statutory auditors for any other services rendered by them;
- d) to discuss with the statutory auditors before the audit commences, about the nature and scope of the audit as well as post-audit discussion to ascertain any area of concern (in absence of management where necessary);
- e) reviewing, with management, performance of statutory and internal auditors, adequacy of the internal control systems and discuss the same periodically with the statutory auditors, prior to the Board making its statement thereon;
- f) reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- g) discussion with internal auditors on any significant findings and follow up thereon;
- reviewing the findings of any internal investigation by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
- to look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- j) to review the functioning of the Whistle Blower mechanism;
- k) to approve any subsequent modification of transactions of the Company with related parties; (explanation): The term "related party transactions" shall have the same meaning as provided in Clause 49 (VII) of the Listing Agreement;
- I) to scrutinize inter-corporate loans and investments;
- m) to evaluate internal financial controls and risk management systems;
- n) to do valuation of Undertakings or assets of the Company, wherever it is necessary;
- to approve appointment of CFO (i.e., the Whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
- p) to review the external auditor's audit reports and presentations and management's response;



- q) to ensure co-ordination between the internal and external auditors, and to request internal audit to undertake specific audit projects, having informed management of their intentions;
- r) to consider any material breaches or exposure to breaches of regulatory requirements or of ethical codes of practice to which the Company subscribes, or of any related codes, policies and procedures, which could have a material effect on the financial position or contingent liabilities of the Company;
- s) to review policies and procedures with respect to directors' and officers' expense accounts, including their use of corporate assets, and consider the results of any review of these areas by the internal auditors or the external auditors;
- t) to review with the management, the statement of uses/application of funds raised through an issue (public issue, rights issue, preferential issue, etc), the statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
- u) the Auditors of the Company and the Key Managerial Personnel shall have right to be heard in the meetings of the Audit Committee when it considers the Auditor's Report but shall not have the right to vote;
- v) to consider other topics, as defined by the Board;
- w) to carry out any other function as is mentioned in the terms of reference of the Audit Committee;
- x) <u>Review the following information by Audit Committee</u>:

The Audit Committee shall mandatorily review the following information:

- i) Management discussion and analysis of financial condition and results of operations;
- ii) Statement of significant related party transactions (as defined by the audit committee), submitted by management;
- iii) Management letters/letters of internal control weaknesses issued by the statutory auditors;
- iv) Internal audit reports relating to internal control weaknesses; and
- v) The appointment, removal and terms of remuneration of the Chief Internal Auditor shall be subject to review by the Audit Committee.
- Details of the composition of the Audit Committee and attendance of Members are as follows:

Eight Audit Committee meetings were held in the fifteen months period ending 31<sup>st</sup> March 2015. The Committee comprises of Independent and Non-Executive Directors and their meetings were held on 18<sup>th</sup> February 2014, 17<sup>th</sup> April 2014, 12<sup>th</sup> August 2014, 11<sup>th</sup> September 2014, 6<sup>th</sup> November 2014, 10<sup>th</sup> January 2015, 12<sup>th</sup> February 2015, and 20<sup>th</sup> March 2015.

Name	Designation	Category of Directorship	Attendance out of eight meetings held
Mr. D. Sundaram	Chairman	Non-Executive & Independent	7
Mr. D. S. Parekh	Member	Non-Executive	8
Mr. V. Thyagarajan	Member	Non-Executive	5
Mr. P. V. Nayak	Member	Non-Executive & Independent	7
Mr. N. Kaviratne	Member	Non-Executive & Independent	6
Mr. P. V. Bhide	Member	Non-Executive & Independent	8

The Managing Director, the Finance Director, other Executive Directors, the Statutory Auditors and Internal Auditors are invitees to the meetings.

The Chairman of the Audit Committee, Mr. D. Sundaram, was present at the Annual General Meeting of the Company held on 17<sup>th</sup> April 2014.

### 4. Nomination & Remuneration Committee

### • Terms of Reference

The terms of reference of this Committee cover the matters specified for Nomination & Remuneration Committee in the Companies Act, 2013 and Listing Agreements with Stock Exchanges and are as follows:

a) Formulation of the criteria for determining qualification, positive attributes and independence of a Director and they recommend to the Board a policy, relating to the remuneration of the Directors, Key Managerial Personnel and other employees;

While formulating the policy as mentioned above the Committee will ensure that;

- 1) the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors of the quality required to run the Company successfully;
- 2) relationship of remuneration to performance is clear and meets appropriate performance benchmarks and;
- 3) remuneration to Directors, Key Managerial Personnel and senior management involves a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the Company and its goals.
- b) Formulation of criteria for evaluation of Independent Directors and the Board;
- c) Devising a policy on Board diversity;
- d) Identifying persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal and shall carry out evaluation of every Director's performance. The Company shall disclose the remuneration policy and the evaluation criteria in its Annual Report.

Name	Designation	Category of Directorship
Mr. N. Kaviratne	Member	Non-Executive & Independent
Mr. D. S. Parekh	Member	Non-Executive
Mr. A. Bansal	Member	Non-Executive & Independent
Mr. V. Thyagarajan	Member	Non-Executive

During the period under review, the Committee met on 20<sup>th</sup> March 2015 and the Chairman and all the members other than Ms. Bansal attended the meeting.

### Remuneration Policy & evaluation criteria

The Nomination & Remuneration Committee has adopted Policy on Remuneration to the Senior Management and Executive Directors of the Company and a Policy on composition, diversity and evaluation of the Board of the Company. The major terms of both policies are as under:

Remuneration Policy for Senior Management & Executive Directors

- a) All the Executive Directors including the Managing Director is paid such remuneration as may be mutually agreed between the Company and the Executive Directors within the overall limits prescribed under the Companies Act, 2013 and is subject to approval by the Shareholders of the Company.
- b) The remuneration for the Senior Management and Executive Directors mainly consists of salary, benefits, perquisites and retirement benefits which are fixed components and the annual performance bonus and long term incentives are the variable components.



- c) When determining remuneration levels individual's role, experience and performance and independently sourced data for relevant comparator groups are considered.
- d) Ordinarily, salary increases will be broadly in line with the average increases for the wider GlaxoSmithKline workforce. However, increases may be higher to reflect a change in the scope of the individual's role, responsibilities or experience.
- e) The overall performance of the individual is a key consideration when determining salary increases.

### Performance Evaluation of Board

In terms of the provisions of the Companies Act, 2013 and the Listing Agreement the Board has carried out the annual performance evaluation of its own including the various Committee and the individual Directors with a detailed questionnaire covering various aspects of Board's functioning like composition of Board and its Committees, Board culture, performance of specific duties and obligations.

A similar process with a separate exercise was carried out to evaluate the performance of the individual Directors including the Chairman of the Board, who were evaluated on parameters such as the independence of judgement, level of engagement, their contribution, safeguarding the interests of the Company and minority shareholders.

#### Remuneration to Non-Executive Directors

- a) Independent and Non-Executive Directors other than Directors who are in the employment of the GlaxoSmithKline Group Companies are entitled for a sitting fees of Rs.10,000 per meeting of Board or Committee thereof. They will also be entitled for reimbursement of expenses incurred for participation of the Board or Committee Meetings.
- b) All the Directors of the Company, excluding the Managing Director, Directors in the whole-time employment of the Company and Directors who are in the employment of the GlaxoSmithKline Group Companies are entitled to receive commission collectively up to a maximum of one percent of the net profits of the Company computed in accordance with the provisions of the Companies Act, 2013 for such period and such amount as may be decided by the Board of Directors from time to time.
- c) The Independent Directors of the Company are not entitled to participate in the Stock Option Scheme of the Company, if any, introduced by the Company.

The details of the remuneration paid to the Directors during the fifteen months period ending 31<sup>st</sup> March 2015 are given below:

(Rs. in lakhs)

Executive Directors	Salary	Perfor- mance Bonus	Perquisites and Allowances	Contribution to Provident Fund and Superannuation Fund	Total
Dr. H. B. Joshipura	265.84	44.27	112.94	71.78	494.83
Mr. M. B. Kapadia (upto 30.11.2014)	98.52	15.96	221.93	26.60	363.01
Mr. R. C. Sequeira	72.95	6.20	51.29	19.70	150.14
Mr. R. Krishnaswamy	71.22	21.97	71.02	19.23	183.44
Mr. A. Aristidou (w.e.f. 01.12.2014)	27.20	0.00	37.12	4.36	68.68

(Rs. in lakhs)

Independent Directors and Non-Executive Directors	#Commission	Sitting Fees	Total
Mr. D. S. Parekh	8.75	5.70	14.45
Mr. R. R. Bajaaj	6.25	1.10	7.35
Mr. P. V. Nayak	6.25	1.80	8.05
Mr. N. Kaviratne	6.25	1.40	7.65
Mr. V. Thyagarajan	6.25	1.20	7.45
Mr. D. Sundaram	6.25	2.00	8.25
Mr. P. V. Bhide	6.25	1.80	8.05
Mr. A. N. Roy	6.25	1.40	7.65
Ms. A. Bansal	6.25	3.40	9.65

# payable in 2015

Notes:

- a) The agreement between the Company and each of the Executive Directors is for a period of five years (three years in case of Mr. R. C. Sequeira and Mr. A. Aristidou) or normal retirement date, whichever is earlier. Either party to the agreement is entitled to terminate the agreement by giving not less than three months notice (six months notice in case of Managing Director) in writing to the other party.
- b) Performance bonus is paid as a percentage of salary, based on certain pre-agreed performance parameters.
- c) Presently, the Company does not have a scheme for grant of its stock options either to the Executive Directors or employees. However, the Executive Directors and some senior employees of the Company are entitled to Stock Options, Share Value Plan and Performance Share Plan of GlaxoSmithKline plc. During the period, in addition to the above, Dr. H. B. Joshipura, Mr. M. B. Kapadia Mr. R. C. Sequeira and Mr. R. Krishnaswamy were paid an amount of Rs. 1,20,41,451 Rs. 2,11,11,721 Rs. 32,52,178 and Rs. 27,53,599 respectively under the GlaxoSmithKline plc. Share Value Plan.
- d) None of the Directors other than those listed above are paid remuneration.
- e) Mr. D. S. Parekh and Mr. P. V. Nayak hold 612 and 576 shares of the Company, respectively. None of the other Non-Executive Directors hold any shares of the Company.

### 5. Stakeholders Relationship Committee

In compliance with the provisions of Section 178 of the Companies Act, 2013 and clause 49 of the Listing Agreement, the Board has renamed the existing Shareholders/Investors Grievance Committee as Stakeholders Relationship Committee. The composition of the Investors/ Shareholders Grievance Committee is as follows:

Name of the Member	Designation	Category of Directorship
Mr. D. S. Parekh	Chairman	Non-Executive
Mr. R. R. Bajaaj	Member	Non-Executive & Independent
Mr. P. V. Bhide	Member	Non-Executive & Independent
Dr. H. B. Joshipura	Member	Executive

During the period under review, the Committee met on 10<sup>th</sup> January 2015 and the Chairman and all the members attended the meeting.



### Name, designation and address of the Compliance Officer:

Mr. Ajay Nadkarni Company Secretary Dr. Annie Besant Road Mumbai-400 030 Phone: (022) 2495 9433 Fax: (022) 2498 1526 Email: ajay.a.nadkarni@gsk.com

### The complaints received during the period are as follows:

Correspondence in the nature of complaints from	Q1	Q2	Q3	Q4	Q5	Total
Securities and Exchange Board of India	7	6	7	6	6	33
Stock Exchanges	1	_	_	_	_	1
Shareholders	3	5	1	_	_	9
Total	11	11	8	6	6	43

During the period, the above complaints regarding non-receipt of shares sent for transfer demat queries and non-receipt of dividend warrants and annual reports were received from the shareholders, all of which have been resolved. The Company had no transfers pending at the close of the financial year.

### 6. General Body Meetings

• Details of the location of the last three Annual General Meetings (AGM) and details of the resolutions passed or to be passed by Postal Ballot:

Date	Year	Venue	Time
17 <sup>th</sup> April 2014	2013	Birla Matushri Sabhagar,	3.00 p.m.
16 <sup>th</sup> April 2013	2012	19, Sir Vithaldas Thackersey Marg, Marine Lines,	3.00 p.m.
10 <sup>th</sup> April 2012	2011	Mumbai – 400 020	3.00 p.m.

All the resolutions, including special resolutions set out in the respective Notices were passed by the shareholders. No Postal Ballots were used for voting at the meeting held during the year under review.

No Special Resolution is proposed to be passed through Postal Ballot at the forthcoming Annual General Meeting.

### 7. Disclosure

- The Board of Directors has approved a policy for related party transactions and has been uploaded on the Company's website (http://www.gsk-india.com/investor-Policies.html). There are no materially significant related party transactions entered into by the Company with its Promoters, Directors or Management, their subsidiaries or relatives etc. that may have potential conflict with the interests of the Company at large. All transactions entered with the related parties during the fifteen months period ended 31<sup>st</sup> March 2015 as mentioned under the Companies Act, 2013 and Clause 49 of the Listing Agreements were in the ordinary course of business and at on arms length pricing basis. The Register of Contracts containing the transactions in which Directors are interested is placed before the Board regularly for its approval.
- Transactions with related parties are disclosed in Note 47 to the financial statements in the Annual Report.
- During the last three years, there were no strictures or penalties imposed by either the Securities and Exchange Board of India or the Stock Exchanges or any statutory authority for non-compliance of any matter related to the capital markets.

- The Codes of Conduct applicable to all Directors and employees of the Company have been posted on the Company's website. For the year under review, all Directors and senior management personnel of the Company have confirmed their adherence to the provisions of the said Codes.
- The Company has put in place a whistle blower mechanism pursuant to which employees of the Company can raise their concerns relating to fraud, malpractice or any other activity or event which is against the interest of the Company and no one has been denied access to the Audit Committee.

### 8. Means of Communication

- The quarterly and half-yearly results are published in widely circulating national and local dailies such as The Economic Times and Business Standard, in English and Maharashtra Times, in Marathi. These are not sent individually to the shareholders.
- The Company's results and official news releases are displayed on the Company's website. The Company's website address is www.gsk-india.com. The Company had one meeting with and made a presentation to institutional investors and analysts once during the year.
- The Management Discussion and Analysis Report forms a part of this Annual Report.

### 9. General Shareholder Information

•	AGM: Date, Time and Venue	31 <sup>st</sup> July 2015 at 3.00 p.m. at Birla Matushri Sabhagar, 19, Sir Vithaldas Thackersey Marg, Marine Lines, Mumbai - 400 020
•	Financial Year	<ul> <li>i) April to March</li> <li>ii) First Quarter Results – Last Week of July</li> <li>iii) Half-yearly Results – First week of November</li> <li>iv) Third Quarter Results – Second Week of February 2016</li> <li>v) Results for the year ending 31<sup>st</sup> March 2016</li> </ul>
•	Date of Book Closure	- May 2016 25 <sup>th</sup> July 2015 to 31 <sup>st</sup> July 2015 (both days inclusive)
•	Dividend Payment date(s) Listing on Stock Exchange	On or after 1 <sup>st</sup> August 2015 The Stock Exchange, Mumbai, and the National Stock Exchange of India Limited. The Company has paid the listing fees for the

Stock Code – Physical 500660 on The Stock Exchange, Mumbai GLAXO on The National Stock Exchange

period 1<sup>st</sup> April 2014 to 31<sup>st</sup> March 2015.


Demat ISIN Number for NSDL and CDSL INE 159A01016




 High/low of market price of the Company's shares traded along with the volumes on The Stock Exchange, Mumbai and on the National Stock Exchange during the year January 2014 to March 2015 is furnished below:

Period		BSE			NSE	
	High (Rupees)	Low (Rupees)	Volume (No. of Shares)	High (Rupees)	Low (Rupees)	Volume (No. of Shares)
January 2014	3015.00	2945.00	78905	3005.00	2960.45	1806224
February 2014	3049.00	2966.05	388799	3049.00	2965.15	1710669
March 2014	3054.40	2433.00	525842	3054.50	2426.30	1603870
April 2014	2608.00	2405.00	46737	2619.95	2412.25	281060
May 2014	2573.00	2370.00	35092	2573.90	2365.00	249751
June 2014	2550.00	2351.60	31815	2549.00	2421.80	143657
July 2014	2580.00	2435.60	25856	2575.05	2440.50	220249
August 2014	2528.00	2400.00	20312	2530.00	2450.00	124855
September 2014	2834.00	2465.00	322868	2842.00	2470.00	794951
October 2014	2907.55	2650.60	26388	2913.95	2645.00	186881
November 2014	2980.00	2681.00	59458	2984.00	2692.00	294131
December 2014	3242.00	2859.40	124005	3247.00	2850.10	309926
January 2015	3550.00	3070.00	136473	3550.00	3080.00	432972
February 2015	3434.00	3051.55	54961	3445.00	3056.05	199711
March 2015	3479.00	3050.00	135213	3498.00	3060.00	422675

### • Share Performance of the Company in comparison to BSE Sensex





### • Share Performance of the Company in comparison to NSE S&P CNX Nifty

Equity History

Particulars	No. of shares issued (of Rs. 10 each)	Year of issue
Original Holding	18,00,000	1924
Bonus Issue	2,00,000	1947
Bonus Issue	10,00,000	1962
Bonus Issue	24,00,000	1968
Public Issue	18,00,000	1969
Bonus Issue	36,00,000	1977
Bonus Issue	36,00,000	1980
Public cum Rights Issue	56,00,000	1983
Shares allotted to Group Companies	44,89,800	1993
Rights Issue	53,97,700	1993
Bonus Issue	2,98,87,500	1995
Shares issued pursuant to the amalgamation of SmithKline Beecham Pharmaceuticals (India) Limited (SBPIL) with the Company in the ratio of one share of the Company for every two shares of SBPIL issued on 30 <sup>th</sup> November 2001	1,47,00,000	2001
Shares issued pursuant to the amalgamation of Burroughs Wellcome (India) Limited (BWIL) with the Company in the ratio of fourteen shares of the Company for every ten shares of BWIL issued on 29 <sup>th</sup> October 2004	1,28,47,546	2004
Buy back of equity shares	(26,19,529)	2005
Total	8,47,03,017	

 List of top ten shareholders of the Company other than Glaxo Group Limited, GlaxoSmithKline Pte. Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleton Investment Limited who hold 35.99%, 24.33%, 6.94%, 3.97% and 3.77% shares respectively.

Sr. No.	Name of Shareholder	% to Equity
1.	Life Insurance Corporation of India	5.61
2.	General Insurance Corporation of India	1.16
3.	Aberdeen Global Indian Equity (Mauritius) Limited	0.74
4.	The Oriental Insurance Company Limited	0.66
5.	Vanguard emerging markets Stock Index Fund, A Serie's of Vanguard International Equity Index Fund	0.42
6.	Birla Sun Life Trustee Company Private Limited A/c Birla Sun Life MNC Fund	0.30
7.	SBI Life Insurance Co. Ltd.	0.24
8.	The India Fund Inc.	0.23
9.	Birla Sun Life Trustee Company Private Limited A/c. Birla Sun Life Frontline Equity Fund	0.21
10.	Vanguard Total International Stock Index Fund	0.17



The distribution of shareholding as on 31.03.2015 is as follows:

No. of Equity Shares held	Folios	%	Shares	%
Up to 25	29932	30.71	337890	0.40
26 to 50	15512	15.92	668850	0.79
51 to 100	19748	20.26	1608891	1.90
101 to 500	29701	30.48	5756156	6.80
501 to 1000	1788	1.83	1255610	1.48
1001 to 10000	707	0.73	1434116	1.69
10001 and above	65	0.07	73641504	86.94
Grand Total	97453	100.00	84703017	100.00

• Shareholding pattern as on 31.03.2015 is as follows:

Category	No. of Shares	%
Glaxo Group Limited, U.K.	30485250	35.99
GlaxoSmithKline Pte Limited, Singapore	20609774	24.33
Eskaylab Limited, U.K.	5880000	6.94
Burroughs Wellcome International Limited, U.K.	3360000	3.97
Castleton Investment Limited	3192238	3.77
Insurance Companies, FIs & Banks	6976395	8.24
FIIs, NRIs, OCBs	1767763	2.09
Mutual Funds	870295	1.03
Domestic Companies	828735	0.98
Resident Individuals	10491176	12.39
Others	241391	0.28
Total	84703017	100.00

• Registrars and Share Transfer Agents

Share transfer system

Karvy Computershare Private Limited Unit: GlaxoSmithKline Pharmaceuticals Limited Karvy Selenium Tower B, Plot No. 31 & 32 Gachibowli, Financial District, Nanakramguda, Serilingampally Hyderabad, Telangana – 500032 Tel. No.: 040 67162222 Fax No.: 040 - 23001153 Contact Person(s): Mr. M. R. V. Subrahmanyam / Mr. Premkumar Nair

- Email: einward.ris@karvy.com
- All the transfers received are processed by the Registrars and Share Transfer Agents and are approved by the Share Transfer Committee, which normally meets twice in a month or more depending on the volume of transfers. Share transfers are registered and returned within maximum of 18 days from the date of lodgment if documents are complete in all respects.
- Dematerialisation of shares and liquidity 97.25% of the paid-up capital has been dematerialised as on 31.03.2015. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleton Investment Limited, who jointly hold 75.00% of the paid-up share capital of the Company, hold their shares in the dematerialised form.

•	Outstanding GDRs/ADRs/ Warrants or any convertible instruments conversion date and likely impact on equity	Not issued.
•	Plant locations	The Company's plant is located at Nashik (Maharashtra).
•	Address for correspondence	Shareholders' correspondence should be addressed to the Company's Registrars and Share Transfer Agents at the address mentioned above.
		Shareholders may also contact Mr. Ajay Nadkarni, Company Secretary, at the Registered Office of the Company for any assistance.
		Tel. Nos. 2495 9595 Extension 433/434
		Email: ajay.a.nadkarni@gsk.com
		Shareholders holding shares in electronic mode should address all their correspondence to their respective Depository Participant.

### Auditors' Certificate regarding compliance of conditions of Corporate Governance

To the Members of GlaxoSmithKline Pharmaceuticals Limited

We have examined the compliance of conditions of Corporate Governance by GlaxoSmithKline Pharmaceuticals Limited, for the 15 months ended March 31, 2015, as stipulated in Clause 49 of the Listing Agreements of the said Company with stock exchanges in India.

The compliance of conditions of Corporate Governance is the responsibility of the Company's management. Our examination was carried out in accordance with the Guidance Note on Certification of Corporate Governance (as stipulated in Clause 49 of the Listing Agreement), issued by the Institute of Chartered Accountants of India and was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned Listing Agreements.

We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

> For Price Waterhouse & Co., Bangalore LLP Firm Registration Number: 007567S/S-200012 **Chartered Accountants**

Mumbai May 18, 2015

Priyanshu Gundana Partner Membership Number 109553

### Declaration by the CEO under Clause 49 of the Listing Agreement regarding adherence to the Code of Conduct

In accordance with Clause 49 sub-clause I (D) of the Listing Agreement with the Stock Exchanges, I hereby confirm that, all the Directors and the Senior Management personnel of the Company have affirmed compliance to their respective Codes of Conduct, as applicable to them for the fifteen months period ended March 31, 2015.

for GlaxoSmithKline Pharmaceuticals Limited



### Annexure 'C' to Directors' Report Business Responsibility Report

(Pursuant to Clause 49 of the Listing Agreements entered into with the Stock Exchanges)

### About our report

GSK, a science-led global healthcare company makes a range of innovative products that are used by millions of people around the world. While our primary contribution is to develop new products that improve people's health, we also create value as a global company by making direct and indirect economic and social contributions in the countries we operate. As a science-led global healthcare company, we have the opportunity to improve the health and well-being of millions of people around the world. GSK contributes to improving health by developing innovative products and supporting disease prevention. The Company's mission drives us to make a difference to the lives of millions of people with our commitment to effective healthcare solutions.

Environmental sustainability is a priority for GSK. At GSK, we look at practices that incorporate sustainability into the core of our business to make innovative products. We believe it is possible to grow our business and to provide access to healthcare products to an increasing number of people across the world while protecting the resources we need for the future.

Investing in our people and communities helps us to ensure the long-term sustainability of our business. Our employment practices are designed to help us create the right workplace culture in which all employees feel valued, respected, empowered and inspired. All business decisions are guided by our core values. We expect all employees to commit to transparency, show respect for people, demonstrate the highest integrity and be patient focussed. Business responsibility is about our commitment to be open and transparent about our business activities.

Our Business Responsibility Report follows the Securities and Exchange Board of India's (SEBI) proposal and is in accordance with the key principles articulated in the 'National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business'.

This report provides details of the Company in the areas of sustainability, human rights, stakeholder engagement, employees' wellbeing, corporate social responsibility, proactive advocacy and inclusive growth.

### Governance and Accountability

Good governance and transparent reporting are part of our commitment to be open about our business activities. Our commitment to responsible, values-based business underlies everything we do including our sales and marketing practices, policy activities and our relationships with suppliers and how we conduct and report our research. We have a strong values-based culture and our actions are supported by robust policies and compliance process.

We conduct our business in an ethical way. We also engage stakeholders directly to understand and prioritise the issues that are important to them. Our policies on ethics, bribery and corruption cover all our stakeholders including suppliers, vendors, contractors, NGOs, etc.

As a global corporation, we have a common Code of Conduct across the globe. This code sets out fundamental standards for all employees and is supported by the Employees Guide to Business Conduct, which helps employees take ethical decisions and emphasises our values: transparency, respect for people, integrity, and focus on the patient. Every employee at the time of induction is taken through the code of business conduct and specialised training is provided for employees working in manufacturing, sales and marketing, where there are additional requirements. In addition, all managers and employees are required to confirm their compliance with the code on an annual basis. At GSK, we ensure that everything we do is guided by our commitment to our values and our commitment to being in compliance with the regulations within which we have to operate. The foundations of these commitments are laid out in our Code of Conduct and each employee must take personal responsibility to abide by our Code.

We market our prescription medicines and vaccines to healthcare professionals, hospitals and government. Our policies and updated Global Code of Practice for Promotion and Customer Interactions prescribe the nature of our practises. This code as the name suggests is applicable worldwide. Our regional and local policies, standard operating procedures and other codes provide additional guidance to employees. Additionally, we are also a signatory to the OPPI (Organisation of Pharmaceutical Producers of India) code of marketing conduct.

We have a culture of disclosure which is enabled by a strong grievance redressal body and supportive ecosystems. In addition specific process and mechanisms to facilitate reporting of unethical conduct or violation of laid down guidelines as well as for protection of employees that report unethical conducts are in place. All GSK employees have access to whistle blowing that they can use to get advice, and to report suspected cases of misconduct anonymously if required.

### Sustainable products and services

Sustainability in our business is critically important if we are to deliver continued innovation and success to our products. Our commercial success depends on growing a diverse business, creating innovative new products people value, making them widely accessible and operating efficiently. In the process, we are able to grow our business and provide patients, consumers, employees, our shareholders and society. Through our wide range of products and services, GSK touches the lives of millions of patients every day. In the best interest of the patient, we endeavour to work with responsible suppliers who adhere to the same quality, social and environmental standards as GSK and its affiliates worldwide. At GSK, the interest of the patient is of prime importance at every stage from development until the final distribution.

Being a global company, most of GSK's products are approved by major international regulators like USFDA, UKMHRA. Besides, there are mandatory regulatory approvals required in India endorsing the safety of the product.

The Company's commitment is to reduce carbon footprint by 25% in 2020 and have a carbon neutral value chain by 2050; to reduce our water impact across the value chain by 20% and reduce our operational waste by 50% by 2020. With our long-term goal for our value chain to be carbon neutral by 2050, we look at every process associated with our products – from sourcing raw materials to manufacturing, use and product disposal. The Company conducts audits both internally as well as with vendors of the manufacturing process, usage of materials, etc.

A significant proportion of ingredients for our products and packaging material are sourced locally from third party manufacturers belonging to Micro, Small and Medium Enterprises. A qualified team is in place to build capacity and capability, to educate and raise the standard of these vendors.

To ensure compliance to GSK's standards, all these vendors have to go through the GSK Audit and Approval process which are based on global guidelines. Our quality team trains and guides these vendors to ensure that they have infrastructure, facilities, systems and controls in line with GSK's global standards. Additionally, periodic quality audits are held to ensure that the manufacturing processes both internally as well as with vendors remain compliant with our quality standards. These are over and above the specific quality checks with respect to each batch of finished products as well as input raw materials.

One of our products Seretide Evohaler was changed to include environment friendly CFC free propellant.

As our products are related to health, we cannot recycle our products. However, there is a mechanism to segregate the waste given to the authorised vendor for recycling wherever appropriate. We reuse some paper packaging material.

We follow the GMP guidelines with respect to our product packaging. Our products have barcodes and other features to avoid pilferage. Also to validate the authenticity of the product, we have started a unique QR code for one of our products. This feature was introduced as an anti-counterfeit measure.

### Employees' wellbeing

Our employment practices are designed to create a work place culture in which all GSK employees feel valued, respected, empowered and inspired to achieve their goals. There has been a special focus in the areas of Talent Management, Rewards & Recognitions, Capability building and Employee Engagement.

We are committed to being an employer of choice and believe in investing in developing our employees at every level from people in their early careers to those in senior management positions. Identifying and investing in talent to build a strong Leadership pipeline has and will remain a key area of employee development. To enhance the talent pipeline "GMAC – GSK Marketing Accreditation Program" was launched focusing on an 18 month development plan for high potential Sales Managers. We continue to invest in our 'future leaders' programme drawing on fresh talent from leading universities/business schools around the country.



Our aim is to create an inclusive and engaging working environment that empowers employees to contribute and help us achieve our strategic business objectives. Our policies for employees conform to GSK global standards as well as comply with local laws. We are committed to making employment at GSK accessible to people with disabilities as well as make it lucrative for women to be part of our talent force. To read more about our recruitment process log on to – http://www.gsk.com/careers/why-gsk.html

We are committed to conducting our operations in a responsible manner to protect our employees, the environment and community in which we operate. Extensive work has been carried out in our Nashik site as well as amongst our sales force to train and create awareness on Employee Health and Safety. Training programmes like 'Energy for Performance' and 'Personal Resilience' have also been organised to promote employee health, wellbeing and resilience.

GSK places it's Values (Transparency, Respect for People, Integrity and Patient Focus) at the heart of everything it does. In keeping with this approach, the Company undertook a Values Maturity Assessment to understand whether leaders and employees walk the talk. Based on the results, specific action plans are being implemented to improve the scores and further embed values within the organisation.

Emotional and mental health and the ability to cope with pressure are just as important as physical well being. Our Wellness and Wellbeing programme provides GSK employees with access to counselling and mental health and guidance. We have a total of 4657 employees working with GSK of which 564 are women employees and 4 permanent employees with disability.

There are four recognised unions – Selling Area (zonal) based – North, East, West and South to address the grievances of employees working in the field. The union in the West selling area also represents the workers working at Nashik site.

#### Stakeholder engagement

Engagement and dialogue enables us to understand the needs and views of key stakeholders. This engagement and feedback helps us to identify important issues and shape our response in the interest of our shareholders and wider society.

Many of our engagements take place during the routine course of business, in day to day interactions with customers, employees, suppliers and other partners. Besides, we carry out formal and structured engagement, including through meetings, consultations and participation in conferences.

Examples of how we engage with our stakeholders are outlined here.

#### Healthcare professionals (HCPs)

- Sales representative meetings
- Interactions during clinical studies and at conferences
- Engagement with professional organisations

#### Patients

• Market research to understand patient needs

#### Governments and regulators

- Our public policy work.
- Input to policy makers based on our global experience on key issues such as healthcare.

#### Investors

Meetings with investors

#### Employees

- Regular employee surveys
- Consultation with employee representatives on changes to the business

#### Local communities

• Our community development programmes

#### Non-governmental organisations

Partnering in community for Engagement development programmes.

#### Suppliers

- Global and regional supplier review meetings
- Meetings for diverse suppliers

#### **Peer companies**

- Pharmaceutical industry organisation meetings
- Joint projects such as the Pharmaceutical Supply Chain Initiative

#### Human rights

GSK conforms to national laws as well as the global GSK policies. We comply and adhere to all the human rights laws and guidelines of the Constitution of India, national laws and policies and the content of the International Bill of Human Rights.

We have most direct control over human rights in our own operations and aim to act responsibly across all our spheres which includes our employees, suppliers, local communities and society more broadly.

#### Our approach to human rights

**Employees** – Our employment standards cover issues including diversity, equal opportunities, health & safety and protection of employees' human rights.

**Suppliers** – Our Third Party Code of Conduct requires suppliers, contractors and business partners to meet GSK guidelines for ethical standards and human rights. Environmental, Health and Safety (EHS) audits help us identify potential breaches of our human rights clauses.

**Communities** – GSK aims to have good relationships with all the communities around our sites and to operate in ways that do not infringe their human rights.

**Society** – We can have an influence on human rights beyond our own operations. Our efforts to improve access to healthcare support society more broadly to fulfil its right to health.

Read more online - our positions online including:

- Our Human Rights Statement
- GSK on the Convention on Biological Diversity

Search for public policies on www.gsk.com

#### Environment

At GSK, an environmental sustainability strategy is implemented across the entire value chain – from raw materials to product disposal. As we grow our business to bring innovative medicines to people across the world, environment sustainability continues to be a priority and we remain committed to reducing our environmental impact.

Our policy on environment conforms to local laws as well as GSK's global standards. Various initiatives for energy efficiency and renewable energy were undertaken at our Nashik site.

As part of our sustainability initiatives our Nashik site has undertaken various initiatives for energy conservation in the year 2014 and 2015 that have resulted in reduced energy consumption by 212430 units. These include:

- Installation of Energy Meters for all major areas and panels at site, with an energy monitoring system to identify and benchmark area wise energy consumption.
- Undertaking various power saving initiatives to reduce energy consumption, HVAC upgrading, (including replacement of 5 Air handling units), rationalisation of compressed air consumption, cooling towers and other systems. There has been an impact of additional energy consumption of 349847 units due to additional periods of operation of HVAC and increased areas covered under air handling systems for maintaining room temperature conditions in various areas (like sterile ampoules). This has resulted in an overall increase in energy consumption by 137417 units.



 Working on various options to reduce energy consumption in 2015, including conversion to biomass for boiler, consumption and controls optimisation for HVAC systems, boiler and water reduction.

Over and above these measures, there have been continued efforts to monitor noise levels, recycling of waste and monitoring of gaseous emissions from the boiler that have resulted in sustaining a high level of energy efficiency.

The emissions generated by the Company are within limit specified by Maharashtra Pollution Control Board. No showcause notice or warning letter issued by Maharashtra Pollution Control Board. With regard to waste management, our waste is segregated and given to government approved vendors for recycling wherever appropriate. Nashik site runs on zero discharge basis with respect to water. Treated site affluent is used for site gardening.

We publish our positions on our intranet "EHS Manager - Entropy" on the following:

- Climate change
- The impact of climate change on health

Besides, we publish our positions on our website which include:

- Climate change
- Impact of climate change on health
- Genetically modified micro-organisms and EHS
- Pharmaceuticals in the environment
- Ozone depletion and metered-dose inhalers for asthma
- Ozone depleting substances in plant and equipment

#### Public policy and patient advocacy

GSK is a member of various industrial and trade bodies like Confederation of Indian Industries (CII), Bombay Chamber of Commerce and Industries (BCCI), Organisation of Pharmaceutical Producers of India (OPPI) and Pharmaceutical Research and Manufacturers of America (PHRMA). We are a part of various task forces and forums within these chambers and work closely with the industry bodies in devising strategies to improve healthcare in the country as well to provide input to public policy with respect to the same.

#### Inclusive growth

GSK India has a long legacy of giving and partnering with the communities in which we live and operate. We focus on making life-changing, long-term differences in human health by addressing some of the major health-related concerns. We work to fulfill this and other philanthropic efforts, through community-based partnerships. Strong partnerships with community groups are critical, as local organisations have the greatest insights into the needs of their people and the strategies that stand the greatest chances of success.

Among the various CSR projects implemented, we have identified to address the healthcare need of newborn survival. In India, every year over 7.5 lakh children die within the first 28 days. This translates to 27% of world's newborn deaths. What is even more heart breaking is that four out of five newborn deaths result from treatable conditions\*. At GSK, we have partnered with ARTH and CARE to address the entire continuum of care for newborn survival in the high burden districts in Rajasthan and Madhya Pradesh. We have partnered to build capacity of the ASHA workers, train the skilled birth attendants, generate awareness and ensure improved facility based and home based newborn care. Our commitment for project on newborn survival is over INR 3.5 crores to be spent over two years.

We also encourage employee volunteering through programmes such as Orange Day and the PULSE initiative. Orange Day is a day-long employee volunteering initiative wherein our employees volunteer their time with the elderly at old age homes, with children at orphanages, with the youth and with the differently abled. In 2014, over 1,000 employees made a difference by contributing nearly 9,000 volunteering hours. PULSE is a global volunteering initiative that gives an employee a chance to work full-time for a period of 3-6 months with an NGO.

For the 15 month period, your Company's turnover was INR 3253.41 crores and the net profit after tax was INR 471.65 crores. The CSR spend during this period was INR 6.1 crores, which is 1.29 percentage of the net profit after tax.

To read more about our CSR projects and our CSR Policy, log on to – http://www.gsk-india.com/corporate-index.html

\*Source: http://www.searo.who.int/publications/journals/seajph/whoseajphv1i3p279.pdf

#### Patient engagement

Patient is at the core of our business. They are our most important stakeholders. We are constantly seeking new ways of delivering healthcare and making our products available and affordable to people who need them, wherever they live.

In our effort to expand access to our products we have led the industry by adopting a flexible pricing approval to pricing our medicines and vaccines based on a country's ability to pay. This has resulted in significant reduction in prices, representing a good outcome for the patients.

We adhere to national and international standards with respect to product safety and code of engaging with customers.

On our product packaging, we provide all the information as required under the Drugs & Cosmetics Act & Rules.

As on March 31, 2015, from a quality perspective, only seven cases are pending where our response is awaited.

#### Conclusion

Our third Business Responsibility Report discloses details related to our sustainability commitments and management approach across the dimensions for the fifteen months period ended March 31, 2015.

#### Contact

Mr. Raju Krishnaswamy, Executive Director is responsible for implementation of the BR policies.

His details:

DIN No: 03043004 Tel.: +91 22 24959650 Email: raju.x.krishnaswamy@gsk.com

The Company's CIN No: L24239MH1924PLC001151



# Independent Auditors' Report

#### TO THE MEMBERS OF GLAXOSMITHKLINE PHARMACEUTICALS LIMITED

#### **Report on the Financial Statements**

1. We have audited the accompanying financial statements of GlaxoSmithKline Pharmaceuticals Limited (the "Company"), which comprise the Balance Sheet as at March 31, 2015, the Statement of Profit and Loss for the 15 months period from January 1, 2014 to March 31, 2015 (the "period") and Cash Flow Statement for the period then ended, and a summary of significant accounting policies and other explanatory information, which we have signed under reference to this report.

#### Management's Responsibility for the Financial Statements

2. The Company's Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Accounting Standards notified under the Companies Act, 1956 (the "Act") read with the General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

#### Auditors' Responsibility

- 3. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
- 4. An audit involves performing procedures to obtain audit evidence, about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Management, as well as evaluating the overall presentation of the financial statements.
- 5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

- 6. In our opinion, and to the best of our information and according to the explanations given to us, the accompanying financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:
  - (a) in the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2015;
  - (b) in the case of the Statement of Profit and Loss, of the profit for the period ended on that date; and
  - (c) in the case of the Cash Flow Statement, of the cash flows for the period ended on that date.

#### **Report on Other Legal and Regulatory Requirements**

- 7. As required by 'the Companies (Auditor's Report) Order, 2003', as amended by 'the Companies (Auditor's Report) (Amendment) Order, 2004', issued by the Central Government of India in terms of sub-section (4A) of section 227 of the Act [Section 143(11) of the Companies Act, 2013] (hereinafter referred to as the "Order"), and on the basis of such checks of the books and records of the Company as we considered appropriate and according to the information and explanations given to us, we give in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the Order.
- 8. As required by section 227(3) of the Act [Section 143(3) of the Companies Act, 2013], we report that:
  - (a) We have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purpose of our audit;
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
  - (c) The Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
  - (d) In our opinion, the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this report comply with the Accounting Standards notified under the Companies Act, 1956 read with the General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013;
  - (e) On the basis of written representations received from the directors as on March 31, 2015, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2015, from being appointed as a director in terms of clause (g) of sub-section (1) of section 274 of the Act [Section 164(2) of the Companies Act, 2013].

For Price Waterhouse & Co., Bangalore LLP Firm Registration Number: 007567S/S-200012 Chartered Accountants

> Priyanshu Gundana Partner Membership Number: 109553

# Annexure To Independent Auditors' Report

Referred to in paragraph 7 of the Independent Auditors' Report of even date to the members of GlaxoSmithKline Pharmaceuticals Limited on the financial statements as of and for the 15 months period ended March 31, 2015

- i. (a) The Company is maintaining proper records showing full particulars, including quantitative details and situation, of fixed assets, other than the situation of certain plant and equipment, furniture and office equipment, for which the situation recorded, is the location of the Company's different establishments.
  - (b) The fixed assets of the Company have been physically verified by the Management according to a phased programme designed to cover all the items over a period of three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, a portion of the fixed assets has been physically verified by the Management during the period and no material discrepancies have been noticed on such verification.
  - (c) In our opinion, and according to the information and explanations given to us, a substantial part of fixed assets has not been disposed off by the Company during the period.
- ii. (a) The inventory excluding stocks with third parties has been physically verified by the Management during the period. In respect of inventory lying with third parties, these have substantially been confirmed by them. In our opinion, the frequency of verification is reasonable.
  - (b) In our opinion, the procedures of physical verification of inventory followed by the Management are reasonable and adequate in relation to the size of the Company and the nature of its business.
  - (c) On the basis of our examination of the inventory records, in our opinion, the Company is maintaining proper records of inventory. The discrepancies noticed on physical verification of inventory as compared to book records were not material.
- iii. In our opinion, and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the Company and the nature of its business for the purchase of inventory and fixed assets and for the sale of goods and services. Further, on the basis of our examination of the books and records of the Company, and according to the information and explanations given to us, we have neither come across, nor have been informed of, any continuing failure to correct major weaknesses in the aforesaid internal control system.
- iv. According to the information and explanations given to us, there have been no contracts or arrangements that need to be entered in the register maintained under Section 301 of the Act [Section 189 of the Companies Act, 2013].
- v. In our opinion, and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of Sections 58A and 58AA of the Act [Section 73, 74, 75 and 76 of the Companies Act, 2013] and the rules framed there under.
- vi. In our opinion, the Company has an internal audit system commensurate with its size and the nature of its business.
- vii. We have broadly reviewed the books of account maintained by the Company in respect of products where, pursuant to the rules made by the Central Government of India, the maintenance of cost records has been prescribed under clause (d) of sub-section (1) of Section 209 of the Act [Section 148(1) of the Companies Act, 2013], and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- viii. (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally regular in depositing undisputed statutory dues in respect of service tax, sales tax and professional tax, though there has been a slight delay in a few cases, and is regular in depositing undisputed statutory dues, including provident fund, investor education and protection fund, employees' state insurance, income tax, wealth tax, customs duty, excise duty and other material statutory dues, as applicable, with the appropriate authorities.
  - (b) According to the information and explanations given to us and the records of the Company examined by us, there are no dues of wealth tax and custom duty which have not been deposited on account of any dispute. The particulars of dues of income tax, sales tax, service tax and excise duty as at March 31, 2015 which have not been deposited on account of a dispute, are as follows:

Name of the statute	Nature of dues	Amount* (Rs. in lakhs)	Period to which the amount relates	Forum where the dispute is pending	
The Income-tax Act, 1961	Income-tax 39,24.88 including interest, as applicable		Several demands pertaining to Assessment Years 2005-2006 to 2008-2009 and 2011-12.	Appellate Authority – up to Commissioner's level	
		2,86.79	Assessment years 1990-1991 and 1999-2000.	Tribunal	
The Central Sales Tax Act, 1956 and Local Sales Tax Acts	Sales-tax including interest and penalty, as applicable	30,47.89	Several demands pertaining to the period 1983-1984 and 1988 to 2014.		



Name of the statute	Nature of dues	Amount* (Rs. in lakhs)	Period to which the amount relates	Forum where the dispute is pending	
		56,43.11 (include Rs. 52,18.20 Lakhs not deposited due to a stay order)	Several demands pertaining to the period 1990-1991, 1998-1999, 1999-2000 and 2001-2002 to 2008-2009.	Tribunal	
		83.08	Several demands pertaining to the period 1990-1991, 1999-2000 and 2001-2002	The High Court of Judicature at Allahabad, Lucknow, and Kerala	
		42.14	Demand pertaining to the period 1993-1994 and 1995	Supreme Court	
The Finance Act, 1994	Service tax	1,29.20	January 2001 to December 2002	Customs, Excise & Service Tax Appellate Tribunal	
The Central Excise Act, 1944	Excise duty including interest and penalty, as applicable	25.60	Several demands pertaining to the periods March 1992 to March 1994, July 1995 to January 1998.	Appellate Authority– up to Commissioner's level	
		18,09.71	Several Demands Pertaining to the Period October 1994 to January 1995, September 1996 to September 2002, November 2003 to December 2011, September 2012 to March 2013.	Customs, Excise & Service Tax Appellate Tribunal (CESTAT)	
		1,60.83	Demand pertaining to 1977-1980 and 1988-1991.	The High Court of Judicature at Bombay	

\*Net of amounts paid including under protest.

- ix. The Company has no accumulated losses as at the end of the period and it has not incurred any cash losses in the period ended on that date or in the immediately preceding financial year.
- x. According to the records of the Company examined by us and the information and explanation given to us, the Company has not defaulted in repayment of dues to any financial institution or bank or debenture holders as at the balance sheet date.
- xi. According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that the no funds raised on short-term basis have been used for long-term investment.
- xii. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud on or by the Company, noticed or reported during the period, nor have we been informed of any such case by the Management.
- xiii. Matters specified in clauses (iii), (xii), (xiii), (xiv), (xv), (xvi), (xviii), (xix) and (xx) of paragraph 4 of the Order do not apply to the Company.

For Price Waterhouse & Co., Bangalore LLP Firm Registration Number: 007567S/S-200012 Chartered Accountants Priyanshu Gundana Partner Membership Number: 109553

Mumbai, May 18, 2015

# Balance Sheet as at 31st March, 2015

	uu	ui U	100	mai	<b>O</b> 11,	2010		Rupees i	n lakhs
							Note No.	As at 31st March, 2015	As at 31st December, 2013
EQUITY AND LIABILITIES									
SHAREHOLDERS' FUNDS									
Share Capital							 2	84,70.30	84,70.30
Reserves and Surplus							 3	1766,96.51	1932,48.71
NON-CURRENT LIABILITIES									
Long-term borrowings							 4	2,62.60	3,60.50
Other long-term liabilities							 5	5,28.86	4,96.72
Long-term provisions							 6	270,95.87	241,04.04
CURRENT LIABILITIES									
Trade payables							 7	305,88.63	278,01.24
Other current liabilities							 8	131,55.53	86,22.07
Short-term provisions							 9	668,41.92	518,83.23
						TOTAL		3236,40.22	3149,86.81
ASSETS									
NON-CURRENT ASSETS									
Fixed assets									
Tangible assets							 11	123,05.96	100,07.18
Capital work-in-progres	S							115,22.44	61,86.01
Non-current investments							 12	47,66.97	47,66.97
Deferred tax assets (net)							 13	82,91.43	92,10.65
Long-term loans and advan	ces						 14	288,31.03	232,87.39
Other non-current assets							 15	14,04.03	13,55.38
CURRENT ASSETS									
Current investments							 16	_	10,00.25
Inventories							 17	368,85.59	342,39.73
Trade receivables							 18	100,31.79	96,39.32
Cash and bank balances							 19	1898,01.75	2027,13.61
Short-term loans and advan	ces						 20	119,74.32	69,91.37
Other current assets							 21	78,24.91	55,88.95
						TOTAL		3236,40.22	3149,86.81
									1

#### The accompanying notes are an integral part of these financial statements

This is the Balance Sheet referred to in our report of even date

For Price Waterhouse & Co., Bangalore LLP	For and on behalf of the Board	ł		
Firm Registration No. 007567S / S-200012 Chartered Accountants	Chairman	D. S. PAREKH DIN: 9078		
Priyanshu Gundana Partner	Managing Director	Dr. H. B. JOSHIPURA DIN: 274288		
Membership No. 109553	Executive Director	A. A. ARISTIDOU DIN: 7034424		
	Company Secretary	A. A. NADKARNI		
Mumbai, 18th May, 2015	Mumbai, 18th May, 2015			



# Statement of Profit and Loss for the 15 months ended 31st March, 2015

									l l
							Note No.	15 months ended 31st March, 2015	12 months ended 31st December, 2013
Sale of products								3358,54.49	2593,39.32
Excise duty								(105,13.51)	(73,22.08)
Sale of products (net)								3253,40.98	2520,17.24
Other operating revenue								34,16.82	25,97.50
Revenue from operations							29	3287,57.80	2546,14.74
Other Income							30	198,67.17	200,96.86
				TOTAL RE	VENUE			3486,24.97	2747,11.60
Cost of materials consumed	d						31	726,73.46	538,56.74
Purchases of traded goods							32	779,89.39	670,00.11
Changes in inventories of fi	nished go	oods, worl	k-in-progre	ess and tra	aded good	ds	33	(1,38.69)	(50,74.71)
Employee benefits expense	)						34	493,02.23	362,04.85
Depreciation expense							11	25,35.25	19,88.14
Other expenses							35	662,12.90	504,19.90
			Т	OTAL EXP	PENSES			2685,74.54	2043,95.03
Profit before exceptional ite	ms and ta	ax						800,50.43	703,16.57
Exceptional Items							40	(51,88.14)	26,15.46
Profit before Tax								748,62.29	729,32.03
Tax expense:									
Current tax								267,78.49	233,00.35
Deferred tax								9,19.22	(5,56.56)
Net Profit								471,64.58	501,88.24
	1	Lathata an							
Earnings per equity share (		i diluted)	(HS.)				50	FF 00	50.05
Face value Rs. 10 each							50	55.68	59.25

#### The accompanying notes are an integral part of these financial statements

This is the Statement of Profit and Loss referred to in our report of even date

For Price Waterhouse & Co., Bangalore LLP	For and on behalf of the Board				
Firm Registration No. 007567S / S-200012 Chartered Accountants	Chairman	D. S. PAREKH DIN: 9078			
Priyanshu Gundana Partner	Managing Director	Dr. H. B. JOSHIPURA DIN: 274288			
Membership No. 109553	Executive Director	A. A. ARISTIDOU DIN: 7034424			
	Company Secretary	A. A. NADKARNI			
Mumbai, 18th May, 2015	Mumbai, 18th May, 2015				

### GlaxoSmithKline Pharmaceuticals Limited

# Cash Flow Statement for the 15 months ended 31st March, 2015

Rupees in lakhs

	IST March, 2015					nupees	
	,					15 months ended 31st March, 2015	12 months ended 31st December, 2013
a.	CASH FLOW FROM OPERATING ACTIVITIES						
	Profit before taxation and exceptional items					800,50.43	703,16.57
	Adjustments for :						
	Provision written back as no longer required					(42.99)	(42.32)
	Profit on sale / disposal of tangible assets (net)					(58.00)	(1,64.92)
	Interest income					(197,20.45)	(173,48.20)
	Dividend income					(107,20.10)	(25,00.00)
	Interest expense					46.90	(20,00.00)
	Depreciation					25,35.25	19,88.14
	Unrealised foreign currency (loss) / gain						(4.18)
	Operating profit before working capital changes					628,11.14	522,78.18
	Adjustments for :						
	Inventories					(26,45.86)	(60,35.44)
	Trade Receivables					(3,92.47)	19,50.48
	Short-term loans and advances					(49,82.95)	(12,88.58)
	Other current assets					(1.57)	8.66
	Other non-current assets					(48.65)	(39.88)
	Long-term loans and advances					(3,01.88)	(13,35.36)
	Trade payables					27,87.39	42,82.35
	Provisions					7,81.57	29,97.11
	Other current liabilities					17,55.09	(3,73.05)
	Other long-term liabilities					32.14	
	Cash generated from operations					597,93.95	524,44.47
	Direct taxes paid (net of refunds)					(250,13.31)	(242,05.33)
	Cash flow before exceptional items					347,80.64	282,39.14
	Exceptional items:						
	Payments under Voluntary Retirement Scheme					(4,74.75)	(3,90.28)
	Non recurring expenses for rationalisation initiatives					(2,18.16)	(11,06.72)
	Net cash generated from operating activities				Α	340,87.73	267,42.14
b.	CASH FLOW FROM INVESTING ACTIVITIES						
	Purchase of tangible fixed assets					(163,12.28)	(58,22.17)
	Sale of tangible fixed assets					73.24	6,50.90
	Sale of property (Exceptional item)					—	21,41.02
	Expenses relating to sale of property (Exceptional it					-	(23.21)
	Sale / redemption of current investments Investment in bank deposits (having original maturit	 v more i	 han 3 mo	 nthe)		10,00.01 (276,250.00)	44,90.90 (214,975.00)
	Redemption / Maturity of bank deposits (having original maturity	-				(210,200.00)	(214,975.00)
	3 months)					291,450.00	213,675.00
	Interest received					178,00.86	171,60.10
	Dividend received						25,00.00
	Net cash from investing activities				в	177,61.83	197,97.54

### GlaxoSmithKline Pharmaceuticals Limited



## Cash Flow Statement (Contd.)

								Rupees	in lakhs
								15 months ended 31st March, 2015	12 months ended 31st December, 2013
c.	CASH FLOW FROM FINANCING	ACTIVITIE	ES						
	Repayments of borrowings							(1,02.69)	(45.09)
	Interest paid							(46.90)	(33.09)
	Dividend paid							(422,14.19)	(421,37.90)
	Tax on distributed profit							(71,97.64)	(67,92.08)
	Net cash used in financing activ	rities					с	(495,61.42)	(490,08.16)
	Net increase/(decrease) in cash	and cash	equival	ents			(A+B+C)	22,88.14	(24,68.48)
	Cash and cash equivalents as at	1st January	v, 2014 (o	opening b	alance)			112,38.61	137,07.09
	Cash and cash equivalents as at 3	31st March	, 2015 (c	losing bal	ance)			135,26.75	112,38.61
	Net increase/(decrease) in cash	and cash	equival	ents				22,88.14	(24,68.48)
NO	TES:								
1.	Cash and cash equivalents include	e:							
	Cash on hand							0.76	1.67
	Term deposits with original m	naturity peri	iod of les	ss than thi	ee months	s		60,02.00	23,54.00
	Balances with banks							54,97.77	69,94.03
	Unclaimed dividend accounts	S						20,26.22	18,88.91
	Total cash and cash equivale	nts						135,26.75	112,38.61
2.	Other Bank balances include:								
	Term deposits with original maturit	ty period o	f more th	nan three	months			1762,75.00	1914,75.00

3. The Cash Flow Statement has been prepared under the "Indirect Method" as set out in Accounting Standard-3 on Cash Flow Statements, notified under sub-section (3C) of Section 211 of the Companies Act, 1956.

This is the Cash Flow Statement referred to in our report of even date

For Price Waterhouse & Co., Bangalore LLP	For and on behalf of the Board					
Firm Registration No. 007567S / S-200012 Chartered Accountants	Chairman	D. S. PAREKH DIN: 9078				
Priyanshu Gundana Partner	Managing Director	Dr. H. B. JOSHIPURA DIN: 274288				
Membership No. 109553	Executive Director	A. A. ARISTIDOU DIN: 7034424				
	Company Secretary	A. A. NADKARNI				
Mumbai, 18th May, 2015	Mumbai, 18th May, 2015					

# Notes to the Financial Statements for the 15 months ended 31st March, 2015

#### **GENERAL INFORMATION**

GlaxoSmithKline Pharmaceuticals Limited ('the Company') is a public limited company and is listed on the BSE Ltd. (Bombay Stock Exchange) and the National Stock Exchange of India Ltd. (NSE). The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

#### **1** STATEMENT OF ACCOUNTING POLICIES

#### (a) Basis for preparation of accounts

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on an accrual basis. Pursuant to circular 15/2013 dated September 13, 2013 read with circular 08/2014 dated April 4, 2014, till the standards of accounting or any addendum thereto are prescribed by Central Government in consultation and recommendation of the National Financial Reporting Authority, the existing Accounting Standards notified under the Companies Act, 1956 shall continue to apply. Consequently, these financial statements have been prepared to comply in all material aspects with the accounting standards notified under Section 211(3C) [Companies (Accounting Standards) Rules, 2006, as amended] and other relevant provisions of the Companies Act, 1956.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Revised Schedule VI to the Companies Act, 1956. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

#### (b) Tangible Fixed Assets and Depreciation

Fixed assets are stated at cost of acquisition, including any attributable cost for bringing the asset to its working condition for its intended use, less accumulated depreciation. Interest on borrowings attributable to new projects is capitalised and included in the cost of fixed assets as appropriate.

Depreciation is provided on the straight-line method over the useful life of the assets as under:

Buildings	29 years
Plant and Equipment other than Gas Installations	10 years
Gas Installations	6 years
Personal Computers and Laptops	3 years
Other Computer Equipment	4 years
Furniture and Fixtures	10 years
Office Equipment	10 years
Vehicles	4 years

Depreciation on capital projects of Rs. 100 lakhs or more is provided pro-rata for the number of months availability for use and for other assets for the full year. Depreciation on sale / disposal of assets is provided pro-rata up to the end of the month of sale / disposal.

An asset purchased on or after 1st April, 1993 and where the actual cost does not exceed Rs. 5,000 (other than on turnkey contracts) is depreciated at the rate of 100%.

Leasehold land is not amortised.

Leasehold improvements are amortised over the period of the lease.

Assets that have been retired from active use and held for disposal and Assets identified and evaluated technically as obsolete and held for disposal are stated at lower of book value and estimated net realisable value / salvage value, and are shown separately in the Financial Statements.

Capital work-in-progress comprises cost of fixed assets that are not yet ready for their intended use at the year end.

(c) Impairment of Assets

Assessment is done at each Balance Sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is



made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased.

#### (d) Investments

Long term investments are stated at cost, except where there is a diminution in value other than temporary in which case the carrying value is reduced to recognise the decline. Current investments are stated at lower of cost and fair value. The premium on account of investments in debentures / bonds and Government of India Securities held as long-term investments is recognised over the life of the security.

Investments that are readily realisable and are intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non current investments.

#### (e) Provisions and Contingent Liabilities

A provision is recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources will be required to settle the obligation and in respect of which a reliable estimate can be made. A provision is not discounted to its present value and is determined based on the best estimate required to settle the obligation at the year end date. These provisions are reviewed at each year end date and adjusted to reflect the best current estimate.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

#### (f) Inventories

Inventories are valued at lower of cost and net realisable value. Cost is determined on first-in first-out basis. The cost of work-in-progress (other than those lying at third party manufacturing sites which is valued at material cost) and finished goods comprises of raw materials, direct labour, other direct costs and related production overheads, but excludes interest expense. Net realisable value is the estimate of the selling price in the ordinary course of business, less the costs of completion and selling expenses.

#### (g) Cash and Cash Equivalents

Cash and cash equivalents include cash in hand and demand deposits with banks with original maturities of three months or less.

#### (h) <u>Revenue Recognition</u>

Sales are recognised when the significant risk and rewards of ownership in the goods are transferred to buyer as per the terms of contract and are recorded inclusive of excise duty but are net of trade discounts and sales tax.

Interest on investments is recognised on a time proportion basis taking into account the amounts invested and the rate of interest. Dividend income on investments is recognised when the right to receive the payment is established.

#### (i) Foreign Currency Transactions

Foreign currency transactions are accounted at the exchange rates prevailing at the date of the transaction. Gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies, are recognised in the Statement of Profit and Loss.

#### (j) Proposed Dividend

Dividend proposed by the Board of Directors is provided for in the books of account pending approval at the Annual General Meeting.

#### (k) Research and Development

Revenue expenditure on research and development is recognised as expense in the year in which it is incurred and the expenditure on capital assets is depreciated over the useful lives of the assets.

#### (I) Excise Duty

The excise duty in respect of closing inventory of finished goods is included as part of inventory. The amount of Central Value Added Tax (CENVAT) credits in respect of materials consumed for sales is deducted from cost of materials consumed.

The excise duty related to the difference between the closing stock and opening stock of finished goods has been recognised separately under "Operating and other expenses".

#### (m) Long-term Incentive

In terms of a long-term incentive plan, the eligible members of the senior management are entitled to receive an incentive payment at the end of a three year 'restricted period', provided they remain in continuous employment with the Company for the aforesaid period. The value of such incentive is based on the price of shares of GlaxoSmithKline plc, U.K. An amount equal to one-third of the aggregate approximate value of the incentive is recognised as expense each year based on the fair value of such shares.

#### (n) Taxes on Income

Current tax is determined as the amount of tax payable in respect of taxable income for the period. Deferred tax is recognised, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax assets and deferred tax liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liabilities on a net basis. Deferred tax assets and deferred tax assets and deferred tax assets and deferred tax assets and be used to taxes on income levied by the same governing taxation laws.

#### (o) Employee Benefits

#### (i) Long-term Employee Benefits

In case of Defined Contribution plans, the Company's contributions to these plans are charged to the Statement of Profit and Loss as incurred.

Liability for Defined Benefit plans is provided on the basis of valuations, as at the Balance Sheet date, carried out by an independent actuary. The actuarial valuation method used for measuring the liability for Gratuity and Post Retirement Medical is Projected Unit Credit method. The obligations for Gratuity and Post Retirement Medical are measured as the present value of estimated future cashflows discounted at rates reflecting the prevailing market yields of Indian Government securities as at the Balance Sheet date for the estimated term of the obligations. The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors. The expected rate of return of plan assets is the Company's expectation of the average long term rate of return expected on investments of the fund during the estimated term of the obligations. Plan assets are measured at fair value as at the Balance Sheet date.

Provident Fund contributions are made to a Trust administered by the Company. The actuarial valuation method, carried out by an independent actuary, used for measuring the liability for Providend Fund is Projected Accrued Benefit method. This approach determines the present value of the interest rate guarantee under three interest rate scenarios: base case scenario, rising interest rate scenario and falling interest rate scenario. The Defined Benefit Obligation of the interest rate guarantee is set equal to the average of the present values determined under these scenarios in respect of accumulated provident fund contributions as at the valuation date.

The liability for leave encashment and compensated absences is provided on the basis of valuation, as at Balance Sheet date, carried out by an independent actuary.

- (ii) The expenditure on voluntary retirement schemes is charged to the Statement of Profit and Loss in the year in which it is incurred.
- (iii) Actuarial gains and losses comprise experience adjustments and the effects of changes in actuarial assumptions and are recognised in the Statement of Profit and Loss in the year in which they arise.

#### (p) Earnings Per Share

Basic earnings per share is calculated by dividing the net profit for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares, that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.



				 Rupees ir	n lakhs
				As at 31st March, 2015	As at 31st December, 2013
2	SHARE CAPITAL				
	AUTHORISED				
	9,00,00,000 equity shares of Rs. 10 each	 		 90,00.00	90,00.00
	ISSUED				
	8,47,07,710 equity shares of Rs. 10 each	 		 84,70.77	84,70.77
	SUBSCRIBED AND PAID-UP				
	8,47,03,017* equity shares of Rs. 10 each, fully paid up	 		 84,70.30	84,70.30
			TOTAL	 84,70.30	84,70.30

\* excludes 4,693 equity shares of Rs. 10 each of the Company (3,352 equity shares of Rs. 10 each of erstwhile Burroughs Wellcome (India) Limited) held in abeyance.

			As at 31st M	arch, 2015	As at 31st December, 201		
			Number of Shares	Rupees in lakhs	Number of Shares	Rupees in lakhs	
(a)	Reconciliation of the number of shares :						
	Balance at the beginning of the period	 	84,703,017	84,70.30	84,703,017	84,70.30	
	Issued during the period	 	_	_		—	
	Balance at the end of the period	 	84,703,017	84,70.30	84,703,017	84,70.30	

(b) Rights, preferences and restrictions attached to equity shares:

The Company has one class of equity shares having a par value of Rs. 10 per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

(c) Shares held by subsidiaries of ultimate holding company in aggregate

	Number of	Rupees	Number of	Rupees
	Shares	in lakhs	Shares	in lakhs
Equity shares of Rs. 10 each [representing 75.00% of total shareholding (Previous year - 50.67%)]	63,527,262	63,52.73	42,917,488	42,91.75

(d) Details of equity shares held by shareholders holding more than 5% shares of the aggregate shares in the Company:

	Number of Shares	% Shareholding	Number of Shares	% Shareholding
Glaxo Group Limited, U.K	30,485,250	35.99%	30,485,250	35.99%
GlaxoSmithKline Pte Limited, Singapore	20,609,774	24.33%	_	—
Eskaylab Limited, U.K	5,880,000	6.94%	5,880,000	6.94%
Life Insurance Corporation of India	4,749,658	5.61%	4,822,848	5.69%

							Rupees in	lakhs	
							As at 31st March, 2015	As at 31st December, 2013	
3	RESERVES AND SURF	PLUS							
	CAPITAL RESERVE								
	Balance as at the beginning o	of the period	k		 		1,65.51	1,65.51	
	Additions/Deductions				 		_	—	
	Balance as at the end of the	period			 	(a)	1,65.51	1,65.51	
	CAPITAL REDEMPTION RES	SERVE							
	Balance as at the beginning of	of the period	k		 		2,61.95	2,61.95	
	Additions/Deductions				 		—	_	
	Balance as at the end of the p	period			 	(b)	2,61.95	2,61.95	
	GENERAL RESERVE								
	Balance as at the beginning of	of the period	k		 		828,27.98	778,09.16	
	Transfer from Surplus in State	ement of Pro	ofit and Los	s	 		47,16.46	50,18.82	
	Balance as at the end of the	period			 		875,44.44	828,27.98	
	SURPLUS IN STATEMENT O	F PROFIT	AND LOSS	6					
	Balance as at the beginning of	of the period	k		 		1099,93.27	1142,94.60	
	Profit for the period				 		471,64.58	501,88.24	
	Less : Appropriations				 				
	Proposed Dividend				 		(529,39.38)	(423,51.50)	
	Tax on dividend				 		(107,77.40)	(71,19.25)	
	Transfer to General Reserve	e			 		(47,16.46)	(50,18.82)	
	Balance as at the end of the p	period			 		887,24.61	1099,93.27	
					TOTAL		1766,96.51	1932,48.71	
								l	

(a) Includes Central Government subsidy Rs. 15.00 lakhs and capital profit on reissue of shares forfeited of erstwhile Burroughs Wellcome (India) Limited Rs. 0.51 lakhs.

(b) On account of buy back of equity shares.

	Rupees in	n lakhs
	As at 31st March, 2015	As at 31st December, 2013
 	 2,62.60	3,60.50
TOTAL	 2,62.60	3,60.50
		As at 31st March, 2015

#### Terms of repayment

Interest free Sales Tax Loan from SICOM Limited as at 31st March, 2015 of Rs. 3,11.55 lakhs (Previous year - Rs. 4,14.24 lakhs) includes NIL (Previous year - Rs. 4.80 lakhs repayable in one installment) availed under the 1988 Sales Tax deferment Scheme, closing on 31st January, 2014 and Rs. 3,11.55 lakhs (Previous year - Rs. 4,09.44 lakhs) under the 1993 Sales Tax deferment Scheme repayable in twenty one instalments (previous year twenty seven instalments) closing on 30th April, 2021. The current maturity amount of Rs. 48.95 lakhs (Previous year - Rs. 53.74 lakhs) of the loan has been disclosed under Note 8 - Other Current Liabilities.

4



								Rupees in	n lakhs
								As at 31st March, 2015	As at 31st December, 2013
5	OTHER LONG TERM LIA	BILITIES	5						
	Security Deposits received							 2,36.72	2,81.72
	Other long term liabilities							 2,92.14	2,15.00
						Т	OTAL	 5,28.86	4,96.72
6	LONG TERM PROVISION	IS							
	For Pricing matters (Refer Note 2	23)						 122,70.82	122,70.82
	For employee benefits :								
	Gratuity							 42,07.25	24,50.66
	Leave encashment and com			es				 40,49.66	29,65.19
	Post retirement medical and	d other ben	efits					 34,63.73	30,74.67
	For long-term incentive plan							 6,22.52	6,59.55
	For divestment / restructuring							 12,02.83	16,13.72
	For others							 12,79.06	10,69.43
						Т	OTAL	 270,95.87	241,04.04
7	<b>TRADE PAYABLES</b> Micro and Small enterprises (Ref	fer Note 26)	)					 2,54.30	3,79.01
	Others							 303,34.33	274,22.23
						Т	OTAL	 305,88.63	278,01.24
8	OTHER CURRENT LIABII	orrowings :							
	Interest free sales tax loan f	rom SICON	/ Limited	d (Refer	Note 4)			 48.95	53.74
	Subsidiary company							 1,50.60	2,14.38
	Unclaimed dividends*							 20,26.22	18,88.91
	Salaries, wages and bonus paya							 52,79.60	28,10.37
	Statutory dues including provide	nt fund and	tax deo	ducted a	t source			 17,27.81	21,33.88
	Creditors for capital goods							 30,34.15	3,88.30
	Rationalisation relating to a manu	utacturing s	site					 1,32.84	6,07.59
	Other Payables							 7,55.36	5,24.90

\* There are no amounts due and outstanding to be credited to Investor Education and Protection Fund.

					Rupees in	n lakhs
					As at 31st March, 2015	As at 31st December, 2013
9	SHORT TERM PROVISIONS					
	For proposed equity dividend	 			 529,39.38	423,51.50
	For provision for taxation (net) (Refer note 51 (a))	 			 15,86.49	
	For tax on distributed profit	 			 107,77.40	71,97.64
	For employee benefits :					
	Gratuity	 			 _	22.01
	Leave encashment and compensated absences	 			 2,52.24	3,79.14
	Post retirement medical and other benefits	 			 1,99.61	2,01.85
	For long-term incentive plan	 			 1,08.06	6,07.28
	For rationalisation relating to a manufacturing site	 			 1,35.43	3,52.96
	For other (including statutory levies)	 			 8,43.31	7,70.85
			тс	DTAL	 668,41.92	518,83.23

### **10 MOVEMENT IN PROVISIONS**

	Rationalisation relating to a manufacturing site	Pricing matters	Long-term Incentive Plan	Divestment / Restructuring	Others
		January 2	2014 - March 2	2015	
Opening Balance	3,52.96	122,70.82	12,66.83	16,13.72	18,40.28
Add: Provision during the period	_	_	5,31.68	_	11,07.99
Less: Amounts utilised/reversed during the period	2,17.53	_	10,67.93	4,10.89	8,25.90
Balance at the period end	1,35.43	122,70.82	7,30.58	12,02.83	21,22.37
		January	- December 20	013	
Opening Balance	12,74.50	128,34.05	6,29.55	16,58.97	9,14.72
Add: Provision during the year	_	_	8,53.56	_	9,99.87
Less: Amounts utilised/reversed during the year	9,21.54	5,63.23	2,16.28	45.25	74.31
Balance at the year end	3,52.96	122,70.82	12,66.83	16,13.72	18,40.28

### **11** FIXED ASSETS

Rupee												
		Gross bloc	k (at cost)		Depreciation				Net block			
	As at 31st December 2013	Additions/ Adjustments	Deductions (b)	As at 31st March 2015	As at 31st December 2013	For the Period	On Deductions/ Adjustments (b)	As at 31st March 2015	As at 31st March 2015	As at 31st December 2013		
TANGIBLE ASSETS												
Freehold land	2.00	_	_	2.00	_	_	_	_	2.00	2.00		
Leasehold land	44.27	_	_	44.27	_	—	_	_	44.27	44.27		
Freehold buildings (a)	10,64.27	22,45.26	_	33,09.53	6,87.33	1,24.78	_	8,12.11	24,97.42	3,76.94		
Leasehold buildings	37,85.68	7,60.20	1.69	45,44.19	19,99.96	1,53.97	1.24	21,52.69	23,91.50	17,85.72		
Plant and equipment	203,20.33	1,921.32	35,78.64	186,63.01	135,16.96	17,77.31	27,76.67	125,17.60	61,45.41	68,03.37		
Furniture and fixtures	29,82.63	1,40.04	17.54	31,05.13	24,54.12	1,59.17	17.91	25,95.38	5,09.75	5,28.51		
Vehicles	11,01.13	4,98.97	21.10	15,79.00	7,80.44	3,12.58	18.00	10,75.02	5,03.98	3,20.69		
Office Equipment	6,07.78	76.10	11.66	6,72.22	4,62.10	7.44	8.95	4,60.59	2,11.63	1,45.68		
TOTAL	299,08.09	56,41.89	36,30.63	319,19.35	199,00.91	25,35.25	28,22.77	196,13.39	123,05.96			
Previous year	272,03.63	34,03.52	6,99.06	299,08.09	182,63.42	19,88.14	3,50.65	199,00.91		100,07.18		

Note:

(a) Freehold buildings include investments representing ownership of residential flats (Refer Note 27).

(b) Deductions include Tangible assets held for sale shown under 'Other Current Assets' (Refer note 21) : gross block Rs. 5,23.57 lakhs, accumulated depreciation Rs. 3,98.29 lakhs and net block Rs. 1,25.28 lakhs (Previous year shown under 'Other Non Current Assets' (Refer note 15) - gross block Rs. 4,47.82 lakhs, accumulated depreciation Rs. 1,50.20 lakhs and net block Rs. 2,97.62 lakhs).

50



						Rupees ii	n lakhs
						As at 31st March, 2015	As at 31st December, 2013
12	NON-CURRENT INVESTMENTS						
	(VALUED AT COST UNLESS OTHERWISE STATED)						
	TRADE						
	IN EQUITY INSTRUMENTS						
	Unquoted						
	Biotech Consortium India Limited						
	50,000 Equity Shares of Rs. 10 each fully paid					5.00	5.00
	Dinette Exclusive Club Private Limited						
	500 Equity Shares of Rs. 100 each fully paid					0.50	0.50
	OTHER INVESTMENTS						
	Unquoted						
	National Savings Certificate					0.17	0.17
	(Lodged with Government authorities)						
	IN SUBSIDIARY COMPANY						
	Unquoted						
	Biddle Sawyer Limited						
	9,60,000 Equity Shares of Rs. 10 each fully paid					47,61.30	47,61.30
			т	OTAL		47,66.97	47,66.97
						17.00.07	47.00.07
	Aggregate of Unquoted Investments - At Book value There are no investments purchased and sold / rede	 emed d	 turina th	 No norioc	 1	47,66.97	47,66.97
13	DEFERRED TAX ASSETS (NET)						
10	Deferred tax assets and liabilities are attributable to the follo	wing it	ems:				
	Assets	U					
	Provision for employee benefits					41,03.35	30,53.08
	Costs of voluntary retirement schemes					12,25.25	21,53.41
	Provision for doubtful debts, loans and advances					5,17.12	4,81.44
	Interest on Income-tax refund not accounted but consi	dered	as taxat	ole unde	er the		
	Income-tax Act, 1961					22,02.06	22,02.06
	Expenses allowable for tax purposes when paid					12,55.28	17,99.60
	Liabilities		ΤC	OTAL		93,03.06	96,89.59
	Depreciation (including tangible assets held for sale)					10,11.63	4,78.94
			Т	OTAL		10,11.63	4,78.94
			т	DTAL		82,91.43	92,10.65
						L	

14 LONG TERM LOANS AND ADVANCES (Unsecured, considered good unless otherwise stated)	at 31st December, 2013
(Unsecured, considered good unless otherwise stated)	
Capital advances 64,22.76	
	7,80.74
Less : Allowance for doubtful loans and advances (3,87.93) 60,34.83 (	2,67.13) 15,13.61
Security Deposits	11,92.01
Other loans and advances (Refer Note 52)	
Advance income-tax (net) (Refer Note 51(b)) 166,92.55	159,72.01
Balance with Government Authorities       11,83.17	10,72.78
Sundry Deposits             30,56.55	29,37.81
Loans and advances recoverable in cash or in kind * 4,52.14	5,99.17
TOTAL288,31.03	232,87.39
* includes outstanding loans receivable from related parties	
15 OTHER NON-CURRENT ASSETS	5.00
Remittances in transit [Refer Note 24(iii)]         5.92         Margin money / Deposit against bank guarantee        2,92.21	5.92
Margin money / Deposit against bank guarantee        2,92.21         Tangible assets held for sale (at book value or estimated net        2,92.21	2,43.56
realisable value / salvage value, whichever is lower) 11,05.90	11,05.90
TOTAL 14,04.03	13,55.38
16 CURRENT INVESTMENTS	
(CURRENT PORTION OF LONG TERM INVESTMENTS VALUED AT COST UNLESS OTHERWISE STATED)	
IN DEBENTURES OR BONDS	
Quoted	
LIC Housing Finance Limited	
Nil, (Previous year - 100, 9.35% Non-Convertible           Debentures, 2014 of Rs. 10,00,000 each)	10,00.25
TOTAL	10,00.25
Aggregate of Quoted Investments - At Book value	10,00.25
- At Market value —	10,06.36
There are no investments purchased and sold / redeemed during the period.	



		Rupees in	n lakhs
		As at 31st March, 2015	As at 31st December, 2013
17	INVENTORIES		
	Stores and spares	2,59.31	2,85.74
	Raw and packing materials (includes in-transit Rs. 3,05.27 lakhs; Previous year - Rs. 3,30.96 lakhs)	95,93.12	70,59.52
	Work-in-progress	31,23.41	32,33.86
	Traded goods (includes in-transit Rs. 12,01.55 lakhs; Previous year - Rs. 14,59.10 lakhs)	135,73.98	147,09.26
	Finished goods	103,35.77	89,51.35
	TOTAL	368,85.59	342,39.73
18	TRADE RECEIVABLES		
	(Unsecured, considered good unless otherwise stated)		
	Considered good		
	Outstanding for a period exceeding six months from the date they are due for payment	9,32.19	10,98.65
	Others	90,99.60	85,40.67
	Considered doubtful	00,00.00	00,10.01
	Outstanding for a period exceeding six months from the date they are due for payment	11,27.27	10,22.32
	Others	_	
	Less : Provision for doubtful debts	(11,27.27)	(10,22.32)
	TOTAL	100,31.79	96,39.32
19	CASH AND BANK BALANCES		
	Cash and cash equivalents		
	Cash on hand	0.76	1.67
	Balances with banks		
	Current account	54,30.83	69,32.07
	Term deposit with original maturity period of less than three months	60,02.00	23,54.00
	Other bank balances		
	Term deposit with original maturity period of more than three months but less than twelve months	1545,75.00	1618,00.00
	Term deposit with original maturity period of more than twelve months but maturing within next twelve months	217,00.00	296,75.00
	Unpaid dividend accounts	20,26.22	18,88.91
	Margin money / Deposit against bank guarantee	66.94	61.96
	TOTAL	1898,01.75	2027,13.61

												Rupees i	n lakhs
												As at 31st March, 2015	As at 31st December, 2013
20	SH	OR	T TER	M LOANS AND		ANCE	S						
	(Un	secui	red, con	sidered good unle	ss othe	erwise sta	ated)						
	Bala	ance	with Go	vernment Authoriti	es							14,80.44	9,09.87
	Cur	rent a	account	balances with gro	up com	npanies						26,13.73	19,16.45
	Pre	paid I	Expense	es								10,13.16	1,74.98
	Adv	ance	s recove	erable in cash or ir	i kind *	·						68,66.99	39,90.07
									т	OTAL		119,74.32	69,91.37
	* in	clude	es outsta	anding loans receiv	able fr	om relate	ed partie	es					
21	от	HEF	R CUR	RENT ASSET	6								
	Inte	rest a	accrued	on investments / c	deposit	s						65,48.26	55,27.66
				including capital v alisable value / sal					at book 	value/co 	st or 	12,59.85	46.06
	Oth	ers										16.80	15.23
									т	OTAL		78,24.91	55,88.95
		(i) (ii)	In resp	es discounted with bect of claims mad			 Company	 y not ac	 knowled	 ged as c	 lebts	3,74.00	1,56.84
												3,74.00	1,56.84
		(")	by the	Company	le ugui		Joinpan	y not do		gou us c			
				ales tax matters								34,39.35	34,16.65
				xcise matters								5,93.30	5,93.30
				ervice tax matters								1,29.20	1,29.20
				abour matters								69,31.23	62,81.49
				ther legal matters								22,01.55	22,01.55
		(:::)		hich net of current					 dina			87,75.79	83,31.91
		(iii)		e-tax matters in res	•			are pend	U			177 46 92	199,70.77
			- Notes:	ax on matters in di	spute			••				177,46.83	199,70.77
			Future	cash outflows in es by banks.	respect	t of (i) a	bove ar	e depen	dant on	the retu	rn of		
			Future	cash outflows in t of decisions / jud									
	В.	Con	nmitmer	nts									
		(i)		ted amount of con account and not p			dvances) 		ng to be 	execute	d on 	87,40.19	53,72.63
		(ii)	Uncall	ed liability on partly	y paid :	shares:							
			- ir	Hill Properties Lin	nited							0.12	0.12
			Note:										

Future cash outflow is dependent on the call to be made by Hill Properties Limited.



23 The demand of Rs. 71,79 lakhs made by the Central Government on the Company in respect of Betamethasone bulk drugs and formulations made therefrom during the period May 1981 to August 1987 has been under litigation for a period spanning nearly 30 years. Pursuant to the special leave petition of the Central Government in the Supreme Court of India against the Delhi High Court's Judgment and Order dated 19th October 2001 which was held in favour of the Company, the Supreme Court has, vide its Judgment and Order dated 31st March 2011, upheld the demand. The Company had accrued a liability of Rs. 18,68 lakhs in earlier years and a further provision of Rs. 53,11 lakhs was accrued in 2011.

Based on a legal advice, the Company has filed an Application in the Supreme Court seeking, inter alia, clarifications on some aspects of the Judgement and directions for recomputation of the demand. Simultaneously, the Company without prejudice to and subject to the outcome of the Application filed in the Supreme Court, has tendered as a further deposit, an amount of Rs. 63,60 lakhs, which together with the amount of Rs. 8,19 lakhs previously deposited with the Government, aggregates to the demand of Rs. 71,79 lakhs made by the Government in November 1990. The Company filed a Review Petition in the Supreme Court which was rejected in March 2012.

In October 1996, the Government had claimed interest of Rs. 117,66 lakhs for the period 12th May 1981 to 17th October 1996, for which no provision was made in earlier years. The Government has vide letter dated 4th May 2011 called upon the Company to discharge the entire liability, including upto date interest calculated at 15% p.a., and has vide letter dated 10th October 2011, raised a demand on the Company for the interest amount amounting to Rs. 247,44 lakhs. Without prejudice to the position that interest is not payable, the Company has recognized a provision of Rs. 247,44 lakhs in respect of the Government's claim for interest in 2011. The Company has filed a Writ Petition at Delhi High Court against the above demand which has been admitted. The Company also filed stay applications which have been dismissed and has filed a Special Leave Petition (SLP) before the Supreme Court for stay of the interest demand until final determination of the Writ Petition filed in the Delhi High Court. The Supreme Court on hearing the above SLP, passed an order on 3rd April 2012. The said order stayed the Demand Notice dated 10th October 2011 during the pendency of the Writ Petition at the Delhi High Court subject to the Company depositing Rs. 136,82 lakhs in three equal installments within six month's time from the date of order. All three instalments have been deposited with the Government as of date. The Supreme Court, vide its order dated 5th October 2012, directed the Delhi High Court to dispose of the Writ Petition as expeditiously as possible. The Delhi High Court has listed the Writ Petition for hearing on 27th August, 2015.

- **24** Matters in respect of erstwhile Burroughs Wellcome (India) Limited (BWIL):
  - (i) The Government of India, Ministry of Chemicals and Fertilisers, New Delhi, passed a final order on 21st July, 1993, directing erstwhile BWIL to pay an amount of Rs. 1,91.15 lakhs along with interest due thereon from the date of default into the Drugs Prices Equalisation Account (DPEA) in respect of a bulk drug procured by erstwhile BWIL during the period April 1981 to April 1983.

Erstwhile BWIL filed a writ petition in August 1993 which was admitted by the Bombay High Court. After hearing both the parties, the High Court granted an interim injunction restraining the Government of India from taking any action in furtherance of and/ or implementation of the order dated 21st July, 1993 or from in any manner seeking to compel erstwhile BWIL to deposit any amount into the DPEA, pending the hearing and final disposal of the petition on the condition that erstwhile BWIL furnishes a bank guarantee for Rs. 2,00 lakhs from a nationalised bank and undertakes to pay the amount demanded with interest at the rate of 20% per annum in case the petition fails.

Erstwhile BWIL had accordingly furnished the required bank guarantee. If calculated on the basis of correct data, taking into account set offs claimable for earlier years for which data has been provided by erstwhile BWIL, no amount will be payable by the Company and accordingly no provision in that respect is considered necessary. The Company's stand that the demand is not sustainable has been confirmed by an eminent counsel. The Government of India's application in the Supreme Court praying that the writ petition be transferred to the the Supreme Court from the Bombay High Court was not allowed and the Company's writ petition will now be heard by the Bombay High Court.

- (ii) Erstwhile BWIL had made an application to the Government of India for approval under Section 198(4) of the Companies Act, 1956, in respect of payment of the Managing Director and three whole time Directors amounting to Rs. 10.93 lakhs for the year ended 31st August, 1986, which was in accordance with the minimum remuneration provided in the agreement entered into with them prior to erstwhile BWIL becoming public, which required such Government of India's sanction. The approval is still awaited.
- (iii) Remittances in transit represent monies deposited by customers in favour of erstwhile BWIL with banks in Zambia Rs. 0.31 lakhs and in Tanzania - Rs. 5.61 lakhs, the remittance of which is pending clearance of the authorities in those countries.
- 25 Matters in respect of erstwhile SmithKline Beecham Pharmaceuticals (India) Limited:
  - (i) Rs. 1,44.44 lakhs received from Beckman Instruments International S.A. on account of disputed alleged additional commission has been included under Long term provisions and Income tax paid thereon aggregating to Rs. 64.77 lakhs has been included under long term loans and advances. The Company is contesting the matter with the concerned authorities.
  - (ii) Refund of surtax Rs. 96.81 lakhs, and interest thereon amounting to Rs. 48.52 lakhs, received during 1994, have not been adjusted against the provision for tax in the books of account and recognised as income respectively, since the Income tax department had filed a reference application against the income tax tribunal's order which was pending before the High Court of Karnataka. The Company has received an order dated 18th April, 2007 from the High Court of Karnataka which is partially in the Company's favour. On the basis of the aforesaid order, Income Tax Appellate Tribunal (ITAT), Bangalore will pass an order giving directions. On receipt of the ITAT order, the Company will take appropriate steps in the matter.

			Rupees in	n lakhs
			As at 31st March, 2015	As at 31st December, 2013
26		ures as required by the Micro, Small and Medium Enterprises Development Act, e as under:		
	(a) Th	e principal amount and the interest due thereon remaining unpaid to suppliers		
	(i)	Principal	—	_
	(ii)	Interest due thereon	8.38	4.77
			8.38	4.77
	(b) (i)	The delayed payments of principal amount paid beyond the appointed date during the entire accounting period	1,83.91	95.27
	(ii)	Interest actually paid under Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006	_	_
	(C) (i)	Normal Interest accrued during the period for all the delayed payments, as per the agreed terms	_	_
	(ii)	Normal Interest payable for the period of delay in making payment, as per the agreed terms	_	_
	(d) (i)	Total Interest accrued during the period	3.61	1.58
	(ii)	Total Interest accrued during the period and remaining unpaid	3.61	1.58
		uded in (d) above is Nil being interest on amounts outstanding as at the beginning e accounting period		
	(f) Furtl	her interest remaining due and payable for earlier years	4.77	3.19
		ove information regarding Micro and Small enterprises has been determined xtent such parties have been identified on the basis of information available with the ny.		
27		e fixed Assets include the following investments representing ownership of tial flats:		
	and 1 p	y paid 'A' equity shares of Rs. 1,20,000 each, Rs. 1,18,000 each paid-up partly paid 'B' equity share of Rs. 90,000, Rs. 88,500 paid-up in Hill Properties	7.00	7.22
	Limited	es of Rs. 50 each fully paid-up in Prathamesh Co-operative Housing Society	7.22	1.22
	Limited.		2.00	2.00
		res of Rs. 50 each fully paid-up in Montreal Olympic Premises Co-operative g Society Limited.	48.13	48.13
	5 share	s of Rs. 50 each fully paid-up in Poonam Co-operative Housing Society Limited.	23.62	23.62
	10 shar	es of Rs. 100 each fully paid-up in Anita Co-operative Housing Society Limited.	33.31	33.31
		es of Rs. 50 each fully paid-up in Cooprage Woodhouse Co-operative Housing Limited	45.59	45.59
	5 share Limited.	s of Rs. 50 each fully paid-up in Sea-Face Park Co-operative Housing Society	67.00	67.00
		shares of Rs. 50 each fully paid-up in Red Rose rative Housing Society Limited	19.32	19.32
		of Rs. 100 fully paid-up in The Imperial Condominium	21,52.80	_



						Rupees	in lakhs	
					15 month 31st Marc		12 months 31st Deceml	
28	PROPOSED DIVIDEND							
20	The dividend on Equity Shares of Rs. 10 ea	ach is a	s follow	s:				
	Amount of dividend					529,39.38		423,51.50
	Dividend per Equity Share					62.50		50.00
00	DEVENUE EDOM ODEDATIONS							
29	REVENUE FROM OPERATIONS Sale of products				3358,54.49		2593,39.32	
	Excise duty			••	(105,13.51)		(73,22.08)	
	Cala of analysista (mot)				3253,40.98		2520,17.24	
	Other operating revenue	 		 	34,16.82		25,97.50	
		тот				2007 57 00		0546 14 74
		101	AL			3287,57.80		2546,14.74
	(a) DETAILS OF SALE OF PRODUCTS					1445 10 00		1100 07 00
	Tablets and Capsules Solids including Powders and Ointme	 nte				1445,16.69 836,83.57		1108,67.02 623,85.44
	Liquids - Orals, Topicals and Parentera					459,67.43		333,95.74
						440,33.79		361,90.61
	Others					176,53.01		165,00.51
						3358,54.49		2593,39.32
	(b) OTHER OPERATING REVENUE							
	Service income							
	Clinical research and data manageme	ent			52,02.72		43,66.02	
	Other services				19,58.57		12,07.04	
	Direct expenses relating to the above				(58,39.14)		(45,01.07)	
					13,22.15		10,71.99	
	Export related benefits (net)				10.84		22.20	
	Consignment sales commission				1,35.12		1,33.33	
	Manufacturing charges recovery				7,94.25		4,00.92	
	Others				11,54.46	34,16.82	9,69.06	25,97.50
30	OTHER INCOME							
00	Interest income (Gross):							
	On deposits with banks				186,85.39		155,81.93	
	On loans				34.39		27.48	
	On tax refunds				8,99.23		15,29.43	
	On investments - Government sect							
	than trade - long term [net of pre Rs. 0.24 lakhs (Previous year - Rs. 0.31			0î 	83.53		1,70.94	
	Other				17.91		38.42	
					197,20.45		173,48.20	
	Less : Interest expense:							
	Security deposits				(31.50)		(33.01)	
	Others				(15.40)		(0.08)	
					(46.90)		(33.09)	
					(40.90)		(33.09)	
	Dividend from subsidiant company					196,73.55		173,15.11
	Dividend from subsidiary company Profit on sale / redemption of investments					_		25,00.00 9.10
	Rent received					92.63		65.41
	Profit on sale / disposal of fixed assets (net					58.00		1,64.92
	Provision written back as no longer require					42.99		42.32
		тот	AL			198,67.17		200,96.86
						<u> </u>		
							•	

Other raw materials consumed *         . <td< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>Rupees i</th><th>n lakhs</th><th></th></td<>										Rupees i	n lakhs	
Betamethasone-17 Valerate IP												
Other raw materials consumed *         . <td< th=""><th>31</th><th>COST OF MA</th><th>ATERI</th><th>ALS C</th><th>ONSU</th><th>MED</th><th></th><th></th><th></th><th></th><th></th><th></th></td<>	31	COST OF MA	ATERI	ALS C	ONSU	MED						
Packing materials consumed *		Betamethasone-1	17 Vale	rate IP						75,99.50		66,56.24
TOTAL         726,73.46         538,55.74           Notes:         **% of single raw or packing material accounts for more than 10% of total consummed is based on derived values         *		Other raw materi	als con	sumed '	*					468,02.93		329,05.14
Notes:         *         No single raw or packing material accounts for more than 10% of total consumption         Total         *         *         *         *         No single raw or packing material accounts for more than 10% of total consumption         *		Packing materials	s consi	umed *						182,71.03		142,95.36
* No single raw or packing material accounts for more than 10% of total consumption       So of of materials consumed is based on derived values         VALUE OF IMPORTED AND INDIGENOUS RAW AND PACKING MATERIALS CONSUMED       %       %         Purchased indigenously       84.60       614.82.67         15.40       111.90.79       14.48       77.06.91         100.00       726.73.46       100.00       538.562.4         32       PURCHASE OF TRADED GOODS       779.89.39       670.00.11         Purchase of traded goods        779.89.39       670.00.11         33       CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS       89.51.35       63.68.99         Opening stock        117.09.26       121.28.02         Zeas: Closing stock        31.23.41       32.33.86         Work-in-progress        117.09.26       121.28.02         Zeas: Closing stock         31.23.41       32.33.86         Work-in-progress        117.09.26       121.28.02         Zrotal goods        31.23.41       32.33.86         Work-in-progress						Т	OTAL			726,73.46		538,56.74
10% of total consumption       Cost of materials consumed is based on derived values         VALUE OF IMPORTED AND INDIGENOUS RAW AND       %       %         Purchased indigenously         84.60       614.82.67       85.52       460.59.83         Imported by the company (including duty and other charges)       15.40       111.90.79       14.48       77.26.91         20       PURCHASE OF TRADED GOODS       100.00       728.73.46       100.00       538.56.74         32       PURCHASE OF TRADED GOODS       779.89.39       670.00.11         33       CHANGES IN INVENTORIES OF FINISHED GOODS       779.89.39       670.00.11         33       CHANGES IN INVENTORIES OF FINISHED GOODS       89.51.35       63.58.99         Opening stock       31.23.41       32.33.86       33.32.75         Vorkin-progress         147.09.26       121.28.02         2000S         135.73.88       147.09.26       121.80.02         2000S          135.73.88       147.09.26       121.80.02         2000S           135.73.88       147.09.26       121.80.02         Traded goods       <		Notes:										
VALUE OF IMPORTED AND INDIGENOUS RAW AND PACKING MATERIALS CONSUMED         %         %           Purchased indigenously           84.60         614.82.67         85.52         460.99.83           Imported by the company (including duly and other charges)         15.40         111.90.79         14.48         77.96.91           32         PURCHASE OF TRADED GOODS         779.89.39         670.00.11           Purchase of traded goods           779.89.39         670.00.11           33         CHANGES IN INVENTORIES OF FINISHED GOODS         779.89.39         670.00.11         670.00.11           33         CHANGES IN INVENTORIES OF FINISHED GOODS         89.51.35         63.56.99         1147.09.26         121.28.02           Opening stock         268.94.47         218.19.76         218.02         218.19.76           Users: Closing stock         31.23.41         32.33.86         33.32.75         88.51.35           Work-in-progress           103.55.77         88.51.35         63.50.99           Traded goods            135.73.88         21.28.02         268.94.47         216.19.76           Traded goods            135.73.88<					terial ac	counts f	for more	than				
PACKING MATERIALS CONSUMED         %         %           Purchased indigenously            84.60         614,82.67         85.52         460,59.83           Imported by the company (including duty and other charges)         15.40         111,90.79         14.48         77,96.91           100.00         726,73.46         100.00         538,56.74         100.00         538,56.74           32         PURCHASE OF TRADED GOODS         779,89.39         670,00.11         670,00.11           Work-in-progress           779,89.39         670,00.11           GOODS         Opening stock         32,33.86         33,32.75         63,86.99           Work-in-progress            89,51.35         63,86.89           Traded goods            147,09.26         121,28.02           Less: Closing stock            31,23.41         32,33.86           Work-in-progress             135,73.98         147,09.26           Inside goods             135,73.98         147,09.26		Cost of materials	consu	med is t	based or	n derived	d values					
%         %         %           Purchased indigenously						ENOUS	RAW	AND				
Imported by the company (including duty and other charges)       15.40       111.90.79       14.48       77.96.91         32       PURCHASE OF TRADED GOODS       779.89.39       670.00.11         Purchase of traded goods         779.89.39       670.00.11         33       CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS       33.32.75       63.56.99         Opening stock       Work-in-progress            Work-in-progress             Less: Closing stock             Work-in-progress             Traded goods              Traded goods               Traded goods                  Traded goods <td></td> <td>PACKING MATE</td> <td>RIALS</td> <td>CONSU</td> <td>JMED</td> <td></td> <td></td> <td></td> <td>%</td> <td></td> <td>%</td> <td></td>		PACKING MATE	RIALS	CONSU	JMED				%		%	
32       PURCHASE OF TRADED GOODS         Purchase of traded goods          TOTAL          TOTAL          33       CHANGES IN INVENTORIES OF FINISHED GOODS         GOODS          Opening stock          Work-in-progress          Taded goods          Taded goods          Less: Closing stock         Work-in-progress          Vork-in-progress          Uses: Closing stock         Work-in-progress          Uses: Closing stock         Work-in-progress          Traded goods          Traded goods          Traded goods          ToTAL          ToTAL       31,23,41         32,33,86       89,51,35         103,35,77       89,51,35         1103,35,77       89,51,35         121,28,02       268,94,47         (50,74,71)       (60,74,71)         (60,74,71)       (1,38,69)         260,94,47       (50,74,71)         (60,74,71)       (60,74,71)         (60,7		Purchased indige	enously	·					84.60	614,82.67	85.52	460,59.83
32       PURCHASE OF TRADED GOODS         Purchase of traded goods          TOTAL          33       CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS, WORK-IN-PROGRESS AND TRADED GOODS         Opening stock          Work-in-progress          Less: Closing stock          Work-in-progress          Less: Closing stock          Work-in-progress          Traded goods          ToTAL		Imported by the	compa	ny (inclu	iding du	ty and o	ther cha	rges)	15.40	111,90.79	14.48	77,96.91
Purchase of traded goods         779,89.39       670,00.11         33       CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS        32,33.86       33,32.75         Opening stock          32,33.86       33,32.75         Finished goods           32,33.86       33,32.75         Finished goods            32,33.86       33,32.75         Finished goods             32,33.86       33,32.75         Einished goods             32,33.86       33,32.75         Less: Closing stock             121,28.02         Less: Closing stock              39,51.35         Traded goods                       <									100.00	726,73.46	100.00	538,56.74
Purchase of traded goods         779,89.39       670,00.11         33       CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS        32,33.86       33,32.75         Opening stock          32,33.86       33,32.75         Finished goods           32,33.86       33,32.75         Finished goods            32,33.86       33,32.75         Finished goods             32,33.86       33,32.75         Einished goods             32,33.86       33,32.75         Less: Closing stock             121,28.02         Less: Closing stock              39,51.35         Traded goods                       <												
TOTAL         TOTAL         779,89.39         670,00.11           33         CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS         33,32.75         33,32.75           Opening stock         Work-in-progress         .         .         .         .         32,33.86         33,32.75           Finished goods         .	32	PURCHASE	OF TF	RADED	) GOO	DS						
33       CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS         Opening stock       Work-in-progress		Purchase of trade	ed goo	ds						779,89.39		670,00.11
GOODS, WORK-IN-PROGRESS AND TRADED         GOODS         Opening stock         Work-in-progress          Finished goods          Traded goods          Less: Closing stock         Work-in-progress          Less: Closing stock         Work-in-progress          Work-in-progress          Less: Closing stock         Work-in-progress          Work-in-progress          Traded goods          ToTAL          TOTAL          TOTAL          Staff welfare          Staff welfare          Staff welfare						Т	OTAL			779,89.39		670,00.11
Finished goods           89,51.35       63,58.99         Traded goods                Less: Closing stock	00	GOODS, WO GOODS										
Traded goods		Work-in-progress	;						32,33.86		33,32.75	
Less: Closing stock       268,94.47       218,19.76         Work-in-progress       31,23.41       32,33.86         Finished goods       31,23.41       32,33.86         Finished goods       31,23.41       32,33.86         Traded goods       31,23.41       32,33.86         Traded goods       31,23.41       32,33.86         Traded goods       31,23.41       32,33.86         Traded goods       31,23.41       32,33.86         Total       31,23.41       32,63.86         270,33.16       (1,38.69)       268,94.47         (50,74.71)       (50,74.71)       (50,74.71)         Total       32,610.74       (50,74.71)         Gratuity funds       32,610.74       16,35.09         Gratuity funds       32,610.74       16,35.09         Staff welfare       326,10.74       14,56.81		Finished goods									63,58.99	
Less: Closing stock       Work-in-progress <td></td> <td>Traded goods</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>147,09.26</td> <td></td> <td>121,28.02</td> <td></td>		Traded goods							147,09.26		121,28.02	
Work-in-progress <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>268,94.47</td> <td></td> <td>218,19.76</td> <td></td>									268,94.47		218,19.76	
Finished goods		-										
Traded goods </td <td></td>												
TOTAL        270,33.16       (1,38.69)       268,94.47       (50,74.71)         34       EMPLOYEE BENEFITS EXPENSES                Salaries, wages and bonus           442,85.30       326,10.74         Contributions to : Provident and pension funds         24,54.81       16,35.09         Gratuity funds          7,96.08       5,02.21         Staff welfare          17,66.04       14,56.81		-										
TOTAL        (1,38.69)       (50,74.71)         34       EMPLOYEE BENEFITS EXPENSES       326,10.74         Salaries, wages and bonus         442,85.30         Contributions to : Provident and pension funds        24,54.81         Gratuity funds         7,96.08         Staff welfare         17,66.04										(1.38.69)		(50.74.71)
Salaries, wages and bonus           442,85.30       326,10.74         Contributions to : Provident and pension funds         24,54.81       16,35.09         Gratuity funds          7,96.08       5,02.21         Staff welfare          17,66.04       14,56.81						т	OTAL					(50,74.71)
Salaries, wages and bonus           442,85.30       326,10.74         Contributions to : Provident and pension funds         24,54.81       16,35.09         Gratuity funds          7,96.08       5,02.21         Staff welfare          17,66.04       14,56.81												
Contributions to : Provident and pension funds         24,54.81       16,35.09         Gratuity funds          7,96.08       5,02.21         Staff welfare          17,66.04       14,56.81	34									440.95.20		206 10 74
Gratuity funds            7,96.08         5,02.21           Staff welfare             17,66.04         14,56.81		-										
Staff welfare             17,66.04         14,56.81												
		Staff welfare										
						Т						362,04.85



								Rupees i	n lakhs	
							15 month 31st Marc		12 months 31st Deceml	
5	OPERATING AND (	THER	EXP	ENSES						
	Sales promotion							138,39.34		120,18.32
	Stock point commission							16,63.81		11,67.46
	Freight (net)							67,28.37		54,41.59
	Travelling							79,32.24		58,05.22
	Manufacturing charges							96,63.71		65,52.85
	Repairs - Buildings						3,97.94		3,29.93	
	- Plant and Ma	chinery					17,40.03		9,60.90	
	- Others						15.05	21,53.02	11.74	13,02.57
	Consumption of stores a	nd spare	s					6,58.01		4,15.94
	Power, fuel and water							31,16.79		23,85.43
	Rent							22,91.34		15,40.40
	Rates and taxes							33,93.75		22,63.27
	Printing, postage and tele	phones						15,18.93		12,96.36
	Sales training, briefing ar	d confer	ence					17,46.06		19,43.92
	Excise duty							29.78		8,19.99
	Insurance							7,15.78		4,42.51
	Remuneration to auditors	:								
	Statutory audit fees						48.75		48.75	
	In other capacity in re	spect of:								
	Tax audit fees						6.00		6.00	
	Audit of tax accounts						20.00		20.00	
	Other services						30.75		45.25	
	Reimbursement of exp	penses					6.47		3.44	
							1,11.97		123.44	
	Cost audit fees						9.11	1,21.08	2.75	1,26.19
	Date-expired stocks							45,39.56		34,18.43
	Commission to non whol	e-time D	irector	s				58.75		46.31
	Directors' sitting fees							19.80		14.70
	Miscellaneous							99,88.68		65,60.02
	Reimbursement of expen	ses (net)	(Refe	r note 39)				18,73.24		13,59.49
	Expenses relating to serv	ice incor	ne [Re	efer note 2	29 (b)]			(58,39.14)		(45,01.07)
	-		-		TAL			662,12.90		504,19.90
				.0						

36 The Company has appointed Mr. Andrew Aristidou as Executive Director for the period December 1, 2014 to June 30, 2017 at the Board Meeting held on November 6, 2014. Shareholders of the Company have approved his appointment and remuneration vide postal ballot dated March 26, 2015. The Company has filed the application with the Central Government for approval of his appointment and payment of remuneration on April 30, 2015. Approval of the Central Government is awaited.

37 The recurring expenditure on research and development charged off to revenue amounts to Rs. 2,19.35 lakhs (Previous year - Rs. 2,62.86 lakhs).

38 Miscellaneous expenses in Note 35 include loss on foreign currency transactions (net) Rs. 1,64.38 lakhs (Previous year - Rs. 9,33.91 lakhs)

39 "Reimbursement of expenses (net)" in Note 35 are amounts recovered from GlaxoSmithKline Asia Private Limited Rs. 1,64.65 lakhs (Previous year - Rs. 3,46.92 lakhs), from subsidiary company Rs. 3,03.15 lakhs (Previous year - Rs. 2,94.13 lakhs), from Stiefel India Private Limited Rs. 24.97 lakhs (Previous year - Rs. 18.43 lakhs), from GlaxoSmithKline Pte Limited Rs. 30.96 lakhs (Previous year - Rs. 58.96 lakhs), from GlaxoSmithKline Services Unlimited Rs. 2,19.75 lakhs (Previous year - 92.03 lakhs), GlaxoSmithKline Research and Development Rs. 1,05.74 lakhs (Previous year - NIL), GlaxoSmithKline Brasil Ltda Rs. 46.98 Lakhs (Previous year - Rs. 9.18 Lakhs) and paid to GlaxoSmithKline Consumer Healthcare Limited Rs. 27,69.44 lakhs (Previous year - Rs. 21,79.14 lakhs) towards the value of costs apportioned, in accordance with the agreements on allocation of expenses with the companies.

								_	Rupees	in lakhs
									15 months ended 31st March, 2015	12 months ended 31st December, 2013
40	Exceptional iten									
	Expenses on rational		es mainly	relating	g to a ma	anufactu	ring site	•		
	<ul> <li>Voluntary retireme</li> </ul>	ent scheme								(4.50)
	– Others								—	(2,13.81)
	Provisions for pricing		n back						—	5,63.23
	Profit on sale of prop	•					••		—	21,17.81
	Write down due to rate for one of the dosage					apital wo	ork-in-pi 	rogress 	(30,37.42)	_
	Actuarial gain/(loss)	on employee b	penefits						(21,50.72)	1,52.73
									(51,88.14)	26,15.46
41	C.I.F. value of in	nports in re	espect	of:						
	Raw and packing ma	•							116,14.49	95,75.43
									301,39.10	204,55.85
	Components and spa	are parts for N	lachinery						69.86	
	Capital goods .								15,12.91	15,59.66
									433,36.36	315,90.94
42	Dividend remitte	ed in foreig	n curre	ency:					for 2013	<u>for 2012</u>
	On 3,04,85,250 equit	y shares to GI	axo Grou	p Limite	ed, U.K.				152,42.62	152,42.62
	On 2,06,09,774 equit	-				d, Singap	oore		103,04.89	_
	On 58,80,000 equity	shares to Eska	aylab Lim	ited, U.I	K				29,40.00	29,40.00
	On 33,60,000 equity	shares to Bur	roughs W	Vellcome	e Interna	tional Lir	nited, L	J.K.	16,80.00	16,80.00
	On 31,92,238 equity	shares to Cas	stleton Inv	vestmen	t Limitec	l, Mauriti	us		15,96.12	15,96.12
43	Expenditure in f	oreign cur	rency o	on acc	ount o	f:				
	- Travelling								2,39.59	95.33
	- Royalty								32.83	8.98
	– Others								14,36.86	6,50.17
									17,09.28	7,54.48
44	Earnings in fore	aign exchar	nae on	accou	int of					
	F.O.B. value of expor	-	-						6,31.18	9,46.88
	Recovery of expense	-	-	Jonant	CAPOILEIS	J			13.10	36.86
	Clinical research and		 ment						52,02.72	43,66.02
	Others	a and manage					••		11,45.64	9,05.01
									69,92.64	62,54.77



#### **45** Employee Benefits:

The company obtained actuarial reports as required by the Accounting Standard 15, Employee Benefits (revised 2005) ['the revised AS 15'], notified under sub-section (3C) of Section 211 of the Companies Act, 1956 based on which disclosures have been made in the financial statements for the fifteen months ended 31st March, 2015.

The disclosures as required by the revised AS 15 are as given below:

1 Brief description of the Plans

The Company has various schemes for long-term benefits such as provident fund, superannuation, gratuity and post retirement medical. In case of funded schemes, the funds are recognised by the Income tax authorities and administered through trustees / appropriate authorities. The Company's defined contribution plans are superannuation and employees' pension scheme (under the provisions of the Employees' Provident Funds and Miscellaneous Provisions Act, 1952) since the Company has no further obligation beyond making the contributions. The liability of the Company on the exempt Provident Fund managed by the trustees is restricted to the interest shortfall if any. The employees of the Company are also entitled to leave encashment and compensated absences as per the Company's policy. The Company's defined benefit plans include gratuity, post retirement medical and other benefits.

2	Charge to the Statement	of Profit	and Los	s based	on cont	ributions	5:	Rupees in lakhs	Previous year Rupees in lakhs
	Superannuation							 6,46.41	4,88.18
	Employees' pension sch	eme						 6,22.53	3,12.68

3 The liability for leave encashment and compensated absences as at period end is Rs. 43,01.90 lakhs (Previous year - Rs. 33,37.71 lakhs) #.

#### 4 Disclosures for defined benefit plans as on 31st March, 2015:

			Rupees in lakhs			Previous year Rupees in lakhs	
		Gratuity	Post retirement medical and other benefits	Provident Fund	Gratuity	Post retirement medical and other benefits	Provident Fund
		(Funded plan)	(Non-funded plan)	(Funded plans)	(Funded plan)	(Non-funded plan)	(Funded plan)
(i)	Change in Defined Benefit Obligation	pian)	piany	pians)	pian)	plany	pian)
	Opening defined benefit obligation	52,63.32	32,76.52	276,81.92	45,89.25	36,52.80	251,67.92
	Current service cost	4,54.31	45.46	11,84.63	3,36.05	45.01	8,44.41
	Interest cost	6,14.20	3,59.61	32,04.73	3,96.00	2,91.86	20,96.11
	Actuarial loss/(gain)	11,25.57	3,77.81	8,43.36	3,17.43	(4,52.18)	(11,43.63)
	Contributions by employee	—	—	32,43.09	—	—	22,92.08
	Liabilities assumed on acquisition/ (settled on divestiture)	(8.06)	_	(6,64.67)	(8.11)	_	(59.14)
	Benefits paid	(7,19.69)	(3,96.06)	(16,94.19)	(3,67.30)	(2,60.97)	(15,15.82)
	Closing defined benefit obligation	67,29.65	36,63.34	337,98.87	52,63.32	32,76.52	276,81.92
(ii)	Change in Fair Value of Assets						
	Opening fair value of plan assets	28,12.66		276,81.92	28,68.72		251,67.92
	Expected return on plan assets	2,72.43		34,14.49	2,29.84		25,16.42
	Actuarial gain/(loss)	(43.00)		6,33.60	81.40		(15,63.95)
	Contributions by employer	2,00.00		11,84.63	_		8,44.41
	Contributions by employee	_		32,43.09	—		22,92.08
	Assets Acquired on acquisition/ (settled on divestiture)	_		(6,64.67)	_		(59.14)
	Benefits paid	(7,19.69)		(16,94.19)	(3,67.30)		(15,15.82)
	Closing fair value of plan assets	25,22.40		337,98.87	28,12.66		276,81.92

			Rupees in lakhs	;		Previous year Rupees in lakhs	
		Gratuity	Post retirement medical and other benefits	Provident Fund	Gratuity	Post retirement medical and other benefits	Providen Fund
		(Funded plan)	(Non-funded plan)	(Funded plans)	(Funded plan)	(Non-funded plan)	(Fundeo plan
(iii)	Amount recognised in the Balance Sheet						
	Present value of obligations as at period end	67,29.65	36,63.34	337,98.87	52,63.32	32,76.52	276,81.92
	Fair value of plan assets as atperiod end	25,22.40		337,98.87	28,12.66		276,81.92
	Net (asset) / liability recognised as at period end #	42,07.25	36,63.34		24,50.66	32,76.52	
(iv)	Expenses recognised in the Statement of Profit and Loss						
	Current service cost Interest on defined benefit	4,54.31	45.46	11,84.63	3,36.05	45.01	8,44.41
	obligation	6,14.20	3,59.61	32,04.73	3,96.00	2,91.86	20,96.11
	Expected return on plan assets Net actuarial loss/(gain)	(2,72.43)		(34,14.49)	(2,29.84)		(25,16.42
	recognised in the current period	11,68.57	3,77.81	2,09.76	2,36.03	(4,52.18)	4,20.3
	Total expense	19,64.65	7,82.88	11,84.63	7,38.24	(1,15.31)	8,44.4
(v)	Asset information						
	Government of India Securities	42%		38%	40%		34%
	Corporate Bonds	27%		37%	27%		38%
	Special Deposit Scheme	28% 3%		16% 8%	25% 8%		209
	Others	3%		0%	070		89
(vi)	Principal actuarial assumptions used						
	Discount rate (p.a.) Expected rate of return on plan	7.90%	7.90%	7.90%	9.15%	9.15%	9.15
	assets (p.a.) Salary escalation rate	8.00% 7.00%		8.17% - 8.48%	7.50% 7.00%		8.55% - 9.44
	Annual increase in health care premiums (p.a.)		5%			5%	
(vii)	Effect of change in Assumed Health Care Cost Trend rate						
	1% increase		43.75			39.94	
	Effect on defined benefit obligation		4,27.90			3,49.38	
	1% decrease						
	Effect on the aggregate of service cost and interest cost		(34.60)			(32.08)	
	Effect on defined benefit obligation		(3,44.17)			(2,84.83)	
	Expected employer's contribution for the next period.	7,00.00	1,99.61	12,67.55	7,00.00	2,01.85	9,03.5

# excludes impact of actualisation of gratuity Rs. 22.01 lakhs, leave encashment and compensated absences Rs. 6.62 lakhs in the previous year



					Rup	ees in lakhs
(ix)	Net asset/liability recognised in the Balance Sheet (including experience adjustment impact)	15 Months March 2015	2013	2012	2011	2010
	Gratuity					
	Defined benefit obligation	67,29.65	52,63.32	45,89.25	47,30.42	46,72.26
	Plan assets	25,22.40	28,12.66	28,68.72	31,41.46	32,27.37
	Deficit/ (Surplus)	42,07.25	24,50.66	17,20.53	15,88.96	14,44.89
	Experience adjustments on plan liabilities	3,39.31	3,82.18	2,59.55	1,87.34	1,58.29
	Experience adjustments on plan assets	(43.00)	81.40	(1,78.15)	49.91	1,75.62
	Post retirement medical and other benefits					
	Defined benefit obligation	36,63.34	32,76.52	36,52.80	29,86.89	28,06.34
	Plan assets	_	_	_	_	_
	Deficit/(Surplus)	36,63.34	32,76.52	36,52.80	29,86.89	28,06.34
	Experience adjustments on plan liabilities	(1,14.49)	(1,08.91)	5,02.91	2,72.60	5,20.13
	Experience adjustments on plan assets				—	—

46 The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

#### 47 Related Party disclosures

1

Related party disclosures, as required by Accounting Standard 18, "Related Party Disclosures", notified under sub-section (3C) of Section 211 of the Companies Act, 1956 are given below:

- Relationships (during the period): Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company (i) Glaxo Group Limited, U.K. GlaxoSmithKline Pte Limited, Singapore Eskaylab Limited, U.K. Burroughs Wellcome International Limited, U.K. Castleton Investment Limited, Mauritius Holding company / ultimate holding company of the above shareholders \* GlaxoSmithKline plc, U.K. GlaxoSmithKline Finance plc, U.K. Setfirst Ltd. U.K. SmithKline Beecham Limited, U.K. Wellcome Limited, U.K. The Wellcome Foundation Limited, U.K. Wellcome Consumer Healthcare Limited, U.K. \* no transactions during the period
  - Subsidiary of the Company
     Biddle Sawyer Limited, a wholly owned subsidiary of the Company

(iii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the period: GlaxoSmithKline Asia Private Limited, India GlaxoSmithKline Brasil Ltda, Brazil GlaxoSmithKline Consumer Healthcare Limited, India GlaxoSmithKline Biologicals S.A., Belgium GlaxoSmithKline Services Unlimited, U.K. Glaxo Operations UK Limited, U.K Laboratoire GlaxoSmithKline S.A.S., France GlaxoSmithKline Export Limited, U.K. GlaxoSmithKline Research & Development Ltd GlaxoSmithKline Pte Limited, Singapore GlaxoSmithkline Philippines Inc., Philippines GlaxoSmithKline Australia Pty Limited, Australia GlaxoSmithKline Trading Services Limited, Ireland GlaxoSmithKline Limited, Hong Kong GlaxoSmithKline South Africa (Pty) Ltd, South Africa GlaxoSmithKline LLC, U.S.A Stiefel India Private Limited, India Glaxo Wellcome Ceylon Ltd., Sri Lanka US Pharmaceuticals, U.S.A. US GMS Financial Services, U.S.A.

(iv) Directors and members of GSK India Management Team and their relatives:

Mr. A. Aristidou (w.e.f 1st December, 2014)	Mr. P.V. Nayak
Ms. A. Bansal (w.e.f 19th February, 2013)	Mr. R. Bartaria
Mr. A.N. Roy	Mr. R.C. Sequeira
Mr. C.T. Renganathan (up to 31st December, 2014)	Mr. R.R. Bajaaj
Mr. D.S. Parekh	Mr. R. Krishnaswamy
Mr. D. Sundaram	Mr. S. Harford *
Dr. H.B. Joshipura	Dr. S. Joglekar (up to 21st February, 2014)
Mr. H. Buch	Mr. S. Khanna
Mr. K. Hazari	Mr. S. Dheri
Mr. M.B. Kapadia (up to 30th November, 2014)	Mr. S. Venkatesh (w.e.f 25th June, 2014)
Mr. N. Kaviratne	Ms. V. Desai (w.e.f 11th February, 2014)
Mr. P. Bhide	Mr. V. Thyagarajan

- \* no transactions during the period
- 2 The following transactions were carried out with the related parties in the ordinary course of business.
  - (i) Dividend paid to parties referred to in item 1(i) above:

#### Rupees in lakhs January 14 -March 15 2013 Glaxo Group Limited, U.K. .. 152,42.62 152,42.62 .. .. .. .. .. GlaxoSmithKline Pte Limited, Singapore 103,04.89 ... .. .. ... .. Eskaylab Limited, U.K. 29,40.00 29,40.00 .. .. .. ... ... ... .. Burroughs Wellcome International Limited, U.K. 16,80.00 16,80.00 ... .. ... .. 15,96.12 15,96.12 Castleton Investment Limited, Mauritius .. .. .. .. ..

(ii) Details relating to parties referred to in items 1(ii) and 1(iii) above:

					Ru	upees in lakhs
					Other com the GSK G	
			January 14 - March 15	2013	January 14 - March 15	2013
Purchase of materials/traded goods			—		542,80.41	436,34.10
Sale of materials/sale of products			_	—	3,82.35	4,79.63
Expenses recharged to other companies			2,90.85	2,63.56	21,77.00	16,57.31
Expenses recharged by other companies			_	—	59,82.25	28,00.34
Manufacturing charges recovered			1,45.16	98.29	6,49.09	3,02.63
Consignment sales commission received			67.26	63.61	21.22	30.95
Clinical research and data management rec	overie	s	_	_	52,02.72	43,66.02
Central Value Added Tax credits availed on related party (net)	behalf 	of a 	_	_	4,61.79	3,39.62
Employee benefits transferred to a related p	barty		_	_	16.83	14.83
Dividend received			_	25,00.00	—	
Outstanding (payables)/receivables at the per	iod en	d (net) #	(1,50.60)	(2,14.38)	(66,63.46)	(89,05.81)
	Sale of materials/sale of products Expenses recharged to other companies Expenses recharged by other companies Manufacturing charges recovered Consignment sales commission received Clinical research and data management rec Central Value Added Tax credits availed on related party (net) Employee benefits transferred to a related p Dividend received	Sale of materials/sale of products Expenses recharged to other companies Expenses recharged by other companies Manufacturing charges recovered Consignment sales commission received Clinical research and data management recoverie Central Value Added Tax credits availed on behalf related party (net) Employee benefits transferred to a related party Dividend received	Sale of materials/sale of products            Expenses recharged to other companies            Expenses recharged by other companies            Manufacturing charges recovered            Consignment sales commission received            Clinical research and data management recoveries           Central Value Added Tax credits availed on behalf of a related party (net)           Employee benefits transferred to a related party	the comp         January 14 - March 15         Purchase of materials/traded goods          Sale of materials/sale of products           Sale of materials/sale of products           Expenses recharged to other companies           Expenses recharged by other companies           Manufacturing charges recovered           Manufacturing charges recovered           Consignment sales commission received           Clinical research and data management recoveries           Central Value Added Tax credits availed on behalf of a related party (net)           Employee benefits transferred to a related party           Dividend received	March 152013Purchase of materials/traded goodsSale of materials/sale of productsExpenses recharged to other companiesExpenses recharged by other companiesManufacturing charges recovered1,45.16Onsignment sales commission received67.26Consignment sales commission receivedCentral Value Added Tax credits availed on behalf of a related party (net)Employee benefits transferred to a related partyDividend receivedDividend received	Subsidiary of the company (ii)Other com the GSK GJanuary 14 - March 15January 14 - March 15January 14 - March 15Purchase of materials/traded goodsSale of materials/sale of productsSubsidiary 0f March 15Other companiesSubsidiary 0f March 15January 14 - March 15January 14 - March 15Purchase of materials/sale of productsSale of materials/sale of productsSubsidiary 0f March 152013January 14 - March 15Sale of materials/sale of productsSale of materials/sale of productsSubsidiary 0f March 15Other companiesSubsidiary 0f Manufacturing charges recoveredManufacturing charges recoveredSubsidiary 0f Manufacturing charges recoveredOther companies67.26G3.6121.22Clinical research and data management recoveriesCentral Value Added Tax credits availed on behalf of a related party (net)Employee benefits transferred to a related partyDividend receivedManufacturing charges recovered<

# Transactions with the above parties are accounted in the respective current accounts.



(iii) Disclosure in respect of material transactions with parties referred to in item 1(iii) above:

					R	upees in lakhs
					January 14 - March 15	2013
(a)	Purchase of materials/traded goods					
	GlaxoSmithKline Asia Private Limited, India				152,68.08	178,75.66
	GlaxoSmithKline Biologicals S.A., Belgium				122,90.70	71,50.54
	GlaxoSmithKline Export Limited, U.K				244,48.19	172,48.31
(b)	Sale of materials/sale of products					
	GlaxoSmithKline Trading Services Limited, Ireland				3,82.35	4,79.63
(c)	Expenses recharged to other companies					
					6,15.72	7,33.87
	GlaxoSmithKline Consumer Healthcare Limited, India				3,90.66	
	GlaxoSmithKline Services Unlimited, U.K				2,89.40	3,47.35
	GlaxoSmithKline Trading Services Limited, Ireland				6,76.64	5,37.00
(d)	Expenses recharged by other companies					
	GlaxoSmithKline Consumer Healthcare Limited, India				29,97.00	23,61.99
	Glaxo Operations UK Limited, U.K				18,89.69	3.12
	GlaxoSmithKline Services Unlimited, U.K				6,36.55	2,06.81
(e)	Manufacturing charges recovered					
	GlaxoSmithKline Asia Private Limited, India				6,49.09	3,02.63
(f)	Consignment color commission received					
(f)	Consignment sales commission received					00.05
	GlaxoSmithKline Asia Private Limited, India				21.22	30.95
(g)	Clinical research and data management recoveries					
	GlaxoSmithKline Biologicals S.A., Belgium				31,84.22	22,54.07
	GlaxoSmithKline Services Unlimited, U.K				16,65.31	21,11.95
(h)	Central Value Added Tax credits availed on behalf of a	a relat	ed partv	(net)		
( )	Olever Overitte Klimer, Aleije, Deinester Lieseiteret, Jacobie				461.79	3,39.62
						0,00.02
(i)	Employee benefits transferred to a related party					
	GlaxoSmithKline Asia Private Limited, India				16.83	14.83
(j)	Outstanding (payables) / receivables at the period end	(net)				
0/	GlaxoSmithKline Asia Private Limited, India				(18,66.63)	(42,65.64)
	GlaxoSmithKline Consumer Healthcare Limited, India				19,63.87	15,74.56
	GlaxoSmithKline Biologicals S.A., Belgium				1,03.49	(24,76.08)
	Oleve Oreith Kline Evenent Lineited 111K				(54,22.00)	(40,46.21)
	Olava Oscilla Klima Taradia a Osmira a Linchad Inden d				92.79	88.05
	Clave CmithKling Conviged Unlimited U.K.				39.71	2,66.53
	Clave Operations LIK Limited LLK				(18,41.15)	_

(iv) Details relating to persons referred to in item 1(iv) above:

			F	Rupees in lakhs
			January 14 - March 15	2013
1	Remuneration/commission/sitting fees	 	 21,06.75	14,84.26
2	Payments under the long-term incentive plan	 	 6,16.81	1,10.29
3	Interest income on loans given	 	 0.68	0.75
4	Outstanding loans receivable	 	 16.13	23.59

(v) Disclosure in respect of material transactions with persons referred to in item 1(iv) above:

							R	lupees in lakhs
							January 14 - March 15	2013
(a)	Remuneration/com	missic	on/sitting	g fees				
	Dr. H.B. Joshipura					 	 4,94.83	4,00.13
	Mr. M.B. Kapadia					 	 3,63.02	2,34.33
(b)	Payments under the	e long	-term inc	centive p	olan			
	Dr. H.B. Joshipura					 	 1,20.41	33.35
	Mr. M.B. Kapadia					 	 2,11.12	23.18
	Mr. R.C. Sequeira					 	 32.52	11.04
(C)	Interest income on	loans	given					
	Mr. H. Buch					 	 0.28	0.23
	Mr. R. Bartaria					 	 0.04	0.18
	Mr. S. Dheri					 	 0.34	0.27
(d)	Outstanding loans	receiva	able					
	Mr. H. Buch					 	 7.29	7.47
	Mr. R. Bartaria					 	   _	5.98
	Mr. S. Dheri					 	 8.84	9.00

48 The foreign currency outstanding balances that have not been hedged by any derivative instrument or otherwise as at the Balance Sheet date are as follows:

Bu	nees	ın	lakhs

Particulars	Pound Sterling	United States Dollar		Japanese Yen	Singapore Dollar	UAE Dirham	Australian Dollar	South African Rand	Chinese Yuan	Hong Kong Dollar	Thailand Baht
Receivables	3.82 (1.42)	30,00.33 (9,64.84)	5,88.67 (11,59.09)	2.29 (2.56)	0.88 (0.20)	(0.38)	0.11		0.01 (0.01)	0.15	0.21
Payables	29,48.85 (16,20.16)	51,91.64 (61,32.22)	3,17.70 (2,08.00)				98.14	6.13	_		_

(Figures in brackets pertain to the year 2013)

- 49 Disclosures as required by Accounting Standard 19, "Leases", notified under sub-section (3C) of Section 211 of the Companies Act, 1956, are given below:
  - (i) The Company has taken various residential, office and godown premises under operating lease or leave and licence agreements. These are not non-cancellable and range between 11 months and 3 years under leave and licence, or longer for other leases and are renewable by mutual consent on mutually agreeable terms. The Company has given refundable interest free security deposits under certain agreements.
  - (ii) Lease payments are recognised in the Statement of Profit and Loss under 'Rent' in Note 35.



#### 50 Earnings per share

			15 months ended 31st March, 2015	12 months ended 31st December, 2013
Net Profit		Rupees in lakhs	471,64.58	501,88.24
Weighted average number of shares	 	 Nos.	8,47,03,017	8,47,03,017
Earnings per share (Basic and Diluted)	 	 Rs.	55.68	59.25
Face value per share	 	 Rs.	10	10

- 51 (a) Provision for tax is net of advance tax and tax deducted at source amounting to Rs. 251,92.00 lakhs (Previous year Rs. Nil).
  - (b) Advance income-tax (net) represents payments in excess of provisions of Rs. 2980,21.26 lakhs (Previous year Rs. 2980,21.26 lakhs) and includes a net tax refund with interest of Rs. 110,35.00 lakhs which has been held as provision pending the final outcome of a litigation.
- 52 Other Loans and advances are net of allowances for doubtful loans and advances aggregating Rs. 29,96.83 lakhs (Previous year Rs. 29,96.83 lakhs).
- 53 During the period, a complaint filed against the company and others by Bio Med (P) Ltd is pending determination before the Competition Commission of India (CCI).
- 54 In April 2014, GlaxoSmithKline Plc (GSK), London, UK, entered into an inter-conditional agreement with Novartis AG (Novartis), Basel, Switzerland where GSK (i) will acquire the Novartis's Vaccines Business and manufacturing capabilities and facilities from Novartis, and (ii) GSK sell the rights to its Marketed Oncology Portfolio, related R&D activities and AKT Inhibitors currently in development to Novartis. Globally, this transaction with Novartis was completed on March 2nd 2015.

In connection to the above transactions, the GlaxoSmithKline Pharmaceuticals Limited ("Company") Board in its meeting held on 12th February 2015, approved the transactions on an Asset Sale basis with Novartis Healthcare Private Limited, a private unlisted Company incorporated under the Companies Act 1956. Pursuant to the global deal, the Company will have its distribution rights terminated for the oncology portfolio in return for accessing the distribution rights of the acquired vaccines portfolio. The transaction would be profit neutral for the Company.

GSK Plc and Novartis AG have obtained the approval from Competition Commission of India. The Company has filed application with Foreign Investment Promotion Board (FIPB). The closing of the asset sales between the companies is subject to the receipt of all applicable legal and regulatory approvals, consent, permissions and sanctions as may be necessary from concerned authorities.

54 The accounting year of the company has been changed from January - December to April - March with effect from the current year. Consequently, the current year's financial statements are for the 15 months from 1st January, 2014 to 31st March, 2015. The previous year figures relate to the 12 months ended 31st December, 2013.

In view of the above, the current year's figures are not comparable with those of the previous year. Previous year's figures have been regrouped wherever necessary.

The accompanying notes are an integral part of the financial statements.

For Price Waterhouse & Co., Bangalore LLP Firm Registration No. 007567S / S-200012 Chartered Accountants

Priyanshu Gundana Partner Membership No. 109553

Mumbai, 18th May, 2015

For and on behalf of the Board

ChairmanD. S. PAREKH<br/>DIN: 9078Managing DirectorDr. H. B. JOSHIPURA<br/>DIN: 274288Executive DirectorA. A. ARISTIDOU<br/>DIN: 7034424Company SecretaryA. A. NADKARNIMumbai, 18th May, 2015

# Statement pursuant to Section 212 of the Companies Act, 1956

Name of the subsidiary company	Financial year ending of the subsidiary	Number of equity shares held	Extent of holding	For the financial year of the subsidiary		For the previous financial years since it became a subsidiary		
				Profits/(losses) so far as it concerns the members of the holding company and not dealt with in the holding company's accounts.	Profits/(losses) so far as it concerns the members of the holding company and dealt with in the holding company's accounts.	Profits/(losses) so far as it concerns the members of the holding company and not dealt with in the holding company's accounts.	Profits/(losses) so far as it concerns the members of the holding company and dealt with in the holding company's accounts.	
				Rs. lakhs	Rs. lakhs	Rs. lakhs	Rs. lakhs	
Biddle Sawyer Limited	31.03.2015	9,60,000 shares of Rs. 10 each	100%	4,76.51		132,41.82		

For and on behalf of the Board

Chairman	D. S. PAREKH
	DIN: 9078
Managing Director	Dr. H. B. JOSHIPURA
	DIN: 274288
Executive Director	A. A. ARISTIDOU
	DIN: 7034424
Company Secretary	A. A. NADKARNI

Mumbai, 18th May, 2015

#### Directors' Report to the Members

The Directors have pleasure in submitting their Report for the fifteen months period ended 31<sup>st</sup> March 2015. The Accounting year of the Company has been changed from January-December to April-March in line with the provisions of the Companies Act, 2013, which prescribe a uniform financial year. Accordingly, current year's Annual Accounts and Report of the Company are for a period of fifteen months from 1<sup>st</sup> January 2014 to 31<sup>st</sup> March 2015. These figures, therefore, are not comparable with those of the previous year ended 31<sup>st</sup> December 2013.

#### **Financial Results**

	Fifteen months period ended 31 <sup>st</sup> March 2015	Year ended 31 <sup>st</sup> December 2013
	Rs. in lakhs	Rs. in lakhs
Revenue from Operations	19,06.31	18,16.42
Profit before tax	7,05.84	7,13.03
Provision for Tax	2,29.85	2,34.83
Deferred Tax charge/(credit)	(0.52)	(0.24)
Net profit after tax	4,76.51	4,78.44
Opening surplus brought forward	9,10.85	33,85.81
Closing surplus carried forward	13,87.36	9,10.85

#### Dividend

The Directors do not recommend any Dividend for the fifteen months period ended  $31^{\mbox{\tiny st}}$  March 2015.

#### Operations

The Net Sales for the fifteen months period ended  $31^{\rm st}$  March 2015 was Rs. 1906.31 Lakhs. The Profit before Tax was Rs. 7.06 crores.

#### Directors

Mr. Raju Krishnaswamy retires by rotation and being eligible offers himself for re-appointment. The Board recommends his re-appointment.

#### **Directors' Responsibility Statement**

Your Directors confirm:

- (i) that in the preparation of the annual accounts, the applicable accounting standards have been followed;
- (ii) that the Directors have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the fifteen months period ended 31<sup>st</sup> March 2015 and of the profit of the Company for that period;
- (iii) that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (iv) that the Directors have prepared the annual accounts on a going concern basis.

#### Information Pursuant to Section 217 of the Companies Act, 1956

There are no employees covered within the purview of the provisions of Sub-Section (2A) of Section 217 of the Companies Act, 1956, as amended by Companies (Particulars of Employees) Rules, 1975.

Additional information on Conservation of Energy, Technology Absorption, Foreign Exchange earnings and outgo as required to be disclosed in terms of Section 217(1)(e) of the Companies Act, 1956, read with Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988, is annexed.

#### Appointment of Auditors

Members are requested to re - appoint Cornelius and Davar, Chartered Accountants, as the Auditors of the Company for the ensuing year and fix their remuneration.

#### Appreciation

The Directors place on record their appreciation of the co-operation received from the Company's suppliers and trade associates during the year.

#### Disclaimer

The Ministry of Corporate Affairs vide its Circular No. 8/2014 dated 4<sup>th</sup> April 2014 clarified that the financial statements and the documents required to be attached thereto, the Auditor's and Boards' Report in respect of the financial year under reference shall continue to be governed by the relevant provisions of the Companies Act, 1956 schedules and rules made thereunder. Accordingly, whilst the financial statements and the Auditor's Report as aforesaid are prepared as per the requirements of the Companies Act, 1956.

For and on behalf of the Board

Mumbai,	
Dated: 18th	May, 2015

Dr. H. B. Joshipura Chairman

#### Annexure to Directors' Report

#### A. CONSERVATION OF ENERGY:

- (a) Energy Conservation Measures taken : Nil
- (b) Additional proposal or activities, if any : Nil
- (c) Impact of measures taken : Nil
- (d) Total energy consumption and energy Conservation per unit of production : As per form A annexed hereto.

#### B. TECHNOLOGY ABSORPTION:

 (a) Efforts made in technology absorption : As per Form B annexed hereto.

#### FORM 'A'

FORM FOR DISCLOSURE OF PARTICULARS WITH REGARD TO CONSUMPTION OF ENERGY

I.	Pov	wer and Fuel Consumption:	Fifteen months period ended 31 <sup>st</sup> March 2015	Year ended 31 <sup>st</sup> December 2013
	1.	Electricity:		
		(a) Purchased	Nil	Nil
		Units Kwh		
		Total Amount Rs.		
		Rate/Unit Rs.		
		(b) Own Generation	Nil	Nil
	2.	Coal	Nil	Nil
	3.	Furnace Oil & LSHS	Nil	Nil
	4.	Others	Nil	Nil

II. Consumption per Unit of Production Standard:

Electricity (Units):

There is no specific standard as the consumption per unit depends on product mix of formulations (capsules, liquids, tablets etc.)

#### FORM 'B'

## FORM FOR DISCLOSURE OF PARTICULARS WITH REGARD TO TECHNOLOGY ABSORPTION

- 1) Specific Areas in which R&D is carried out by the Company : Nil
- 2) Benefits derived as a result of the above R&D : Nil
- 3) Future plan of action : Nil
- 4) Expenditure on R&D

1)

2)

31 <sup>st</sup>	March	2015
------------------	-------	------

Nil

Nil

- Rs. in lakhs
- Capital Nil Becurring Nil
- Recurring Total
- Total
   Total R&D expenditure as percentage of total turnover

Technology absorption, adaption and innovation

 Efforts in brief made towards technology absorption, adaption and innovation:

Adaptive development of products and processes with the objective of cost reduction.

- Benefits derived as a result of above efforts: Product improvement and cost reduction which are reflected in the quality and stability of products.
- 3) In case of imported technology (imported during the last 5 years)
  - (a) Technology Imported NA
  - (b) Year of Import NA
  - (c) Has technology been fully absorbed NA
  - (d) If not fully absorbed, areas where this has not taken place, reasons therefor, and future plan of action – NA

#### C. FOREIGN EXCHANGE EARNING AND OUTGO

- Activities relating to exports : Initiative taken to explore the exports markets.
- (2) Total Foreign Exchange earned and used:

		31 <sup>st</sup> March 2015 Rs. in lakhs
(1)	Foreign Exchange earned	Nil
(2)	Foreign Exchange outgo – CIF Value of imports	5,90.29
(3)	Travelling & Subscription	Nil

#### Auditors' Report

To Members of BIDDLE SAWYER LIMITED

- (1) We have audited the attached Balance Sheet of BIDDLE SAWYER LIMITED as at 31<sup>st</sup> March, 2015, and also the Profit and Loss Account of the Company for the Fifteen Months period ended on that date, annexed thereto both of which, we have signed under reference to this report. These financial statements are the responsibility of the Company's management. Our responsibilities are to express opinion on these financial statements based on our audit.
- (2) We conducted our audit in accordance with auditing standards accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatements. An audit also includes examining on a test basis, evidence supporting the amounts and disclosure in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
- (3) As required by the Companies (Auditor's Report) Order, 2003, issued by the Central Government in terms of Section 227 (4A) of the Companies Act, 1956, of India (the Act) and on the basis of such checks as we considered appropriate and according to the confirmation and explanation given to us, we enclose in the Annexure a statement on the matter specified in paragraphs 4 and 5 of the said Order.
- (4) Further to our comments in paragraph 3, we report that:
  - We have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of our audit;
  - (b) In our opinion, proper books of account as required by law have been kept by the Company, in so far as appears from our examination of the books of the Company.
  - (c) The Balance Sheet and Profit and Loss Account and cash flow statement referred to in this report are in agreement with the books of accounts.
  - (d) In our opinion, the Balance sheet and the Profit & Loss Account and cash flow statement, complies with the mandatory accounting standards referred to in Section 211(3C) of the Companies Act, 1956.
  - (e) On the basis of our review of the confirmation received from the Companies in which the Directors of the Company serve as Director and the information and explanations given to us, none of the Directors of the Company prima facie are disqualified from being appointed as Directors under clause (g) of subsection (1) of Section 274 of the Companies Act, 1956.
  - (f) Subject to the above, in our opinion, and to the best of our information and according to explanations given to us, the said accounts give the information required by Companies Act, 1956, in the manner so required and gives a true and fair view:
    - (i) in the case of the Balance sheet, of the state of affairs of the Company as at 31<sup>st</sup> March, 2015,
    - (ii) in the case of the Profit and Loss Account, of the Profit of the Company for the fifteen months period ended on that date.

#### And

(iii) in the case of the Cash Flow Statement, of the cash flow for the fifteen months period ended on that date.

For CORNELIUS & DAVAR Chartered Accountants

RUSTOM D. DAVAR (Proprietor) Membership No.: F. 10620

Place: Mumbai Date: 18th May, 2015

#### Annexure to the Auditors' Report

(Referred to in paragraph (3) of our report of even date)

- (i) (a) The Company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
  - (b) The fixed assets have been physically verified by the management and no material discrepancies have been noticed on such verification.
  - (c) In our opinion, the Company has not disposed of a substantial part of fixed assets during the year and the going concern status of the Company is not affected.
- (ii) (a) As explained to us, the inventory has been physically verified by management at reasonable intervals during the year. In our opinion, the frequency of such verification is reasonable.
  - (b) In our opinion and according to the information and explanations given to us, the procedures of physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the Company and the nature of its business.
  - (c) In our opinion and according to the information and explanations given to us, the Company has maintained proper records of inventory.
- (iii) The Company has not taken or granted any loans, secured or unsecured from/to companies, firms, or other parties covered in the register maintained under section 301 of the Companies Act, 1956.
- (iv) In our opinion and according to the information and explanations given to us, there are adequate internal control procedures commensurate with the size of the Company and the nature of its business with regard to purchases of inventory and fixed assets and with regard to the sale of goods and services. Further, on the basis of our examination of the books of account and according to the information and explanations given to us, we have not come across nor have we been informed of any instance of major weaknesses in the aforesaid internal controls.
- (v) In our opinion and according to the information and explanations given to us, there are no contracts or arrangements referred to in Section 301 of the Act during the year that need to be entered in the register maintained under that Section. Accordingly, clause (v)(b) of paragraph 4 of the Order is not applicable to the Company for the current year.
- (vi) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from public.
- (vii) The Company has internal audit system commensurate with size of the Company and the nature of its business.
- (viii) We have broadly reviewed the books of account maintained by the company, pursuant to the Rules made by the Central Government of India for the maintenance of cost records, under clause (d) of sub-section (1) of Section 209 of the Act and are of the opinion that prima facie, the prescribed accounts and records have been generally been maintained and are under preparation. We have not, however, made a detailed examination of the records with a view to determining whether they are accurate or complete.

- (ix) (a) According to the books of accounts and records as produced and examined by us in accordance with the generally accepted auditing practices in India, in our opinion, the Company is generally regular in depositing with appropriate authorities undisputed statutory dues including provident fund, Investor Education and Protection Fund, employees' state insurance, income-tax, sales-tax, wealth-tax, service-tax, customs duty,excise duty, cess and other material statutory dues applicable to it. According to the information and explanations given to us, no undisputed amount payable in respect of aforesaid dues were outstanding as at 31<sup>st</sup> March, 2015, for a period of more than six months from the date of becoming payable.
  - (b) According to the books of accounts and records as produced and examined by us in accordance with the generally accepted auditing practices in India, there are no dues of income tax, wealth tax, service tax, customs duty, excise duty and cess which have not been deposited on account of any dispute. The particulars of dues of sales tax as at 31<sup>st</sup> March, 2015 which have not been deposited on account of a dispute, is as follows:

Name of the statute	Nature of dues	Amount (Rs in '000)	Period to which the amount relates	Forum where the dispute is pending
West Bengal, VAT Act 2003	Sales Tax	19.96	Assessment Year 2009- 2010	Joint. Commissioner

- (x) The Company does not have any accumulated losses as at 31<sup>st</sup> March, 2015. The Company has not incurred cash losses during the financial year covered by our audit or in the immediately preceding financial year.
- (xi) According to the books of accounts and records of the Company, there has been no default in repayment of dues to any financial institution or bank during the year. The Company has not issued any debentures.
- (xii) According to the information and explanations given to us, the Company has not granted loans and advances on the basis of security by way of pledge of shares, debentures and other securities. Therefore, the provisions of clause 4(xii) of the Companies (Auditor's Report) Order, 2003, are not applicable to the Company.

- (xiii) In our opinion, the Company is not a chit fund or a nidhi mutual benefit fund/society. Therefore, the provisions of clause 4(xiii) of the Companies (Auditor's Report) Order, 2003, are not applicable to the Company.
- (xiv) In our opinion, the Company is not dealing in or trading in shares, securities, debentures and other investments. Accordingly, the provisions of clause 4(xiv) of the Companies (Auditor's Report) Order, 2003, are not applicable to the Company.
- (xv) According to the information and explanations given to us, the Company has not given any guarantees for loans taken by others from banks or financial institutions. Therefore, the provisions of clause 4(xv) of Companies (Auditor's Report) Order, 2003, are not applicable to the Company.
- (xvi) According to the information and explanations given to us, the company has not taken any term loans. Therefore, the provisions of clause 4(xvi), of Companies (Auditor's Report) Order, 2003, are not applicable to the Company.
- (xvii) According to the information and explanations given to us and on an overall examination of the Balance sheet of the Company, we report that no funds raised on short-term basis have been used for longterm investment.
- (xviii) According to the information and explanations given to us, during the period covered by our audit report, the Company has not made preferential allotment of shares to parties and companies covered in the register maintained under Section 301 of the Companies Act, 1956.
- (xix) According to the information and explanations given to us, the Company has not issued any debentures.
- (xx) During the period covered by our audit report, the Company has not raised any money by public issues.
- (xxi) To the best of our knowledge and belief and according to the information and explanations given to us, no fraud on or by the Company has been noticed or reported during the course of our audit.

For CORNELIUS & DAVAR Chartered Accountants

RUSTOM D. DAVAR (Proprietor) Membership No.: F. 10620

Place: Mumbai Date: 18<sup>th</sup> May, 2015

				Note	As at 31st	As at 31s
				Note	As at 31st March.	Decembe
					2015	201
					Rs. '000	Rs. '00
I.	EQ	UITY AND LIABILITIES				
	(1)	Shareholders' Funds				
		Share Capital		2	96,00	96,0
		Reserves and Surplus		3	23,96,28	19,19,7
	(2)	Non-Current Liabilities				
		Other Long-term liabilities		4	1,35	1,3
		Long-term provisions		5	1,25,33	1,25,3
	(3)	Current Liabilities				
		Trade payables		6	2,15,28	7,62,0
		Other current liabilities		7	4,09	5,3
		Short-term provisions		8		31,3
		Tot	al		28,38,33	29,41,2
п.	ASS	SETS				
	(1)	Non-current assets				
	• •	Fixed assets		9	2,08	2,0
		Deferred tax assets (net)		10	18,80	18,2
		Long-term loans and advances		11	4,85,58	4,86,0
		Other non-current assets		12	1,45	-
	(2)	Current assets				
		Inventories		13	6,72,68	4,57,2
		Trade receivables		14	1,50,60	2,14,3
		Cash and bank balances		15	12,58,89	14,44,8
		Short-term loans and advances		16	2,42,85	3,02,7
		Other current assets		17	5,40	15,6
		Tot	al		28,38,33	29,41,2
				L		
		mpanying notes are an integral part of these the report of even date attached	inan	cial stateme	For and on beh	alf of the Roa
		NELIUS & DAVAR		r. Hasit B. J		rew A. Aristid
		Accountants	U	r. Hasit B. J Chairm DIN: 274	an	Director Director DIN: 7034424
RUS	том	D. DAVAR		DIN: 274	200 L	/111. /034424
	prieto					
		hip No. F. 10620 Iumbai				
		lumbai Bth May, 2015				

Profit and Loss	s State	emen	t for	the 15	m	onths en	ded 31st Ma	rch, 2015
						Note No	15 Months Ended 31st March, 2015 Bs. '000	Year Ended 31st December, 2013 Rs. '000
Revenue from ope	rations	(Gros	(2)			21	20,07,79	19,06,25
Less: Excise duty							1,01,48	89,83
Revenue from ope	rations	(Net)					19,06,31	18,16,42
Other Income						22	1,27,18	1,14,13
Total Revenue							20,33,49	19,30,55
Expenses:								
Cost of materials of	consum	ied				23	7,50,27	5,11,90
Purchase of Stock						31	1,34	1,16,35
Changes in inve					ds,	24	(2,30,96)	(35,24)
work-in-progress a Other expenses	Sto	ск-Iп-I 				25	8,07,00	6,24,51
Total Expenses							13,27,65	12,17,52
Profit before tax							7,05,84	7,13,03
Tax expense:								
Current tax							2,29,85	2,34,83
Deferred tax							(52)	(24
Profit for the perio	d						4,76,51	4,78,44
Earnings per share Face value of shar	`			d) (Rs.)		26	49.64	49.84
The accompanying no	otes are a	an integ	gral par	t of these	fina	ncial statem	ents	
As per our report of e	ven date	attach	ed				For and on bel	half of the Board
For CORNELIUS & D Chartered Accountants						Dr. Hasit B. <i>Chairn</i>	nan	drew A. Aristidou Director
RUSTOM D. DAVAR (Proprietor) Membership No. F. 10 Place : Mumbai Date : 18th May, 201						DIN: 274	1288 [	DIN: 7034424

							15 Months	Yea
							Ended 31st March, 2015 Rs. '000	Ended 31s Decembe 201 Rs. '00
a.	CASH FLOW FROM			C 4 CT				
a.	Profit before tax			G ACI			7,05,84	7,13,0
	Adjustments for:						7,00,04	7,10,0
	Interest income	•					(1,27,18)	(98,5
	Operating profit be	etore v	vorking	capita	al char	iges	5,78,66	6,14,5
	Adjustments for: Inventories						(0.15.41)	(1 47 0
	Trade receivabl						(2,15,41) 63,78	(1,47,0
	Long-term loan		 advanc				63,76	(55,3
	Short-term loan						 50.95	(62.6
	Trade payables						59,85 (5,46,78)	(63,6 5,43,8
	Other current li						(3,40,78)	(4
	Cash generated fro						(61,20)	891,7
				,			(2,60,75)	(2,03,5
	Net cash from ope	rating	activiti	es		Α	(3,21,95)	6,88,2
b.	CASH FLOW FROM							
	(Purchase)/sale of period more than 12			its wit	h mat	urity	(1,45)	7,01,0
	Interest received						1,37,45	1,61,5
	Net cash from/(use	ed in)	investi	ng act	ivities	в	1,36,00	8,62,5
c.	CASH FLOW FROM Dividend paid	VI FIN		G ACT	IVITIE: 	S	_	(25,00,0
c.		VIFIN 	ANCINO 	G ACT  	IVITIE:  			
c.	Dividend paid	 			IVITIE:  			(4,05,5
c.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr	  inanc	  ing acti	 vities h and	  cash	  C	  	(4,05,5)
c.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi	 inanc rease)  ivalent	 ing acti in casi  ts as at	 vities h and 	  cash (A	 C +B)		(25,00,0 (4,05,5 (29,05,5 (13,54,7
с.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance)	 inanc rease)  ivalent	 ing acti in casl  ts as at 	 vities h and  1st Jar 	  (A nuary, 2	 C +B) 2014 	  	(4,05,5)
c.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi	 inanc rease)  ivalent	 ing acti in casl  ts as at 	 vities h and  1st Jar 	  (A nuary, 2	 C +B) 2014 		(4,05,5 (29,05,5 (13,54,7
C.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr	inanc rease)  ivalent  ivalent	 ing acti in casl  ts as at  ts as at 	 vities h and  1st Jar  31st M 	  (A nuary, 2  larch, 2 	 C +B) 2014 	14,44,84 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8
c.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr	inanc rease)  ivalent  ivalent	 ing acti in casl  ts as at  ts as at 	 vities h and  1st Jar  31st M 	  (A nuary, 2  larch, 2 	 C +B) 2014 	14,44,84	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8
	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents	inanc rease)  ivalent  ivalent  rease)	 ing acti in casi  ts as at  ts as at  in casi	 vities h and  1st Jar  31st M  h and	 cash (A nuary, 2  larch, 2  cash	 C +B) 2014  2015	14,44,84 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8
NC	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents	 iinanc ease)  iivaleni   	 ing acti in casl  ts as at  in casl 	 vities h and  1st Jar  31st M  h and 	 cash (A nuary, 2  larch, 2  cash	 C +B) 2014  2015	14,44,84 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8
	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents	 inanc ease)  ivaleni  ivalen  ease) 	 ing acti in casi ts as at  in casi  in casi  ts includ	 vities h and  1st Jar  31st M  h and 	 cash (A nuary, 2  larch, 2  cash	 C +B) 2014  2015	14,44,84 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8 (13,54,7
NC	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents	 iinanc ivalent         	 ing acti in casl  ts as at  in casl  ts includ 	 vities h and  1st Jar  31st M  h and  	  <b>cash</b> (A nuary, 4   <b>cash</b> 	 C +B) 2014  2015	14,44,84 12,58,89 (1,85,95)	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8 (13,54,7
NC	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents Cash and cash equi Cash and cash equi Cash and cash equi	 iinanc ivalent         	 ing acti in casl  ts as at  in casl  ts includ 	 vities h and  1st Jar  31st M  h and  	  <b>cash</b> (A nuary, 4   <b>cash</b> 	 C +B) 2014  2015 	14,44,84 12,58,89 (1,85,95) 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8 (13,54,7
NC	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents Cash and cash equi Cash and cash equi Cash and cash equi	 iinanc ease)  iivalen  ease)  iivalen   iivalen   iivalen         	 ing acti in casi  ts as at  in casi  ts inclut  ts inclut  valents ent hass ent hass	 vities h and  1st Jar  31st M  h and          	  cash (A huary, :   cash          	 C ++B) 2014  2015    	14,44,84 12,58,89 (1,85,95) 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,8 (13,54,7
NC 1. 2.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents TES: Cash and cash equi Cash and bank bala Total cash and cash The Cash Flow S under the "Indire Accounting Standar issued by the Institu India.	 iinanc iinanc iivalent  iivalent   iivalen   iivalen         	 ing acti in casl  ts as at  in casl  ts includ  ts includ  valents ethod" n Cash Chartere	 vities h and  1st Jar  31st M  h and          	  cash (A huary, :   cash          	 C ++B) 2014  2015    	14,44,84 12,58,89 (1,85,95) 12,58,89 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5
NC 1. 2.	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents DTES: Cash and cash equ Cash equ Cash and cash equ Cash equ C	 iinanc iinanc iivalent  iivalent   iivalen   iivalen         	 ing acti in casl  ts as at  in casl  ts includ  ts includ  valents ethod" n Cash Chartere	 vities h and  1st Jar  31st M  h and          	 cash (A huary, 1 larch, 2  cash         	 C +B) 2014  2015    ared t in ents ts of : Hasit	14,44,84 12,58,89 (1,85,95) 12,58,89 12,58,89 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,5 (13,54,7 14,44,5 14,44,5 14,44,5
NC 1. 2. As	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents TES: Cash and cash equi Cash equi C	 iinanc iinanc iivalent  iivalent   iivalen   iivalen         	 ing acti in casl  ts as at  in casl  ts includ  ts includ  valents ethod" n Cash Chartere	 vities h and  1st Jar  31st M  h and          	 cash (A huary, 1 larch, 2  cash         	 C +B) 2014  2015    ared t in ents ts of 	14,44,84 12,58,89 (1,85,95) 12,58,89 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,5 (13,54,7 14,44,5 14,44,5 14,44,5
NCC 1. 2. As   Prot Prot	Dividend paid Tax on Dividend Net cash used in f Net increase/(decr equivalents Cash and cash equi (opening balance) Cash and cash equi (closing balance) Net increase/(decr equivalents DTES: Cash and cash equ Cash equ Cash and cash equ Cash equ C	 iinanc iinanc iivalent  iivalent   iivalen   iivalen         	 ing acti in casl  ts as at  in casl  ts includ  ts includ  valents ethod" n Cash Chartere	 vities h and  1st Jar  31st M  h and          	 cash (A huary, 1 larch, 2  cash         	 C +B) 2014  2015    ared t in ents ts of 	14,44,84 12,58,89 (1,85,95) 12,58,89 12,58,89 12,58,89 12,58,89	(4,05,5 (29,05,5 (13,54,7 27,99,5 14,44,6 (13,54,7 14,44,6 14,44,6 14,44,6 14,44,6 14,44,6

#### SIGNIFICANT ACCOUNTING POLICIES:

#### (a) Basis of Accounting

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under convention on accrual basis. Pursuant to circular 15/2013 dated September 13, 2013 read with circular 08/2014 dated April 4, 2014, till the standards of accounting or any addendum thereto are prescribed by Central Government in consultation and recommendation of the National Financial Reporting Authority, the existing Accounting Standards notified under the Companies Act, 1956 shall continue to apply. Consequently, these financial statements have been prepared to comply in all material aspects with the accounting standards notified under Section 211(3C) [Companies (Accounting Standards) Rules 2006, as amended] and other relevant provisions of the Companies Act, 1956. All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Revised Schedule VI to the Companies Act, 1956. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current- non current classification of assets and liabilities. (b) Fixed Assets and Depreciation

Fixed assets are stated at cost of acquisition, including any attributable cost for bringing the asset to its working condition for its intended use, less accumulated depreciation. Interest on borrowings attributable to new projects is capitalised and included in the cost of fixed assets as appropriate.

The Company provides for depreciation on a straight line method. The depreciation rates used by the Company are equal to or higher than the principal rates specified in Schedule XIV to the Companies Act,1956 and where higher are as follows:

		S. L. N	<ol> <li>Rates %</li> </ol>
Buildings		 	3.50
Plant and Machinery (excluding Gas Installations)		 	10.00
Furniture and Fittings		 	10.00
Vehicles and Mainframe Computers		 	25.00
Personal Computers and Laptops		 	33.33
No write-offs are made in respect of leasehold lar	nd.		

Assets identified and evaluated technically as obsolete and held for disposal are stated at lower of book value and estimated net realisable value / salvage value

#### Investments (c)

Long term investments are stated at cost, except where there is a diminution in value other than temporary in which case the carrying value is reduced to recognise the decline. Current Investments are stated at cost or fair value whichever is less.

#### Inventories (d)

Raw materials, Packaging materials and Stores, Spares and Loose tools are valued at cost, on First-in First-out basis. Work-in-process is valued at cost of manufacturing which includes an appropriate portion of overheads upto the stage of completion. Finished goods is valued at lower of cost and estimated net realisable value.

#### (e) Revenue Recognition

Sales are recognised upon delivery of products and are recorded inclusive of excise duty but are net of trade discounts.

#### Foreign Currency transactions

Foreign currency transactions are accounted at the exchange rates prevailing at the date of the transaction. Gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies, are recognised in the Profit and Loss Account. Premium in respect of forward contracts is accounted over the period of the contract.

Research and Development (g)

> Capital expenditure on Research and Development is treated in the same way as expenditure on Fixed Assets. The revenue expenditure on Research and Development is written off in the year in which it is incurred.

#### Provision for Retirement Benefits

The Company has its own Gratuity Fund recognised by the Income Tax authorities and the fund is administered through Trustees. The Superannuation fund benefits is administered by a trust formed for this purpose through the Group Schemes of the Life Insurance Corporation of India, and the liability towards Superannuation is provided according to the rules of the Fund.

#### Excise Duty (i)

The excise duty in respect of closing inventory of finished goods is included as part of inventory. The amount of CENVAT credits in respect of materials consumed for sales is deducted from cost of materials consumed.

#### Taxes on Income

Current tax is determined as the amount of tax payable in respect of taxable income for the period. Deferred tax is recognised, subject to the consideration of prudence, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.

#### (k) Other Accounting Policies

These are consistent with the generally accepted accounting principles.

~					
			As at 31st rch, 2015 Rs. '000		As at 31st ber, 2013 Rs. '000
Δ+	horised				
1,50	00,000 (Previous year: 1,500,000) Equity ares of Rs. 10 each		1,50,00		1,50,00
Iss	ued, Subscribed & Paid-Up				
Sha	,000 (Previous year: 960,000) Equity ares of Rs. 10 each fully paid-up.		96,00		96,00
bee	the above 750,000 ordinary shares have in allotted as fully paid-up Bonus shares capitalisation of General Reserve)				
	Total		96,00		96,00
(a)	Shares held by holding company Equity Shares of Rs. 10 each 960,000 (Previous year: 960,000) held by GlaxoSmithKline Pharmaceuticals				
	Limited, the Holding Company		96,00		96,00
(b)	Reconciliation of the number of shares				-
		Number of Shares	Rs. '000	Number of Shares	Rs. '000
	Balance at the beginning of the year	960,000	96,00	960,000	96,00
	Issued during the year	-	-	-	-
	Balance at the end of the year	960,000	96,00	960,000	96,00
(c)	Rights, preferences and restrictions attached to equity shares:				
	The company has only one class of equity shares having a par value of Rs 10/- per share. Each share holder of equity shares is entiled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend. In the				
(d)	event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Details of shareholders holding more than 5% shares in the company:				
(d)	event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Details of shareholders holding more	Number of Shares		Number of Shares	
(d)	event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Details of shareholders holding more				

SHARE CAPITAL

2

at 31st cember, 2013 Rs. '000
cember, 2013
Rs. '000
2,91
—
2,91
9,58,17
47,84
0,06,01
3,85,81
4,78,44
5,00,00)
(4,05,56)
(47,84)
9,10,85
9,19,77

		As at 31st March, 2015 Rs. '000	As at 31st December, 2013 Rs. '000		As at 31st March, 2015 Rs. '000	As at 31st December, 2013 Rs. '000
4	OTHER LONG TERM LIABILITIES			10 DEFERRED TAX ASSET (Net)		
	Security Deposit	63 72	63 72	Deferred Tax Asset Provision for pricing of formulation	18,15	18,15
	Total	1,35	1,35	Expenses allowable for tax purposes when paid	65	13
	lotal			Total	18,80	18,28
5	LONG TERM PROVISIONS			11 LONG-TERM LOANS AND ADVANCES		
	Drugs Prices Equalisation Account (Refer note 19)	71,24	71,24			
	Provision for pricing of formulation	54,09	54,09	Balance with Government Authorities             Advance Income Tax	34,97 4,10,30	34,97 4,10,72
	Total	1,25,33	1,25,33	Unsecured, considered good	4,10,00	4,10,72
				Advances recoverable in cash or kind	26,68	26,68
				Sundry Deposits	13,63	13,63
6	TRADE PAYABLES			Total	4,85,58	4,86,00
	Micro and Small enterprises	4,95	3,67			
	Other Sundry Creditors	2,10,33	7,58,39			
	Total	2,15,28	7,62,06	12 OTHER NON-CURRENT ASSETS		
	There are no delays in payments to Micro and Small			Deposits with banks of maturity period more than 12 months	1.45	_
	enterprises as required to be disclosed under the Micro, Small and Medium Enterprises Development Act, 2006			Total	1.45	
	The above information has been determined to the extent such parties have been identified on the basis of information available with the Company. This has been relied upon by the Auditors.			13 INVENTORIES		
				Raw materials	2,35,21 48,05	2,45,59 53,22
7	OTHER CURRENT LIABILITIES			Packing materials	48,05 51,07	53,22 3,13
	Statutory dues	4,09	5,39	Finished goods	3,38,03	92,27
	Total	4,09	5,39	Stock-in-trade	32	63,06
				Total	6,72,68	4,57,27
8	SHORT TERM PROVISIONS					
	Provision for interim equity dividend	_	_	14 TRADE RECEIVABLES		
	Provision for tax on distributed profit Provision for Income Tax	-	31.32			
	Provision for Income Tax		31.32	Less than six months, Unsecured, considered good	150,60	214,38
	Iotai		01.02	Total	150,60	214,38
	L			L		

#### 9 TANGIBLE FIXED ASSETS

			GROSS	BLOCK			DEPREC	CIATION		NET BLOCK			
Sr. No.	Particulars	As at 01/01/2014	Additions	Deductions	As at 31/03/2015	As at 01/01/2014	for the year	Deductions	As at 31/03/2015	As at 31/03/2015	As at 31/12/2013		
1.	Land	2,08	-	-	2,08	-	-	-	-	2,08	2,08		
2.	Factory Building	16,98	-	-	16,98	16,98	-	-	16,98	-	-		
3.	Plant & Machinery	1,10,32	-	-	1,10,32	1,10,32	-	-	1,10,32	-	-		
4.	Furniture & Fixtures	13,48	-	-	13,48	13,48	-	-	13,48	-	-		
5.	Cycles	5	-	-	5	5	-	-	5	-	-		
6.	Computers	56,41	_	-	56,41	56,41	-	-	56,41	-	-		
	Total	1,99,32	-	-	1,99,32	1,97,24	-	-	1,97,24	2,08	2,08		
	Previous Year	1,99,32	_	-	1,99,32	1,97,24	-	-	1,97,24	2,08			

Rs. '000

	As at 31st March, 2015 Rs. '000	As at 31st December, 2013 Rs. '000	
15 CASH AND BANK BALANCES			
Bank balances In current accounts Other bank balances	58,89	1,43,39	21
Long term deposits with maturity period more than 3 months but less than 12 months	12,00,00 12,58,89	13,01,45 14,44,84	
16 SHORT-TERM LOANS AND ADVANCES			
Unsecured, considered good Advances to suppliers	2,42,77 8 2,42,85	3,02,62 8 3,02,70	22
17 OTHER CURRENT ASSETS			
Unsecured, considered good Interest accrued on Bank Deposits/Investments Total	<u> </u>	15,67 15,67	23
18 CONTINGENT LIABILITIES			
Claims against the Company not acknowledged as debts	14,25,85 19,96	12,92,67 —	
Guarantee given by the Company to the Customs Authorities	2,00,00	2,00,00	24
Company had filed its reply contending that no amount is payable into DPEA	49,29	49,29	
19 DRUGS PRICES EQUALISATION ACCOUNT			
The Company received a letter dated 20th/24th August, 1998 from the Central Government demanding an amount of Rs, 4,40,79,918 comprising Rs. 1,42,74,110 in respect of prices relating to Salbutamol formulations during the period April, 1979 to December, 1983 with interest thereon amounting to Rs. 2,98,05,808 upto 31st July, 1998. The Company had been legally advised that the demand of Rs, 1,42,74,110 is not sustainable and it, therefore follows that the interest demand also cannot be sustained. The total demand has been challenged by the Company in a Writ Petition filed in the Bombay High Court. The Bombay High Court has granted an interim stay of the demand, subject to the Company depositing 50% of the principal amount. Accordingly, the Company has deposited an amount of Rs. 71,50,000 with the Government on 3rd May, 1999. This is a normal interim order passed by the High court in such matters and does not in any way reflect upon the merits or otherwise of the case. The amount will be refunded if the Company succeeds at the final hearing of the matter. The Government's application in the Supreme Court praying that this writ petition be transferred to the Supreme Court from the Bombay High Court was not allowed and the Company's writ petition will now be heard by the Bombay High Court.			25
20 INTERIM DIVIDEND The interim dividend for the year is as follows:			
On Equity Shares of Rs. 10 each Amount of dividend		25,00,00 2,60	

							15 Months Ended 31st March, 2015 Rs. '000	Year Ended 31st December, 2013 Rs. '000
21	REVENUE FROM OPE	RATIO	ONS	(NET)				
	Sale of Products							
	Finished Goods						19,56,24	15,77,51
	Stock-in-Trade						51,55	3,28,74
	Other Operating Reven	ue					—	—
	Revenue from operation	ns (gr	oss)				20,07,79	19,06,25
	Less : Excise Duty						1,01,48	89,83
						Total	19,06,31	18,16,42
22	OTHER INCOME							
	Interest Income						1,27,18	98,50
	Miscellaneous Income							15,63
						Total	1,27,18	1,14,13
						iotai		1,14,10
00	COST OF MATERIAL			n				
دع							0 70 54	4 50 10
	Raw materials consume Packing materials cons			ote 29)			6,73,54 76,73	4,56,19
	Facking materials cons	umeu						55,71
						Total	7,50,27	5,11,90
	(Cost of materials con values)	sume	disi	based	on de	rived		
24	GOODS, WORK-IN-PF TRADE	NTO ROGR		OF AND		HED K-IN-		
	Opening inventories						00.07	70.70
	Finished Goods Work-in-Progress						92,27 3,13	78,76 5,19
	Stock-in-Trade						63,06	39,27
	Closing inventories							
	Finished Goods						(3,38,03)	(92,27)
	Work-in-Progress						(51,07)	(3,13)
	Stock-in-Trade					 Tatal	(32)	(63,06)
						Iotal	(2,30,96)	(35,24)
25	OTHER EXPENSES							
	Selling & Distribution E	xpens	es				3,62,05	3,65,31
	Manufacturing Charges						2,07,27	1,02,36
	Repairs – Building						9	1,52
	Rent Rates and Taxes						4,71	5,99
	Excise Duty						17,27 39,04	49,49 (27,09)
	Remuneration of audito						00,04	(27,00)
	Statutory audit fees						3,09	2,47
	Tax audit fees						84	67
	Other services						47	52
	Reimbursement of ex	pense	es				88	60
	Cost audit fees						25	17
	Reimbursement of ex Pharmaceuticals Limite		es to	Glaxo	Smith	Kline	98,69	81,82
	Exchange loss (net)						9,64	_
	Miscellaneous Expense	S					62,71	40,68
						Total	8,07,00	6,24,51

	15 Months Ended 31st March, 2015 Rs. '000	Year Ended 31st December, 2013 Rs. '000
26 EARNINGS PER SHARE		
Earnings per share		
Earnings per share is calculated by dividing the profit attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. The numbers used in calculating basic and diluted earnings per equity share are as stated below:		
Profit after taxation (Rs. '000)	4,76,51	4,78,44
Weighted average number of shares (Nos.)	96,00,00	96,00,00
Earnings per share (Basic and Diluted) - Rs	49.64	49.84
Face value per share - Rs	10	10
27 CIF VALUE OF IMPORTS		
Raw and packing materials	5,90,29	4,79,11
Total	5,90,29	4,79,11
		.,,
28 VALUE AND PERCENTAGE OF IMPORTED / INDIGENOUS MATERIALS CONSUMED Raw and packing materials Imported 89 Indigenous 11 Total	6,71,19 79,08 7,50,27	% 85 4,34,74 15 <u>77,16</u> 5,11,90
29 RAW AND PACKING MATERIALS CONSUMED		
Alpha D3	5,49,41	3,71,69
Others	1,24,13	84,50
Packing Material		55,71
Total	7,50,27	5,11,90
30 SALES OF TRADED GOODS		
Tablets	51,55	3,28,74
Total	51,55	3,28,74
31 PURCHASE OF TRADED GOODS		
	1,34	1,16,35
Tablets		

#### 32 SEGMENT REPORTING

The Company has only one segment namely pharmaceuticals; hence no separate disclosure of segment-wise information has been made.

#### **33 RELATED PARTY DISCLOSURES**

 Related parties with whom there were transactions during the year are listed below:

Holding Company:

The Company is a wholly owned subsidiary of GlaxoSmithKline Pharmaceuticals Limited.

2. The following transactions were carried out with the related parties at normal commercial terms in the ordinary course of business.

		Rs. '000			
	Holding Company				
	15 Months Period Ended 31st March, 2015	Year Ended 31st December, 2013			
1. Payment of manufacturing charges	145,16	98,29			
2. Payment of common costs	110,89	91,93			
3. Payment of CSA commission	75,57	71,47			
4. Payment of marketing commission	2,15,91	2,04,21			
5. Dividend payable	—	25,00,00			
6. Outstanding payable/(receivable) by the Company (net) <sup>@</sup>	(1,50,60)	(2,14,38)			
<sup>®</sup> Transactions with the above parties are accounted in the respective current accounts.					

#### 34 UNHEDGED FOREIGN CURRENCY EXPOSURE

The foreign currency exposures not hedged as at the year end are as under:

				Rs. '000	
Currency Exchange	As at 31 20	st March, 15	As at 31st December, 2013		
	USD	Euro	USD	Euro	
Net unhedged exposure in currency	(216,18)	40,39	(424,57)	45,46	

#### 35 CHANGE IN FINANCIAL YEAR

The accounting year of the company has been changed from January - December to April - March with effect from the current year. Consequently, the current year's financial statements are for the 15 months from 1st January, 2014 to 31st March, 2015.

The previous year figures relate to the 12 months ended 31st December, 2013. In view of the above, the current year's figures are not comparable with those of the previous year.

As per our report of even date attached For CORNELIUS & DAVAR Chartered Accountants For and on behalf of the Board
Dr. Hasit B. Joshipura
Chairman
Director
DIN: 274288
DIN: 7034424

RUSTOM D. DAVAR (Proprietor) Membership No. F. 10620 Place : Mumbai Date : 18th May, 2015



## Independent Auditors' Report

#### To the Board of Directors of GlaxoSmithKline Pharmaceuticals Limited

1. We have audited the accompanying consolidated financial statements (the "Consolidated Financial Statements") of GlaxoSmithKline Pharmaceuticals Limited ("the Company") and its subsidiary; hereinafter referred to as the "Group" (refer Note 1A to the attached consolidated financial statements) which comprise the consolidated Balance Sheet as at March 31, 2015, the consolidated Statement of Profit and Loss for the 15 months period from January 1, 2014 to March 31, 2015 (the "period") and consolidated Cash Flow Statement for the period then ended, and a summary of significant accounting policies and other explanatory information which we have signed under reference to this report.

#### Management's Responsibility for the Consolidated Financial Statements

2. The Company's Management is responsible for the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with accounting principles generally accepted in India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

#### Auditors' Responsibility

- 3. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
- 4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Management, as well as evaluating the overall presentation of the consolidated financial statements.
- 5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

- 6. We report that the consolidated financial statements have been prepared by the Company's Management in accordance with the requirements of Accounting Standard (AS) 21 Consolidated Financial Statements notified under the Companies Act, 1956 read with the General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013.
- 7. Based on our audit and on consideration of reports of other auditor on separate financial statements as referred to in paragraph 8 below, and to the best of our information and according to the explanations given to us, in our opinion, the accompanying consolidated financial statements give a true and fair view in conformity with the accounting principles generally accepted in India:
  - (a) in the case of the consolidated Balance Sheet, of the state of affairs of the Group as at March 31, 2015;
  - (b) in the case of the consolidated Statement of Profit and Loss, of the profit for the period ended on that date; and
  - (c) in the case of the consolidated Cash Flow Statement, of the cash flows for the period ended on that date.

#### Other Matter

8. We did not audit the financial statements of subsidiary included in the consolidated financial statements, which constitute total assets of Rs 2,687.73 lakhs and net assets of Rs 2,341.68 lakhs as at March 31, 2015, total revenue of Rs. 2,033.49 lakhs, net profit of Rs 689.51 lakhs and net cash outflows amounting to Rs 37.33 lakhs for the period then ended. These financial statements and other financial information have been audited by other auditors whose report has been furnished to us, and our opinion on the consolidated financial statements to the extent they have been derived from such financial statements is based solely on the report of such other auditor.

For Price Waterhouse & Co Bangalore LLP Firm Registration Number: 007567S/ S -20012 Chartered Accountants

Place : Mumbai Date : May 18, 2015 Priyanshu Gundana Partner Membership Number : 109553

## Consolidated Balance Sheet as at 31st March, 2015

					Rupees ir	n lakhs
				Note No.	As at 31st March, 2015	As at 31st December, 2013
EQUITY AND LIABILITIES						
SHAREHOLDERS' FUNDS						
Share Capital	 	 		 2	84,70.30	84,70.30
Reserves and Surplus	 	 		 3	1744,27.51	1905,03.20
NON-CURRENT LIABILITIES						
Long-term borrowings	 	 		 4	2,62.60	3,60.50
Other long-term liabilities	 	 		 5	5,30.21	4,98.07
Long-term provisions	 	 		 6	272,21.20	242,29.37
CURRENT LIABILITIES						
Trade payables	 	 		 7	308,03.89	285,63.28
Other current liabilities	 	 		 8	130,09.02	84,13.08
Short-term provisions	 	 		 9	668,41.92	519,14.55
			TOTAL		3215,66.65	3129,52.35
ASSETS						
NON-CURRENT ASSETS						
Fixed assets						
Tangible assets	 	 		 11	123,08.04	100,09.26
Intangible assets	 	 		 12		_
Capital work-in-progress	 	 			115,22.44	61,86.01
Non-current investments	 	 		 13	5.67	5.67
Deferred tax assets (net)	 	 		 14	83,10.23	92,28.93
Long-term loans and advances	 	 		 15	293,16.61	237,73.39
Other non-current assets	 	 		 16	14,05.48	13,55.38
CURRENT ASSETS						
Current investments	 	 		 17		10,00.25
Inventories	 	 		 18	375,58.27	346,97.00
Trade receivables	 	 		 19	100,31.79	96,39.32
Cash and bank balances	 	 		 20	1910,60.64	2041,58.45
Short-term loans and advances		 		 21	122,17.17	72,94.07
Other current assets	 	 		 22	78,30.31	56,04.62
			TOTAL		3215,66.65	3129,52.35
					L	1

#### The accompanying notes are an integral part of these consolidated financial statements

This is the Consolidated Balance Sheet referred to in our report of even date

For Price Waterhouse & Co., Bangalore LLP	For and on behalf of the Board				
Firm Registration No. 007567S / S-200012 Chartered Accountants	Chairman	D. S. PAREKH DIN: 9078			
Priyanshu Gundana Partner	Managing Director	Dr. H. B. JOSHIPURA DIN: 274288			
Membership No. 109553	Executive Director	A. A. ARISTIDOU DIN: 7034424			
	Company Secretary	A. A. NADKARNI			
Mumbai, 18th May, 2015	Mumbai, 18th May, 2015				



## Consolidated Statement of Profit and Loss for the 15 months ended 31st March, 2015

									nupees in	
								Note No.	15 months ended 31st March, 2015	12 months ended 31st December, 2013
Sale of p	products								3378,62.28	2612,45.57
Excise d	uty								(106,14.99)	(74,11.91)
Sale of p	products (net)								3272,47.29	2538,33.66
Other op	perating revenue								32,04.40	24,35.61
Revenue	from operations							 30	3304,51.69	2562,69.27
Other Inc	come							 31	199,94.34	176,95.36
					т	OTAL RE	/ENUE		3504,46.03	2739,64.63
Cost of r	materials consume	d						 32	734,23.73	543,68.64
Purchase	es of traded goods	S						 33	779,90.73	671,16.46
Changes	in inventories of f	inisheo	d goods, w	ork-in-pro	gress and	traded go	ods	 34	(3,69.65)	(51,09.95)
Employe	e benefits expense	э						 35	493,02.23	362,04.85
Deprecia	ation expense							 11	25,35.25	19,88.14
Other ex	penses							 36	668,07.47	508,66.89
					тс	OTAL EXPI	INSES		2696,89.76	2054,35.03
Profit bet	fore exceptional ite	ems an	d tax						807,56.27	685,29.60
Exceptio	nal Items							 41	(51,88.14)	26,15.46
Profit be	fore Tax								755,68.13	711,45.06
Tax expe	ense:									
С	urrent tax								270,08.34	235,35.18
De	eferred tax								9,18.70	(5,56.80)
Net Profi	it								476,41.09	481,66.68
	s per equity share ue Rs. 10 each	(basic 	and diluted 	) (Rs.) 				 47	56.24	56.87

The accompanying notes are an integral part of these consolidated financial statements

This is the Consolidated Statement of Profit and Loss referred to in our report of even date

For Price Waterhouse & Co., Bangalore LLP	For and on behalf of the Board				
Firm Registration No. 007567S / S-200012 Chartered Accountants	Chairman	D. S. PAREKH DIN: 9078			
Priyanshu Gundana Partner	Managing Director Dr. H. B. JOSHIPU DIN: 274288				
Membership No. 109553	Executive Director	A. A. ARISTIDOU DIN: 7034424			
	Company Secretary	A. A. NADKARNI			
Mumbai, 18th May, 2015	Mumbai, 18th May, 2015				

## GlaxoSmithKline Pharmaceuticals Limited

## Consolidated Cash Flow Statement for the 15 months ended 31st March, 2015

							Rupees in	lakhs
							15 months ended 31st March, 2015	12 months ended 31st December, 2013
a.	CASH FLOW FROM OPERATING ACTIVITIES							
	Profit before taxation and exceptional items						807,56.27	685,29.60
	Adjustments for :							
	Provision written back as no longer required						(42.99)	(42.32)
	Profit on sale / disposal of tangible assets (ne	t)					(58.00)	(1,64.92)
	Interest income						(198,47.62)	(174,46.77)
	Interest expense						46.90	33.16
	Depreciation						25,35.25	19,88.14
	Unrealised foreign currency (loss) / gains						_	(4.18)
	Operating profit before working capital changes						633,89.81	528,92.71
	Adjustments for :							
	Inventories						(28,61.27)	(61,82.49)
	Trade Receivables						(3,92.47)	19,50.48
	Short-term loans and advances						(49,23.10)	(13,52.27)
	Other current assets						(1.57)	8.66
	Other non-current assets						(50.10)	661.12
	Long-term loans and advances						(3,01.88)	(13,35.44)
	Trade payables						22,40.61	48,26.22
	Provisions						7,50.25	29,97.11
	Other current liabilities						18,17.57	(4,28.84)
	Other long-term liabilities						32.14	_
	Cash generated from operations						596,99.99	540,37.26
	Direct taxes paid (net of refunds)						(252,42.74)	(244,08.84)
	Cash flow before exceptional items						344,57.25	296,28.42
	Exceptional items:							
	Payments under Voluntary Retirement Scheme						(4,74.75)	(3,90.28)
	Non recurring expenses for rationalisation initiatives	S					(2,18.16)	(11,06.72)
	Net cash generated from operating activities					Α	337,64.34	281,31.42
b.	CASH FLOW FROM INVESTING ACTIVITIES							
	Purchase of tangible fixed assets						(163,12.28)	(58,22.17)
	Sale of tangible fixed assets						73.24	6,50.90
	Sale of property (Exceptional item)						_	21,41.02
	Expenses relating to sale of property (Exceptional i	tem)					_	(23.21)
	Sale / redemption of current investments	′					10,00.01	44,90.90
	Investment in bank deposits (having original maturi	ty more	e than 3 r	nonths)			(2774,48.55)	(2149,75.00)
	Redemption / Maturity of bank deposits (having				than			
	3 months)						2927,50.00	2151,13.55
	Interest received						179,38.30	173,21.75
	Net cash from investing activities					в	180,00.72	188,97.74
								]

## GlaxoSmithKline Pharmaceuticals Limited



## Consolidated Cash Flow Statement (Contd.)

										Rupees ir	ı lakhs
										15 months ended 31st March, 2015	12 months ended 31st December, 2013
c.	CAS	H FLOW FROM FIN	NANCING ACT	IVITIES	5						
	Repa	ayments of borrowin	gs							(1,02.69)	(45.09)
	Inter	est paid								(46.90)	(33.16)
	Divic	lend paid								(422,14.19)	(421,37.90)
	Tax	on distributed profit								(71,97.64)	(71,97.64)
	Net	cash used in finan	cing activities						с	(495,61.42)	(494,13.79)
	Net	increase/(decrease	) in cash and	cash e	quivalents				(A+B+C)	22,03.64	(23,84.63)
	Casł	n and cash equivale	nts as at 1st Ja	nuary,	2014 (openiı	ng balan	ice)			113,82.00	137,66.63
	Casł	n and cash equivale	nts as at 31st N	/larch, 2	2015 (closing	g balanc	e)			135,85.64	113,82.00
	Net	increase/(decrease	) in cash and	cash e	quivalents					22,03.64	(23,84.63)
	NOT	'ES:									
	1.	Cash and cash equ	ivalents include	e:							
		Cash on hand								0.76	1.67
		Term deposits	with original m	aturity	period of les	s than tl	hree mont	hs		60,02.00	23,54.00
		Balances with	banks							55,56.66	71,37.42
		Unclaimed div	idend accounts	i						20,26.22	18,88.91
		Total cash and	l cash equivale	nts						135,85.64	113,82.00
	2.	Other Bank balance	es include:								
		Term deposits with	original maturi	ty perio	d of more th	an three	e months			1774,75.00	1927,76.45

3. The Consolidated Cash Flow Statement has been prepared under the "Indirect Method" as set out in Accounting Standard-3 on Cash Flow Statements, notified under sub-section (3C) of Section 211 of the Companies Act, 1956.

This is the Consolidated Cash Flow Statement referred to in our report of even date

For Price Waterhouse & Co., Bangalore LLP	For and on behalf of the Board				
Firm Registration No. 007567S / S-200012 Chartered Accountants	Chairman	D. S. PAREKH DIN: 9078			
Priyanshu Gundana Partner	Managing Director	Dr. H. B. JOSHIPURA DIN: 274288			
Membership No. 109553	Executive Director	A. A. ARISTIDOU DIN: 7034424			
	Company Secretary	A. A. NADKARNI			
Mumbai, 18th May, 2015	Mumbai, 18th May, 2015				

#### **1A** GENERAL INFORMATION

GlaxoSmithKline Pharmaceuticals Limited ('the Company') is a public limited company and is listed on the BSE Ltd (Bombay Stock Exchange) and the National Stock Exchange of India Ltd (NSE). The Company and its subsidiary (jointly referred to as the 'Group' hereinunder) are engaged inter alia, in the business of manufacturing, distributing and trading in pharmaceuticals.

The subsidiary considered in these consolidated financial statements is :

Name of the Company	Country of incorporation	% voting power held as at 31st March, 2015	% voting power held as at 31st December, 2013
Biddle Sawyer Limited (BSL)	India	100	100

#### **1B** STATEMENT OF ACCOUNTING POLICIES

(a) Basis for preparation of accounts

The consolidated financial statements are prepared under the historical cost convention and comply in all material aspects with the applicable accounting principles in India and the accounting standards notified under sub-section (3C) of Section 211 of the Companies Act, 1956 and the other relevant provisions of the Companies Act, 1956.

All assets and liabilities have been classified as current or non-current as per the Group's normal operating cycle and other criteria set out in the Revised Schedule VI to the Companies Act, 1956.

#### (b) Principles of consolidation

The consolidated financial statements relate to GlaxoSmithKline Pharmaceuticals Limited (the 'Company') and its wholly owned subsidiary. The consolidated financial statements have been prepared on the following basis:

- The financial statements of the Company and its subsidiary have been combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-group balances and intra-group transactions resulting in unrealised profits or losses.
- The consolidated financial statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner as the Company's separate financial statements.
- The excess of cost to the Company of its investment in the subsidiary is recognised in the financial statements as goodwill, which is amortised over a period of ten years.

These are set out in the notes to the financial statements under "Statement of Accounting Policies" of the financial statements of the Company and BSL.

					Rupees in	lakhs
					As at 31st March, 2015	As at 31st December, 2013
2	SHARE CAPITAL					
	AUTHORISED 9,00,000,000 equity shares of Rs. 10 each		 		 90,00.00	90,00.00
	ISSUED 8,47,07,710 equity shares of Rs. 10 each		 		 84,70.77	84,70.77
	SUBSCRIBED AND PAID-UP 8,47,03,017* equity shares of Rs. 10 each, fully paid	d up	 		 84,70.30	84,70.30
				TOTAL	 84,70.30	84,70.30

\* excludes 4,693 equity shares of Rs. 10 each of the Company [3,352 equity shares of Rs. 10 each of erstwhile Burroughs Wellcome (India) Limited] held in abeyance.

			As at 31st Mar	rch, 2015	As at 31st December, 2013		
			Number of Shares	Rupees in lakhs	Number of Shares	Rupees in lakhs	
(a)	Reconciliation of the number of shares : Balance at the beginning of the period Issued during the period	   	84,703,017	84,70.30 —	84,703,017	84,70.30 —	
	Balance at the end of the period	 	84,703,017	84,70.30	84,703,017	84,70.30	

<sup>(</sup>c) Other Significant Accounting Policies



#### Notes to the Consolidated Financial Statements for the 15 months ended 31st March, 2015 — continued

#### 2 SHARE CAPITAL (Contd.)

(b) Rights, preferences and restrictions attached to equity shares:

The Company has one class of equity shares having a par value of Rs. 10 per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

(c) Shares held by subsidiaries of ultimate holding company in aggregate

	Number of	Rupees	Number of	Rupees
	Shares	in lakhs	Shares	in lakhs
Equity shares of Rs. 10 each (representing 75.00% of total shareholding [previous year 50.67%])	63,527,262	63,52.73	42,917,488	42,91.75

(d) Details of equity shares held by shareholders holding more than 5% shares of the aggregate shares in the Company:

	Number of	%	Number of	%
	Shares	Shareholding	Shares	Shareholding
Glaxo Group Limited, U.K	30,485,250	35.99%	30,485,250	35.99%
GlaxoSmithKline Pte Limited, Singapore	20,609,774	24.33%	—	_
Eskaylab Limited, U.K	5,880,000	6.94%	5,880,000	6.94%
Life Insurance Corporation of India	4,749,658	5.61%	4,822,848	5.69%

#### **RESERVES AND SURPLUS** 3

						Rupees in	lakhs
						As at 31st March, 2015	As at 31st December, 2013
CAPITAL RESERVE							
Balance as at the beginning of the pe	eriod		 			1,70.97	1,70.97
Additions/Deductions			 				
Balance as at the end of the period			 		(a)	1,70.97	1,70.97
CAPITAL REDEMPTION RESERVE							
Balance as at the beginning of the pe	eriod		 			2,62.00	2,62.00
Additions/Deductions			 				_
Balance as at the end of the period			 		(b)	2,62.00	2,62.00
GENERAL RESERVE							
Balance as at the beginning of the pe	eriod		 			816,04.13	765,37.47
Transfer from Surplus in Statement of	f Profit a	and Loss	 			47,16.46	50,66.66
Balance as at the end of the period			 			863,20.59	816,04.13
SURPLUS IN STATEMENT OF PRO	FIT AND	LOSS					
Balance as at the beginning of the pe	eriod		 			1084,66.10	1152,42.39
Profit for the period			 			476,41.09	481,66.68
Less : Appropriations			 				
Proposed Dividend			 			(529,39.38)	(423,51.50)
Tax on dividend			 			(107,77.40)	(75,24.81)
Transfer to General Reserve			 			(47,16.46)	(50,66.66)
Balance as at the end of the period			 			876,73.95	1084,66.10
				TOTAL		1744,27.51	1905,03.20
							1

(a) Includes Central Government subsidy Rs. 15.00 lakhs and capital profit on reissue of shares forfeited of erstwhile Burroughs Wellcome (India) Limited Rs. 0.51 lakhs.

(b) Includes Rs. 2,61.95 lakhs on account of buy back of equity shares.

		Rupees in	lakhs
		As at 31st March, 2015	As at 31st December, 2013
4	LONG TERM BORROWINGS		
1.1	Unsecured		
	Interest free sales tax loan from SICOM Limited	2,62.60	3,60.50
	TOTAL	2,62.60	3,60.50
	Terms of repayment		
	Interest free Sales Tax Loan from SICOM Limited as at 31st March, 2015 of Rs. 3,11.55 lakhs (previous year Rs. 4,14.24 lakhs) includes NIL (previous year Rs. 4.80 lakhs repayable in one installment) availed under the 1988 Sales Tax deferment Scheme, closing on 31st January, 2014 and Rs. 3,11.55 lakhs (previous year Rs. 4,09.44 lakhs) under the 1993 Sales Tax deferment Scheme repayable in twenty one instalments (previous year twenty seven instalments) closing on 30th April, 2021. The current maturity amount of Rs. 48.95 lakhs (previous year Rs. 53.74 lakhs) of the loan has been disclosed under Note 8 - Other Current Liabilities.		
5	OTHER LONG TERM LIABILITIES		
	Security deposits received	2,37.35	2,82.35
	Other long term liabilities	2,92.86	2,15.72
	TOTAL	5,30.21	4,98.07
6	LONG TERM PROVISIONS		
	For Pricing matters (Refer Note 24 and 25)	123,96.15	123,96.15
	For employee benefits </th <td>42.07.25</td> <td>24,50.66</td>	42.07.25	24,50.66
	Leave encashment and compensated absences	40,49.66	29,65.19
	Post retirement medical and other benefits	34,63.73	30,74.67
	For long term incentive plan <td>6,22.52 12,02.83</td> <td>6,59.55 16,13.72</td>	6,22.52 12,02.83	6,59.55 16,13.72
	For others	12,79.06	10,69.43
	TOTAL	272,21.20	242,29.37
7	TRADE PAYABLES		
÷	Micro and Small enterprises	2,59.25	3,82.68
	Others	305,44.64	281,80.60
	TOTAL	308,03.89	285,63.28
8	OTHER CURRENT LIABILITIES		
	Current Maturity of Long Term Borrowings		
	Interest free sales tax loan from SICOM Limited (Refer Note 4)	48.95	53.74
	Unpaid dividend*	20,26.22 52,79.60	18,88.91 28,10.37
	Statutory dues including provident fund and tax deducted at source	17,31.90	21,39.27
	Creditors for capital goods	30,34.15	3,88.30
	Rationalisation relating to a manufacturing site	1,32.84	6,07.59
	Other Payables	7,55.36	5,24.90
		130,09.02	84,13.08
•	* There are no amounts due and outstanding to be credited to Investor Education and Protection Fund.		
9		500.00.00	400 54 50
	For proposed equity dividend	529,39.38 15,86.49	423,51.50 31.32
	For tax on distributed profit	107,77.40	71,97.64
	For employee benefits		
	Gratuity	-	22.01
	Leave encashment and compensated absences	2,52.24 1,99.61	3,79.14 2,01.85
	For long term incentive plan	1,08.06	6,07.28
	For rationalisation relating to a manufacturing site	1,35.43	3,52.96
	For others (including statutory levies)	8,43.31	7,70.85
	TOTAL	668,41.92	519,14.55



#### **10** MOVEMENT IN PROVISIONS

						Rupees in lakhs
		Rationalisation				
		relating to a	Drising	Long torm	Divectment /	
		manufacturing	Pricing	Long term	Divestment /	Othoro
		site	matters	Incentive Plan	Restructuring	Others
			Jan	uary 2014-March	2015	
Opening Balance		3,52.96	123,96.15	12,66.83	16,13.72	18,40.28
Add : Provision during the period			—	5,31.68	—	11,07.99
Less: Amounts utilised/reversed during the pe	2,17.53		10,67.93	4,10.89	8,25.90	
Balance at the period end	1,35.43	123,96.15	7,30.58	12,02.83	21,22.37	
			Ja	nuary-December	2013	
Opening Balance		12,74.50	129,59.38	6,29.55	16,58.97	9,14.72
Add : Provision during the year				8,53.56	_	9,99.87
Less : Amounts utilised/reversed during the y	ear	9,21.54	5,63.23	2,16.28	45.25	74.31
Balance at the period end		3,52.96	123,96.15	12,66.83	16,13.72	18,40.28

#### **11 FIXED ASSETS**

									Ru	pees in lakhs
		Gross block	a (at cost)			Depre	ciation		Net block	
					On					
	As at 31st			As at	As at 31st		Deductions/	As at 31st	As at 31st	As at 31st
	December	Additions/ I	Deductions	31st March	December	For the	Adjustments	March	March	December
	2013	Adjustments	(b)	2015	2013	Period	(b)	2015	2015	2013
TANGIBLE ASSETS										
Freehold land	4.08	—	_	4.08	—	—	_	—	4.08	4.08
Leasehold land	44.27	_	_	44.27	_	_	_	—	44.27	44.27
Freehold buildings (a)	10,81.25	22,45.26	_	33,26.51	7,04.31	1,24.78	_	8,29.09	24,97.42	3,76.94
Leasehold buildings	37,85.68	7,60.20	1.69	45,44.19	19,99.96	1,53.97	1.24	21,52.69	23,91.50	17,85.72
Plant and equipment	204,87.06	1,921.32	35,78.64	188,29.74	136,83.69	17,77.31	27,76.67	126,84.33	61,45.41	68,03.37
Furniture and fixtures	29,96.11	1,40.04	17.54	31,18.61	24,67.60	1,59.17	17.91	26,08.86	5,09.75	5,28.51
Vehicles	11,01.18	4,98.97	21.10	15,79.05	7,80.49	3,12.58	18.00	10,75.07	5,03.98	3,20.69
Office Equipment	6,07.78	76.10	11.66	6,72.22	4,62.10	7.44	8.95	4,60.59	2,11.63	1,45.68
TOTAL	301,07.41	56,41.89	36,30.63	321,18.67	200,98.15	25,35.25	28,22.77	198,10.63	123,08.04	
Previous year	274,02.95	34,03.52	6,99.06	301,07.41	184,60.66	19,88.14	3,50.65	200,98.15		100,09.26

Note:

- (a) Freehold buildings include investments representing ownership of residential flats (Refer note 28).
- (b) Deductions include Tangible assets held for sale shown under 'Other Current Assets' (Refer note 22) : gross block Rs. 9,80.77 lakhs, accumulated depreciation Rs. 6,33.52 lakhs and net block Rs. 3,47.25 lakhs (Previous year shown under 'Other Non Current Assets' (Refer note 16) gross block Rs. 4,47.82 lakhs, accumulated depreciation Rs. 1,50.20 lakhs and net block Rs. 2,97.62 lakhs).

#### **12 INTANGIBLE ASSETS**

	Ru	pees	in	lakhs
--	----	------	----	-------

									-	
		Gross block	< (at cost)			Deprec	Net block			
	As at 31st			As at 31st	As at 31st			As at 31st	As at 31st	As at 31st
	December			March	December	For the	On	March	March	December
	2013	Additions	Deductions	2015	2013	Year	Deductions	2015	2015	2013
Goodwill (a)	42,14.97	_	_	42,14.97	42,14.97	_	_	42,14.97	—	—
TOTAL	42,14.97	—	_	42,14.97	42,14.97	—	_	42,14.97	—	—
Previous year	42,14.97	_	_	42,14.97	42,14.97	_	_	42,14.97	—	_

Note:

(a) Amortised over a period of ten years.

				Rupees in lakhs		
				As at 31st March, 2015	As at 31st December, 2013	
NON-CURRENT INVESTMENTS						
(VALUED AT COST UNLESS OTHERWISE STATED)						
TRADE						
IN EQUITY INSTRUMENTS						
Unquoted						
Biotech Consortium India Limited						
50,000 Equity Shares of Rs. 10 each fully paid				5.00	5.00	
Dinette Exclusive Club Private Limited						
500 Equity Shares of Rs. 100 each fully paid				0.50	0.50	
OTHER INVESTMENTS						
Unquoted						
National Savings Certificate				0.17	0.17	
(Lodged with Government authorities)						
	-	FOTAL		5.67	5.67	
		01/12				
Aggregate of Unquoted Investments - At Book value				5.67	5.67	
There are no investments purchased and sold / redeeme	ed during	the perio	d.			
DEFERRED TAX ASSETS (NET)						
Deferred tax assets and liabilities are attributable to the followir	na items:					
Assets	ig normo.					
Provision for employee benefits				41,03.35	30,53.08	
Costs of voluntary retirement schemes				12,25.25	21,53.41	
Provision for doubtful debts, loans and advances				5,17.12	4,81.44	
Provision for pricing matters				18.15	18.15	
Interest on Income-tax refund not accounted but consider	 and an tax	 bla und	 or tho	10.13	10.15	
Income-tax Act, 1961	eu as iaxa			22,02.06	22,02.06	
Expenses allowable for tax purposes when paid				12,55.93	17,99.73	
	-	FOTAL		93,21.86	97,07.87	
Liabilities				10.11.00	170.04	
Depreciation (including tangible assets held for sale)				10,11.63	4,78.94	
	-	FOTAL		10,11.63	4,78.94	
	-					
		FOTAL		83,10.23	92,28.93	
					1	



		Rupees ir	n lakhs
		As at 31st March, 2015	As at 31st December, 2013
15	LONG TERM LOANS AND ADVANCES		
	(Unsecured, considered good unless otherwise stated)		
	Capital advances	64,22.76	17,80.74
	Less : Allowance for doubtful loans and advances	(3,87.93) 60,34.83	(2,67.13) 15,13.61
	Security Deposits	14,11.79	11,92.01
	Other loans and advances (Refer Note 49)		
	Advance income-tax (net) (Refer Note 48(b))	171,02.85	163,82.73
	Balance with Government Authorities	12,18.14	11,07.75
	Sundry Deposits	30,70.18	29,51.44
	Loans and advances recoverable in cash or in kind $*$	4,78.82	6,25.85
	TOTAL	293,16.61	237,73.39
	* includes outstanding loans receivable from related parties		
16	OTHER NON-CURRENT ASSETS		
	Remittances in transit [Refer Note 26(iii)]	5.92	5.92
	Margin money / Deposit against bank guarantee	2,92.21	2,43.56
	Deposits with banks of maturity period more than 12 months	1.45	_
	Tangible assets held for sale (at book value or estimated net	11.05.00	
	realisable value / salvage value, whichever is lower)		11,05.90
	TOTAL	14,05.48	13,55.38
17	CURRENT INVESTMENTS		
	(CURRENT PORTION OF LONG TERM INVESTMENTS VALUED AT COST UNLESS OTHERWISE STATED)		
	IN DEBENTURES OR BONDS		
	Quoted		
	LIC Housing Finance Limited		
	Nil, (Previous year : 100, 9.35% Non-Convertible Debentures, 2014 of Rs. 10,00,000 each)	_	10,00.25
	TOTAL		10,00.25
	Aggregate of Quoted Investments - At Book value	-	10,00.25
	At Market value	_	10,06.36
	There are no investments purchased and sold / redeemed during the period.		

		Rupees in	lakhs
		As at 31st March, 2015	As at 31st December, 2013
18	INVENTORIES		
	Stores and spares	2,59.31	2,85.74
	Raw and packing materials (includes in-transit Rs. 3,05.27 lakhs; previous year : Rs. 3,30.96 lakhs)	98,76.38	73,58.33
	Work-in-progress	31,74.48	32,36.99
	Traded goods (includes in-transit Rs. 12,01.55 lakhs; previous year : Rs. 14,59.10 lakhs)	135,74.30	147,72.32
	Finished goods	106,73.80	90,43.62
	TOTAL	375.58.27	346,97.00
19	TRADE RECEIVABLES		
	(Unsecured, considered good unless otherwise stated)		
	Considered good		
	Outstanding for a period exceeding six months from the date they are due for		
	payment	9,32.19	10,98.65
	Others	90,99.60	85,40.67
	Considered doubtful		
	Outstanding for a period exceeding six months from the date they are due for payment	11,27.27	10,22.32
	Others		
	Less : Provision for doubtful debts	(11,27.27)	(10,22.32)
	TOTAL	100,31.79	96,39.32
	TOTAL	100,51.75	30,33.32
20	CASH AND BANK BALANCES		
20	Cash and cash equivalents		
	Cash on hand	0.76	1.67
	Balances with banks	0.70	1.07
	Current account	54,89.72	70,75.46
	Term deposit with original maturity period of less than three months	60,02.00	23,54.00
	Other bank balances	00,02.00	20,0 1.00
	Term deposit with original maturity period of more than three months but less than		
	twelve months	1557,75.00	1631,01.45
	Term deposit with original maturity period of more than twelve months but maturing		
	within next twelve months	217,00.00	296,75.00
	Unpaid dividend accounts	20,26.22	18,88.91
	Margin money / Deposit against bank guarantee	66.94	61.96
	TOTAL	1910,60.64	2041,58.45
21	SHORT TERM LOANS AND ADVANCES		
	(Unsecured, considered good unless otherwise stated)		
	Balance with Government Authorities	14,80.52	9,09.95
	Current account balances with group companies	26,13.73	19,16.45
	Prepaid Expenses	10,13.16	1,74.98
	Advances recoverable in cash or in kind *	71,09.76	42,92.69
	TOTAL	122,17.17	72,94.07
	* includes outstanding loans receivable from related parties		



			Rupees in	lakhs			
			As at 31st March, 2015	As at 31st December, 2013			
22	отн	ER CURRENT ASSETS					
		st accrued on investments / deposits	65,53.66	55,43.33			
		ble assets including capital work-in-progress held for sale (at book value/cost or ated net realisable value / salvage value whichever is lower)	10 50 95	40.00			
	Other	5	12,59.85 16.80	46.06 15.23			
	Cultor	TOTAL	78,30.31	56,04.62			
			70,50.51	30,04.02			
23		ITINGENT LIABILITIES AND COMMITMENTS					
		Contingent Liabilities not provided for:	0.74.00	4 50 04			
	`	<ul> <li>i) Cheques discounted with banks</li> <li>ii) In respect of claims made against the Company not acknowledged as debts</li> </ul>	3,74.00	1,56.84			
	(	by the Company					
		- Sales tax matters	34,59.31	34,16.65			
		- Excise matters	5,93.30	5,93.30			
		- Service tax matters	1,29.20	1,29.20			
		- Labour matters	83,57.08	75,74.16			
		- Other legal matters	22,01.55	22,01.55			
		which net of current tax amount to	97,30.16	91,85.20			
	(	(iii) Income-tax matters in respect of which appeals are pending					
		- Tax on matters in dispute	177,46.83	199,70.77			
	(	iv) Guarantee given by the Company to the Customs authorities	2,00.00	2,00.00			
	<ul> <li>(v) Based on the data obtained by Government, it had directed the Company to pay a tentative amount along with interest due thereon into the Drugs prices Equilisation Account (DPEA) under Drugs (Price Control) Order 1979, in respect of Bulk Drug Amoxicillin Trihydrate, on account of alleged unintended benefit enjoyed by the Company. The Company</li> </ul>						
		had filed its reply contending that no amount is payable into DPEA. Notes:	49.29	49.29			
		Future cash outflows in respect of (i) above are dependant on the return of cheques by banks.					
		Future cash outflows in respect of (ii), (iii) and (v) above are determinable on receipt of decisions / judgements pending with various forums / authorities.					
		Future cash outflows in respect of (iv) above are dependent on the future performance of the obligation by the BSL.					
	В. (	Commitments					
	(	i) Estimated amount of contracts (net of advances) remaining to be executed on capital account and not provided for	87,40.19	53,72.63			
	(	ii) Uncalled liability on partly paid shares: - in Hill Properties Limited	0.12	0.12			
		Note:		l			

Note:

Future cash outflow is dependent on the call to be made by Hill Properties Limited.

24 The demand of Rs. 71,79 lakhs made by the Central Government on the Company in respect of Betamethasone bulk drugs and formulations made therefrom during the period May 1981 to August 1987 has been under litigation for a period spanning nearly 30 years. Pursuant to the special leave petition of the Central Government in the Supreme Court of India against the Delhi High Court's Judgment and Order dated 19th October 2001 which was held in favour of the Company, the Supreme Court has, vide its Judgment and Order dated 31st March 2011, upheld the demand. The Company had accrued a liability of Rs. 18,68 lakhs in earlier years and a further provision of Rs. 53,11 lakhs was accrued in 2011.

Based on a legal advice, the Company has filed an Application in the Supreme Court seeking, inter alia, clarifications on some aspects of the Judgement and directions for recomputation of the demand. Simultaneously, the Company without prejudice to and subject to the outcome of the Application filed in the Supreme Court, has tendered as a further deposit, an amount of Rs. 63,60 lakhs, which together with the amount of Rs. 8,19 lakhs previously deposited with the Government, aggregates to the demand of Rs. 71,79 lakhs made by the Government in November 1990. The Company filed a Review Petition with the Supreme Court which was rejected in March 2012.

In October 1996, the Government had claimed interest of Rs. 117,66 lakhs for the period 12th May 1981 to 17th October 1996, for which no provision was made in earlier years. The Government has vide letter dated 4th May 2011 called upon the Company to discharge the entire liability, including upto date interest calculated at 15% p.a., and has vide letter dated 10th October 2011, raised a demand on the Company for the interest amount amounting to Rs. 247,44 lakhs. Without prejudice to the position that interest is not payable, the Company has recognized a provision of Rs. 247,44 lakhs in respect of the Government's claim for interest in 2011. The Company has filed a Writ Petition at Delhi High Court against the above demand which has been admitted. The Company also filed stay applications which have been dismissed and has filed a Special Leave Petition (SLP) before the Supreme Court for stay of the interest demand until

final determination of the Writ Petition filed in the Delhi High Court. The Supreme Court on hearing the above SLP, passed an order on 3rd April 2012. The said order stayed the Demand Notice dated 10th October 2011 during the pendency of the Writ Petition at the Delhi High Court subject to the Company depositing Rs. 136,82 lakhs in three equal installments within six month's time from the date of order. All three instalments have been deposited with the Government as of date. The Supreme Court, vide its order dated 5th October 2012, directed the Delhi High Court to dispose of the Writ Petition as expeditiously as possible. The Delhi High Court has listed the Writ Petition for hearing on 27th August, 2015.

Further, BSL received a letter dated 20th / 24th August, 1998 from the Central Government demanding an amount of Rs. 4,40.80 lakhs comprising Rs. 1,42.74 lakhs in respect of prices relating to Salbutamol formulations during the period April, 1979 to December, 1983 with interest thereon amounting to Rs. 2,98,05,808 upto 31st July, 1998. The Company had been legally advised that the demand of Rs. 1,42.74 lakhs is not sustainable and it, therefore follows that the interest demand also cannot be sustained. The total demand has been challenged by Company in a Writ Petition filed in the Bombay High Court. The Bombay High Court has granted an interim stay of the demand, subject to Company depositing 50% of the principal amount. Accordingly, the Company has deposited an amount of Rs. 71.50 lakhs with the Government on 3rd May, 1999. This is a normal interim order passed by the High Court in such matters and does not in any way reflect upon the merits or otherwise of the case. The amount will be refunded if the Company succeeds at the final hearing of the matter. The Government's application in the Supreme Court praying that this writ petition be transferred to the Supreme Court from the Bombay High Court was not allowed and the Company's writ petition will now be heard by the Bombay High Court.

#### 26 Matters in respect of erstwhile Burroughs Wellcome (India) Limited (BWIL):

(i) The Government of India, Ministry of Chemicals and Fertilisers, New Delhi, passed a final order on 21st July, 1993, directing erstwhile BWIL to pay an amount of Rs. 1,91.15 lakhs along with interest due thereon from the date of default into the Drugs Prices Equalisation Account (DPEA) in respect of a bulk drug procured by erstwhile BWIL during the period April 1981 to April 1983. Erstwhile BWIL filed a writ petition in August 1993 which was admitted by the Bombay High Court. After hearing both the parties, the High Court granted an interim injunction restraining the Government of India from taking any action in furtherance of and / or implementation of the order dated 21st July, 1993 or from in any manner seeking to compel erstwhile BWIL to deposit any amount into the DPEA, pending the hearing and final disposal of the petition on the condition that erstwhile BWIL furnishes a bank guarantee for Rs. 2,00 lakhs from a nationalised bank and undertakes to pay the amount demanded with interest at the rate of 20% per annum in case the petition fails.

Erstwhile BWIL had accordingly furnished the required bank guarantee. If calculated on the basis of correct data, taking into account set offs claimable for earlier years for which data has been provided by erstwhile BWIL, no amount will be payable by the Company and accordingly no provision in that respect is considered necessary. The Company's stand that the demand is not sustainable has been confirmed by an eminent counsel. The Government of India's application in the Supreme Court praying that the writ petition be transferred to the Supreme Court from the Bombay High Court was not allowed and the Company's writ petition will now be heard by the Bombay High Court.

- (ii) Erstwhile BWIL had made an application to the Government of India for approval under Section 198(4) of the Companies Act, 1956, in respect of payment of the Managing Director and three whole time Directors amounting to Rs. 10.93 lakhs for the year ended 31st August, 1986, which was in accordance with the minimum remuneration provided in the agreement entered into with them prior to erstwhile BWIL becoming public, which required such Government of India's sanction. The approval is still awaited.
- (iii) Remittances in transit represent monies deposited by customers in favour of erstwhile BWIL with banks in Zambia Rs. 0.31 lakhs and in Tanzania - Rs. 5.61 lakhs, the remittance of which is pending clearance of the authorities in those countries.
- 27 Matters in respect of erstwhile SmithKline Beecham Pharmaceuticals (India) Limited:
  - (i) Rs. 1,44.44 lakhs received from Beckman Instruments International S.A. on account of disputed alleged additional commission has been included under long term provisions and Income tax paid thereon aggregating to Rs. 64.77 lakhs has been included under long term loans and advances. The Company is contesting the matter with the concerned authorities.
  - (ii) Refund of surtax Rs. 96.81 lakhs, and interest thereon amounting to Rs. 48.52 lakhs, received during 1994, have not been adjusted against the provision for tax in the books of account and recognised as income respectively, since the Income tax department had filed a reference application against the Income tax tribunal's order which was pending before the High Court of Karnataka. The Company has received an order dated 18th April, 2007 from the High Court of Karnataka which is partially in the Company's favour. On the basis of the aforesaid order, Income Tax Appellate Tribunal (ITAT), Bangalore will pass an order giving directions. On receipt of the ITAT order, the Company will take appropriate steps in the matter.

	Rupees in	lakhs
	As at 31st	As at 31st
	March, 2015	December, 2013
28 Tangible fixed assets include the following investments representing ownership of residential flats:		
5 partly paid 'A' equity shares of Rs. 1,20,000 each, Rs. 1,18,000 each paid-up and		
1 partly paid 'B' equity share of Rs. 90,000, Rs. 88,500 paid-up in Hill Properties Limited.	7.22	7.22
10 shares of Rs. 50 each fully paid-up in Prathamesh Co-operative Housing Society Limited.	2.00	2.00
10 shares of Rs. 50 each fully paid-up in Montreal Olympic Premises Co-operative		
Housing Society Limited.	48.13	48.13
5 shares of Rs. 50 each fully paid-up in Poonam Co-operative Housing Society Limited.	23.62	23.62
10 shares of Rs. 100 each fully paid-up in Anita Co-operative Housing Society Limited.	33.31	33.31
20 shares of Rs. 50 each fully paid-up in Cooprage Woodhouse Co-operative Housing		
Society Limited.	45.59	45.59
5 shares of Rs. 50 each fully paid-up in Sea-Face Park Co-operative Housing Society Limited.	67.00	67.00
20 shares of Rs. 50 each fully paid-up in Red Rose Co-operative Housing Society Limited.	19.32	19.32
1 share of Rs. 100 fully paid-up in The Imperial Condominium	21,52.80	_



29       PROPOSED DIVIDEND       15 months ended       31st March, 2015         The dividend on Equity Shares of Rs. 10 each is as follows: Amount of dividend       15 months ended       31st December         30       REVENUE FROM OPERATIONS Excise duty       529,39.38 62.50       62.50       2612,45.57 (106,14.99)         Sale of products (net)          3378,62.28 (106,14.99)       2612,45.57 (74,11.91)         Sale of products (net)          3272,47.29 32,04.40       2538,33.66 24,35.61	
The dividend on Equity Shares of Rs. 10 each is as follows:       529,39.38         Amount of dividend            Dividend per Equity Share            Sale of products            Sale of products (net)            Sale of products (net)            Sale of products (net)            Sale of products (net)	50.00 2562,69.27 1127,73.27 623,85.44 333,95.74 361,90.61
Amount of dividend           529,39.38         Dividend per Equity Share           62.50         30       REVENUE FROM OPERATIONS          62.50         Sale of products           62.50         Sale of products              Sale of products (net)              Sale of products (net)               Sale of products (net)	50.00 2562,69.27 1127,73.27 623,85.44 333,95.74 361,90.61
30         REVENUE FROM OPERATIONS Sale of products	2562,69.27 1127,73.27 623,85.44 333,95.74 361,90.61
Sale of products             3378,62.28       2612,45.57         Excise duty   <	1127,73.27 623,85.44 333,95.74 361,90.61
Excise duty	1127,73.27 623,85.44 333,95.74 361,90.61
Sale of products (net)	1127,73.27 623,85.44 333,95.74 361,90.61
Other operating revenue	1127,73.27 623,85.44 333,95.74 361,90.61
	1127,73.27 623,85.44 333,95.74 361,90.61
TOTAL <u>3304,51.69</u>	623,85.44 333,95.74 361,90.61
(a) DETAILS OF SALE OF PRODUCTS Tablets and Capsules	623,85.44 333,95.74 361,90.61
Solids including Powders and Ointments	361,90.61
Liquids - Orals, Topicals and Parenterals 459,67.43 Vaccines 440,33.79	
Others	
3378,62.28	2612,45.57
(b) OTHER OPERATING REVENUE	
Service income Clinical research and data management 52,02.72 43,66.02	
Other services 19,58.57 12,07.04	
Direct expenses relating to the above	
Export related benefits (net)           13,22.15         10,71.99           22.20         10.84         22.20	
Consignment sales commission 67.86 69.72	
Manufacturing charges recovery           6,49.09         3,02.63           Others            11,54.46         32,04.40         9,69.07	24,35.61
	24,00.01
31 OTHER INCOME	
Interest income (Gross): On deposits with banks 188,12.56 156,80.50	
On loans	
On tax refunds 8,99.23 15,29.43 On investments - Government securities and other than	
trade - long term [net of premium write-off of Rs. 0.24	
lakhs (Previous year - Rs. 0.31 lakhs)]           83.53         1,70.94           Others            17.91         38.42	
198,47.62 174,46.77	
Less : Interest expense:	
Security deposits            (31.50)         (33.01)           Others             (15.40)         (0.15)	
(46.90) (33.16)	
198,00.72	174,13.61
Profit on sale / redemption of investments — — — — — — — — — — — — — — — — — —	9.10 65.41
Profit on sale / disposal of fixed assets (net) 58.00	1,64.92
Provision written back as no longer required 42.99	42.32
TOTAL <u>199,94.34</u>	176,95.36
32 COST OF MATERIALS CONSUMED	
Betamethasone-17 Valerate IP            75,99.50           Other raw materials consumed *            474,76.47	66,56.24 333,61.33
Packing materials consumed * 183,47.76	143,51.07
TOTAL 734,23.73	543,68.64
Notes :	
* No single raw or packing material accounts for more than 10% of total consumption. Cost of materials consumed is based on derived values	
VALUE OF IMPORTED AND INDIGENOUS RAW AND PACKING MATERIALS CONSUMED % %	
Purchased indigenously          83.84         615,61.75         84.86           Imported by the company (including duty and other charges)         16.16         118,61.98         15.14	461,36.99
Imported by the company (including duty and other charges) 16.16 118,61.98 15.14 100.00 734,23.73 100.00	82,31.65
	040,00.04

								Rupees	n lakhs	
~~~							15 months 31st March	ended	12 months 31st Deceml	
33	PURCHASE (		ED GOO	DS						
	Purchase of trade	ed goods						779,90.73		671,16.46
				тс	DTAL			779,90.73		671,16.46
34	CHANGES II GOODS, WO GOODS	RK-IN-PR								
	Opening stock Work-in-progress		••				32,36.99		33,37.94	
	Finished goods						90,43.62		64,37.75	
	Traded goods						147,72.32		121,67.29	
	nuudu goodo						·			
							270,52.93		219,42.98	
	Less : Closing sto						01 74 40		00.00.00	
	Work-in-progress						31,74.48 106,73.80		32,36.99	
	Finished goods Traded goods		••				135,74.30		90,43.62 147,72.32	
	Haded goods						· · · · · · · · · · · · · · · · · · ·			
							274,22.58	(3,69.65)	270,52.93	(51,09.95)
				тс	DTAL			(3,69.65)		(51,09.95)
35	EMPLOYEE E	BENEFITS	EXPEN	SES						
	Salaries, wages a	nd bonus						442,85.30		326,10.74
	Contributions to :	Provident a	nd pensior	n funds				24,54.81		16,35.09
		Gratuity fun	ids					7,96.08		5,02.21
	Staff welfare							17,66.04		14,56.81
				тс	DTAL			493,02.23		362,04.85
36	OPERATING			ENGE	9					
00	Sales promotion				5			138,38.58		120,13.90
	Stock point com							16,63.81		11,67.46
	Freight (net)							67,28.37		54,42.03
								79,32.35		58,05.22
	Manufacturing ch	arges						97,25.82		65,56.92
	Repairs - Build	lings					3,98.03		3,31.45	
		t and Machir	nery				17,40.03		9,60.90	
	- Othe						15.05	21,53.11	11.74	13,04.09
	Consumption of s		pares					6,58.01		4,15.94
	Power, fuel and v	vater						31,16.79		23,85.43
	Rent							22,96.05		15,46.39
								34,11.02		23,12.76
	Printing, postage Sales training, bri							15,18.96 17,46.97		12,96.36 19,43.92
	Excise duty							68.82		7,92.90
	Insurance							7,15.93		4,42.63
	Remuneration to	auditors :						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		.,
	Statutory audi	t fees					48.75		48.75	
	In other capac	ity in respec	ct of :							
	Tax audit fees						6.00		6.00	
	Audit of tax ac						20.00		20.00	
	Other services						30.75		45.25	
	Reimburseme	nt of expens	es				6.47		3.44	
							1,11.97	4 9 4 9 9	123.44	1 00 10
	Cost audit fee						9.11	1,21.08	2.75	1,26.19
	Date-expired stoc		 D'					46,25.71		35,07.00
	Commission to no Directors' sitting f							58.75 19.80		46.31 14.70
	Miscellaneous	ees						19.80 100,70.29		65,94.19
	Reimbursement c		 (net) (Refe	 r Note 4(	 0)			21,76.39		16,53.62
	Expenses relating	•	. , .		,			(58,39.14)		(45,01.07)
					DTAL			668,07.47		508,66.89



- 37 The Company has appointed Mr. Andrew Aristidou as Executive Director for the period December 1, 2014 to June 30, 2017 at the Board Meeting held on November 6, 2014. Shareholders of the Company have approved his appointment and remuneration vide postal ballot dated March 26, 2015. The Company has filed the application with the Central Government for approval of his appointment and payment of remuneration on April 30, 2015. Approval of the Central Government is awaited.
- 38 The recurring expenditure on research and development charged off to revenue amounts to Rs. 2,19.35 lakhs (Previous year Rs. 2,62.86 lakhs).
- 39 Miscellaneous expenses in Note 36 include loss on foreign currency transactions (net) Rs. 1,74.02 lakhs (Previous year Rs. 9,18.29 lakhs)
- 40 "Reimbursement of expenses (net)" in Note 36 are amounts recovered from GlaxoSmithKline Asia Private Limited Rs. 1,64.65 lakhs (Previous year Rs. 3,46.92 lakhs), from Stiefel India Private Limited Rs. 24.97 lakhs (Previous year Rs. 18.43 lakhs), from GlaxoSmithKline Pte Limited Rs. 30.96 lakhs (Previous year Rs. 58.96 lakhs), from GlaxoSmithKline Services Unlimited Rs. 2,19.75 lakhs (Previous year Rs. 92.03 lakhs), GlaxoSmithKline Research and Development Rs. 1,05.74 lakhs (Previous year NIL), GlaxoSmithKline Brasil Ltda Rs. 46.98 lakhs (Previous Year Rs. 9.18 lakhs) and paid to GlaxoSmithKline Consumer Healthcare Limited Rs. 27,69.44 lakhs (Previous year Rs. 21,79.14 lakhs) towards the value of costs apportioned, in accordance with the agreements on allocation of expenses with the companies.

								Rupees in lakhs			
								15 months ended 31st March, 2015	12 months ended 31st December, 2013		
41	Exceptional items:										
	Expenses on rationalisation initiativ	es mainly	relating to	o a manuf	acturing s	ite					
	<ul> <li>Voluntary retirement scheme</li> </ul>								(4.50)		
	– Others							-	(2,13.81)		
	Provisions for pricing matters written	n back						_	5,63.23		
	Profit on sale of property								21,17.81		
	Write down due to rationalisation of	capital as	ssets inclu	ding capi	tal work-in	-progress	for one				
	of the dosage forms at a manufacture	uring facil	ity					(30,37.42)	_		
	Actuarial gain/(loss) on employee b	enefits	·					(21,50.72)	1,52.73		
								(51,88.14)	26,15.46		
								(01,0011)			

- 42 The disclosures as required by Accounting Standard 15, Employee benefits (revised 2005), notified under sub-section (3C) of Section 211 of the Companies Act, 1956 are set out in Note 45 to the financial statements of the Company. Since there are no employees in BSL, the disclosures for consolidated financial statements are the same as those given for the Company.
- 43 The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

#### **44** Related Party disclosures

Related party disclosures, as required by Accounting Standard 18, "Related Party Disclosures", notified under sub-section (3C) of Section 211 of the Companies Act, 1956 are given below:

1 Relationships (during the period):

GlaxoSmithKline Export Limited, U.K.

GlaxoSmithKline Pte Limited, Singapore

GlaxoSmithKline Research & Development Ltd.

(i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company

(1)		ig) in the company					
	Glaxo Group Limited, U.K. GlaxoSmithKline Pte Limited, Singapore Eskaylab Limited, U.K.	Burroughs Wellcome International Limited, U.K. Castleton Investment Limited, Mauritius					
	Holding company / ultimate holding company of the above s	shareholders *					
	GlaxoSmithKline plc, U.K. GlaxoSmithKline Finance plc, U.K. Setfirst Ltd, U.K. SmithKline Beecham Limited, U.K. * no transactions during the period	Wellcome Limited, U.K. The Wellcome Foundation Limited, U.K. Wellcome Consumer Healthcare Limited, U.K.					
(ii)	Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the period:						
	GlaxoSmithKline Asia Private Limited, India GlaxoSmithKline Brasil Ltda, Brazil GlaxoSmithKline Consumer Healthcare Limited, India GlaxoSmithKline Biologicals S.A., Belgium GlaxoSmithKline Services Unlimited, U.K. Glaxo Operations UK Limited, U.K Laboratoire GlaxoSmithKline S.A.S., France	GlaxoSmithKline Philippines Inc. Philippines GlaxoSmithKline Australia Pty Limited, Australia GlaxoSmithKline Trading Services Limited, Ireland GlaxoSmithKline Limited, Hong Kong GlaxoSmithKline South Africa (Pty) Ltd, South Africa GlaxoSmithKline LLC, U.S.A. Stiefel India Private Limited, India					

Glaxo Wellcome Ceylon Ltd., Sri Lanka

US GMS Financial Services, U.S.A.

US Pharmaceuticals, U.S.A.

93

(iii) Directors and members of GSK India Management Team and their relatives:

Mr. A. Aristidou (w.e.f. 1st December, 2014)	Mr. P.V. Nayak
Ms. A. Bansal (w.e.f. 19th February, 2013)	Mr. R. Bartaria
Mr. A.N. Roy	Mr. R.C. Sequeira
Mr. C.T. Renganathan (up to 31st December, 2014)	Mr. R.R. Bajaaj
Mr. D.S. Parekh	Mr. R. Krishnaswamy
Mr. D. Sundaram	Mr. S. Harford *
Dr. H.B. Joshipura	Dr. S. Joglekar (up to 21st February, 2014)
Mr. H. Buch	Mr. S. Khanna
Mr. K. Hazari	Mr. S. Dheri
Mr. M.B. Kapadia (up to 30th November, 2014)	Mr. S. Venkatesh (w.e.f. 25th June, 2014)
Mr. N. Kaviratne	Ms. V. Desai (w.e.f. 11th February, 2014)
Mr. P. Bhide	Mr. V. Thyagarajan
* no transactions during the period	

#### 2 The following transactions were carried out with the related parties in the ordinary course of business.

(i) Dividend paid to parties referred to in item 1(i) above:

			F	lupees in lakhs
			January 2014 - March 2015	2013
Glaxo Group Limited, U.K	 	 	152,42.62	152,42.62
GlaxoSmithKline Pte. Limited, Singapore	 	 	103,04.89	
Eskaylab Limited, U.K	 	 	29,40.00	29,40.00
Burroughs Wellcome International Limited, U.K.	 	 	16,80.00	16,80.00
Castleton Investment Limited, Mauritius	 	 	15,96.12	15,96.12

(ii) Details relating to parties referred to in item 1(ii) above:

					Other compa the GSK Gro	
					Janaury 2014 - March 2015	2013
1	Purchase of materials/traded goods				542,80.41	436,34.10
2	Sale of materials/sale of products				3,82.35	4,79.63
3	Expenses recharged to other companies.				21,77.00	16,57.31
4	Expenses recharged by other companies				59,82.25	28,00.34
5	Manufacturing charges recovered				6,49.09	3,02.63
6	Consignment sales commission received				21.22	30.95
7	Clinical research and data management recoveri	es			52,02.72	43,66.02
8	Central Value Added Tax credits availed on behalt	f of a re	elated pa	rty (net)	4,61.79	3,39.62
9	Employee benefits transferred to a related party				16.83	14.83
10	Dividend received				_	
11	Outstanding (payables)/receivables at the period	l end (r	net) #		(66,63.46)	(89,05.81)

# Transactions with the above parties are accounted in the respective current accounts.

(iii) Disclosure in respect of material transactions with parties referred to in item 1(ii) above:

				I	Rupees in lakhs
				Janaury 2014 - March 2015	2013
(a)	Purchase of materials/traded goods				
	GlaxoSmithKline Asia Private Limited, India			152,68.08	178,75.66
	GlaxoSmithKline Biologicals S.A., Belgium			122,90.70	71,50.54
	GlaxoSmithKline Export Limited, U.K			244,48.19	172,48.31
(b)	Sale of materials/sale of products GlaxoSmithKline Trading Services Limited, Ireland			3,82.35	4,79.63
(C)	Expenses recharged to other companies				
( )	GlaxoSmithKline Asia Private Limited, India			6,15.72	7,33.87
	GlaxoSmithKline Consumer Healthcare Limited, Ind	dia		3,90.66	—
	GlaxoSmithKline Services Unlimited, U.K			2,89.40	3,47.35
	GlaxoSmithKline Trading Services Limited, Ireland			6,76.64	5,37.00



## Notes to the Consolidated Financial Statements for the 15 months ended 31st March, 2015 - continued

					R	upees in lakhs
					Janaury 2014 - March 2015	2013
(d)	Expenses recharged by other companies GlaxoSmithKline Consumer Healthcare Limited, Glaxo Operations UK Limited, U.K GlaxoSmithKline Services Unlimited, U.K.	India 	 		29,97.00 18,89.69 6,36.55	23,61.99 3.12 2.06.81
(e)	Manufacturing charges recovered GlaxoSmithKline Asia Private Limited, India				6,49.09	3,02.63
(f)	Consignment sales commission received GlaxoSmithKline Asia Private Limited, India				21.22	30.95
(g)	Clinical research and data management recover GlaxoSmithKline Biologicals S.A., Belgium GlaxoSmithKline Services Unlimited, U.K.	ries  			31,84.22 16,65.31	22,54.07 21,11.95
(h)	Central Value Added Tax credits availed on beh GlaxoSmithKline Asia Private Limited, India	alf of a r 	elated p	oarty (net)	461.79	3,39.62
(i)	Employee benefits transferred to a related party GlaxoSmithKline Asia Private Limited, India				16.83	14.83
(j)	Outstanding (payables)/receivables at the perio GlaxoSmithKline Asia Private Limited, India GlaxoSmithKline Consumer Healthcare Limited, GlaxoSmithKline Biologicals S.A., Belgium GlaxoSmithKline Export Limited, U.K. GlaxoSmithKline Trading Services Limited, Irelar GlaxoSmithKline Services Unlimited, U.K. Glaxo Operations UK Limited, U.K.	 India  	net)     	   	(18,66.63) 19,63.87 1,03.49 (54,22.00) 92.79 39.71 (18,41.15)	(42,65.64) 15,74.56 (24,76.08) (40,46.21) 88.05 2,66.53

(iv) Details relating to persons referred to in item 1(iii) above:

#### Rupees in lakhs

			January 2014 – March 2015	2013
1	Remuneration/commission/sitting fees	 	 21,06.75	14,84.26
2	Payments under the long-term incentive plan	 	 6,16.81	1,10.29
3	Interest income on loans given	 	 0.68	0.75
4	Outstanding loans receivable	 	 16.13	23.59

(v) Disclosure in respect of material transactions with persons referred to in item 1 (iii) above:

								R	upees in lakhs
							Γ	January 14 – March 15	2013
(a)	Remuneration/com	missio	n/sitting	g fees					
	Dr. H.B. Joshipura					 		4,94.83	4,00.13
	Mr. M.B. Kapadia					 		3,63.02	2,34.33
(b)	Payments under the	e long-	-term ind	entive pla	an				
	Dr. H.B. Joshipura					 		1,20.41	33.35
	Mr. M.B. Kapadia					 		2,11.12	23.18
	Mr. R.C. Sequeira					 		32.52	11.04
(C)	Interest income on	loans	given						
	Mr. H. Buch					 		0.28	0.23
	Mr. R. Bartaria					 		0.04	0.18
	Mr. S. Dheri					 		0.34	0.27
(d)	Outstanding loans r	eceiva	able						
	Mr. H. Buch					 		7.29	7.47
	Mr. R. Bartaria					 		-	5.98
	Mr. S. Dheri .					 		8.84	9.00

45 The foreign currency outstanding balances that have not been hedged by any derivative instrument or otherwise as at the Balance Sheet date are as follows:
Bupees in lakts

Particulars	Pound Sterling	United States Dollar	Euro	Japanese Yen	Singapore Dollar	UAE Dirham	Australian Dollar	South African Rand	Chinese Yuan	Honkong Dollar	Thailand Baht
Receivables	3.82 (1.42)	30,90.05 (10,50.74)	6,33.15 (12,10.59)	2.29 (2.56)	0.88 (0.20)	(0.38)	0.11	_	0.01 (0.01)	0.15	0.21
Payables	29,48.85 (16,20.16)	54,97.54 (66,42.69)	3,21.79 (2,14.04)	_	_	_	98.14	6.13 —	_	_	_

(Figures in brackets pertain to the year 2013)

- 46 Disclosures as required by Accounting Standard 19, "Leases", notified under sub-section (3C) of Section 211 of the Companies Act, 1956, are given below:
  - (i) The Company has taken various residential, office and godown premises under operating lease or leave and licence agreements. These are not non-cancellable and range between 11 months and 3 years under leave and licence, or longer for other leases and are renewable by mutual consent on mutually agreeable terms. The Company has given refundable interest free security deposits under certain agreements.
  - (ii) Lease payments are recognised in the Statement of Profit and Loss under 'Rent' in Note 36.
- **47** Earnings per share

			15 months ended 31st March, 2015	12 months ended 31st December, 2013
Net Profit		Rupees in lakhs	476,41.09	481,66.68
Weighted average number of shares	 	Nos.	8,47,03,017	8,47,03,017
Earnings per share (Basic and Diluted)	 	Rs.	56.24	56.87
Face value per share	 	Rs.	10	10

(a) Provision for tax is net of advance tax and tax deducted at source amounting to Rs. 251,92.00 lakhs (Previous year - Rs. Nil).
(b) Advance income-tax (net) represents payments in excess of provisions of Rs. 2982,51.11 lakhs (Previous year - Rs. 3037,00.53 lakhs) and includes a net tax refund with interest of Rs. 110,35.00 lakhs which has been held as provision pending the final outcome of a litigation.

49 Other Loans and advances are net of allowances for doubtful loans and advances aggregating Rs. 29,96.83 lakhs (Previous year - Rs. 29,96.83 lakhs).

- 50 During the period, a complaint filed against the company and others by Bio Med (P) Ltd is pending determination before the Competition Commission of India (CCI).
- 51 In April 2014, GlaxoSmithKline Plc (GSK), London, UK, entered into an inter-conditional agreement with Novartis AG (Novartis), Basel, Switzerland where GSK (i) will acquire the Novartis's Vaccines Business and manufacturing capabilities and facilities from Novartis, and (ii) GSK sell the rights to its Marketed Oncology Portfolio, related R&D activities and AKT Inhibitors currently in development to Novartis. Globally, this transaction with Novartis was completed on March 2nd 2015.

In connection to the above transactions, the GlaxoSmithKline Pharmaceuticals Limited ("Company") Board in its meeting held on 12th February 2015, approved the transactions on an Asset Sale basis with Novartis Healthcare Private Limited, a private unlisted Company incorporated under the Companies Act 1956. Pursuant to the global deal, the Company will have its distribution rights terminated for the oncology portfolio in return for accessing the distribution rights of the acquired vaccines portfolio. The transaction would be profit neutral for the Company.

GSK Plc and Novartis AG have obtained the approval from Competition Commission of India. The Company has filed application with Foreign Investment Promotion Board (FIPB). The closing of the asset sales between the companies is subject to the receipt of all applicable legal and regulatory approvals, consent, permissions and sanctions as may be necessary from concerned authorities.

52 The accounting year of the company has been changed from January - December to April - March with effect from the current year. Consequently, the current year's financial statements are for the 15 months from 1st January, 2014 to 31st March, 2015. The previous year figures relate to the 12 months ended 31st December, 2013. In view of the above, the current year's figures are not comparable with those of the previous year. Previous year's figures have been regrouped wherever necessary.

The accompanying notes are an integral part of the consolidated financial statements

For Price Waterhouse & Co., Bangalore LLP	For and on behalf of the Board				
Firm Registration No. 007567S / S-200012 Chartered Accountants	Chairman	D. S. PAREKH DIN: 9078			
Priyanshu Gundana Partner	Managing Director Dr. H. B. JC DIN: 274288				
Membership No. 109553	Executive Director	A. A. ARISTIDOU DIN: 7034424			
	Company Secretary	A. A. NADKARNI			
Mumbai, 18th May, 2015	Mumbai, 18th May, 2015				

## Awards & Recognition

GSK places its values at the heart of everything it does and the various awards conferred validate the same. Some of them are:

- Ranked as one of India's Most Admired Companies by Fortune India magazine (third time in a row) – No. 19 across companies and No. 3 in the Drugs, Pharmaceuticals & Healthcare segment.
- Won the Bronze award in the category 'Disease Awareness Campaign' at the Big Bang Awards 2014. Organised by the Ad Club Bangalore, GSK won this award for the PR Campaign 'ACT – Against Congenital Hypothyroidism'.
- Won the 'Overall Excellence in Procurement' and 'Excellence in Use of Technology' awards at the 2nd Annual CPO Forum organised by Institute of Supply Management (ISM) in recognition of the work done in developing the Global eSourcing programme and the transformational programme in global procurement.



ecountrino

## Innovation & Research

GSK is a science-led global healthcare company that makes innovative products to enable patients to do more, feel better and live longer. In line with its 'patient first' approach, GSK supports the commercial availability of new drugs that would benefit and improve the quality of life of Indian patients suffering from various diseases. Towards this end,



GSK has undertaken constructive steps, which will enable timely access to new and innovative therapeutic options to patients in India.

GSK continues to remain committed to Research and Development of medicines that will improve the quality of life of people around the world and truly make a difference to patients.

GSK conducted clinical studies in infectious diseases, oncology and respiratory diseases. The team has established robust clinical trial processes, with a focus on patient-centricity, in the fast-evolving Indian clinical research landscape. Quality continued to be a priority to strengthen the quality of data, the team meticulously reviewed quality checks, simplified systems and processes to ensure compliance to regulations. This helped generate accurate and meaningful data, and ensure that the rights, dignity and safety of patients taking part in our studies are protected.

# Setting new benchmarks

At GSK, the underlying belief lies in creating an inclusive and engaging working environment that empowers employees to contribute and help us achieve our strategic business objectives. To ensure the same, there has been steady progress and focus on various initiatives in the areas of Talent Management, Rewards & Recognitions, Capability Building & Employee Engagement. This is validated by the fact that GSK has been recognised by Fortune India magazine amongst 'India's Most Admired Companies' consecutively for the third time in a row.

GSK is committed to being an employer of choice and believes in investing in developing our employees. In keeping with this approach, GSK continued to focus on identifying and investing in Talent to build a strong Leadership pipeline. Progammes such as 'GMAC – GSK Marketing Accreditation Program' were launched focusing on an 18 month development plan for high potential Sales Managers. GSK continues to invest in its 'Future Leaders' programme drawing on fresh talent from leading universities/business schools across the country.

During the year, GSK set a new benchmark for the pharma industry by moving away from incentive rewards linked to sales targets for its front line sales force and placed greater emphasis on 'patient focused selling'. This new framework encompasses three areas of capability - Scientific Knowledge, Business Acumen and Customer Engagement. It also encourages novel ways such as multi channel marketing to engage with HCPs.

GSK lays great emphasis on its Values (Transparency, Respect for People, Integrity and Patient Focus) and during the year undertook a Values Maturity Assessment to gauge how leaders and employees walk the talk when it comes to living the values. Based on the results, specific action plans are being put into place to improve the scores and further embed its values in the organisation.

GSK believes in providing opportunities to employees to volunteer in various community outreach programmes and contribute towards the betterment of society. Employees



are encouraged to participate in two community programmes – PULSE and Orange Day. PULSE provides select employees an opportunity to work full-time with an NGO on projects for three to six months while Orange Day allows them to volunteer at identified NGOs for a day. Both these programmes also foster cross functional and cross regional collaboration thereby providing individual development as well.

GSK believes in conducting its operations in a responsible manner to protect its employees, the environment and community in which it operates. Extensive work has been carried out in its Nashik site as well as amongst our sales force to train and create awareness on Employee Health and Safety. Training programmes such as 'Energy for Performance', 'Personal Resilience' and 'Safety Awareness' programmes for our sales force relating to safe two wheeler driving have also been organised to promote employee health and wellbeing.

At GSK, the focus is on enhancing the capability of our employees through regular coaching, Learning & Development platforms, which include classroom and online self learning modules. Extensive sales training programmes along with Leadership programmes such as 'First Line Leader' and 'Leading Delivery' continue to be a key focus with an aim to develop high potential employees to take on leadership roles in future.

## Partnering the community

GSK India has a rich legacy of partnering with the communities in India. Strong partnerships with community groups are critical, as local organisations have the greatest insights into the needs of their people and the strategies that stand the greatest chances of success. The Company focuses on making life-changing, long-term difference in human health by addressing the healthcare burdens of accessibility, affordability and awareness. GSK works to fulfil this and other philanthropic efforts, through the Corporate Social Responsibility (CSR) programmes. During the year the CSR programmes touched the lives of over 2,00,000 people across 8 states of India.



The Company strives to make a difference around healthcare access by supporting health centres and mobile clinics in inaccessible tribal areas and urban slums. These health centres and mobile

clinics are equipped with qualified doctors and paramedics who deliver quality healthcare services to the underserved. In addition, health workers reach out to the community and raise awareness on communicable diseases, family planning and preventive healthcare measures. Female health workers visit expecting mothers and children below the age of five years to ensure proper nutritional intake, ante and post natal care and complete immunisation coverage.

GSK recognises that the health burden is invariably high for the differently abled and the vulnerable. The Company therefore has programmes that provide speech and hearing therapy for children with hearing impairment; physiotherapy, occupational therapy, counselling, and vocational training to the orthopaedically differently abled; vocational skills with stipend to supplement income for cancer survivors and palliative care for the terminally ill.

The aspect of affordability is addressed by providing support for infrastructure development and facility upgradation. GSK is building a centre in Mumbai to provide residential, nutritional, educational, recreational and transportation support for children affected with cancer and their parents during the entire period of treatment. The Company also makes product donations to not-for-profit organisations that provide healthcare consultation and medicines to the underserved. In 2014, the Company contributed towards the Jammu and Kashmir flood relief operations of National Disaster Management Authority by donating over 4,50,000 units of medicines, including anti-inflammatory, antibiotics, antihistaminics, vitamins and minerals. The experience of working with the communities has highlighted the fact that lack of awareness is a major impediment for people seeking healthcare and adopting preventive measures. Hence, the



Company has, partnered with organisations to raise awareness in communities through special camps. Cancer screening and awareness camps, eye check-up camps, orthopaedic camps, dental camps and gynaecological camps are organized as part of this effort. The Company has built a strong network to refer cases identified through these camps for further treatment. Where specialised care is available at a distance, transport services are organised to reduce the cost burden of treatment. There are special programmes targeted at children to raise awareness regarding personal hygiene and sanitation. The Company aims at behavioural change in children to promote healthy practices, some of them as basic as washing hands and boiling water before drinking. Visual aids and interactive games are used to embed the learning.



The Company believes that employee involvement is essential to bring about a social change. Several platforms are provided to enable employees to actively engage to 'Be the Change'. The PULSE

programme gives employees the chance to contribute their expertise, develop their leadership skills and widen their horizons by working with a non-profit organisation, full-time, for a period of 3-6 months. Moreover, each employee spends a minimum of one day volunteering through our Orange Day initiative. During Orange Day, employees across locations spend time with the elderly at old age homes, with children at orphanages, with the youth, training them on work readiness and with the differently abled. Employees also come together to promote a culture of giving through the payroll contribution programme and through fund raising events for GSK's global partnership with Save the Children. Through the latter, globally, till date, employees have raised approximately INR 10 crores, which is being utilised to bring much-needed medicines and vaccines to some of the world's poorest children, to train thousands of healthcare workers, and to alleviate child malnutrition.



## GlaxoSmithKline Pharmaceuticals Limited

GSK House, Dr. Annie Besant Road, Mumbai - 4000 030 Tel: 022-2495 9595 Fax: 022-2495 9494 www.gsk-india.com

1.	Name of the Company	GlaxoSmithKline Pharmaceuticals Limited
2.	Financial statements for the 15 months ended	31 <sup>st</sup> March 2015
З.	Type of Audit observation	Un-qualified
4.	Frequency of observation	Not Applicable

For Price Waterhouse & Co Bangalore LLP Firm Registration No. 007567S / S-200012 Chartered Accountants

NPriyanski Gundana Partner Membership No. 109553

Mumbai, 18<sup>th</sup> May 2015

all fis

Dr. Hasit Joshipura Managing Director DIN: 274288

de.

Andrew Aristidou Executive Director DIN: 7034424

w .

D. Sundaram Audit Committee Chairman DIN: 16304